
<html lang="en"     class="pb-page"  data-request-id="03c94548-5606-474c-8549-32a9308701f0"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.0c02111;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of Novel Pyrrolo[2,3-d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors" /></meta><meta name="dc.Creator" content="Xuewu  Liang" /></meta><meta name="dc.Creator" content="Shuai  Tang" /></meta><meta name="dc.Creator" content="Xuyi  Liu" /></meta><meta name="dc.Creator" content="Yingluo  Liu" /></meta><meta name="dc.Creator" content="Qifu  Xu" /></meta><meta name="dc.Creator" content="Xiaomin  Wang" /></meta><meta name="dc.Creator" content="Abdusaid  Saidahmatov" /></meta><meta name="dc.Creator" content="Chunpu  Li" /></meta><meta name="dc.Creator" content="Jiang  Wang" /></meta><meta name="dc.Creator" content="Yu  Zhou" /></meta><meta name="dc.Creator" content="Yingjie  Zhang" /></meta><meta name="dc.Creator" content="Meiyu  Geng" /></meta><meta name="dc.Creator" content="Min  Huang" /></meta><meta name="dc.Creator" content="Hong  Liu" /></meta><meta name="dc.Description" content="It remains a big challenge to develop HDAC inhibitors effective for solid tumors. Previous studies have suggested that the feedback activation of JAK-STAT3 pathway represents a key mechanism leadin..." /></meta><meta name="Description" content="It remains a big challenge to develop HDAC inhibitors effective for solid tumors. Previous studies have suggested that the feedback activation of JAK-STAT3 pathway represents a key mechanism leadin..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 15, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c02111" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02111" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c02111" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02111" /></link>
        
    
    

<title>Discovery of Novel Pyrrolo[2,3-d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c02111" /></meta><meta property="og:title" content="Discovery of Novel Pyrrolo[2,3-d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0019.jpeg" /></meta><meta property="og:description" content="It remains a big challenge to develop HDAC inhibitors effective for solid tumors. Previous studies have suggested that the feedback activation of JAK-STAT3 pathway represents a key mechanism leading to resistance to HDAC inhibitors in breast cancer, suggesting the therapeutic promise of JAK/HDAC dual inhibitors. In this work, we discovered a series of pyrrolo[2,3-d]pyrimidine-based derivatives as potent JAK and HDAC dual inhibitors. Especially, compounds 15d and 15h potently inhibited JAK1/2/3 and HDAC1/6 and displayed antiproliferative and proapoptotic activities in triple-negative breast cancer cell lines. Besides, compounds 15d and 15h also diminished the activation of LIFR-JAK-STAT signaling triggered by tumor-associated fibroblasts, which suggests that these compounds could potentially overcome the drug resistance caused by the tumor microenvironment. More importantly, compound 15d effectively inhibited the tumor growth in MDA-MB-231 xenograft tumor model. Overall, this work provides valuable leads and novel antitumor mechanisms for the treatment of the SAHA-resistant triple-negative breast cancers." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c02111"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02111">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-13/achre4.2021.54.issue-13/20210706/achre4.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-26/aamick.2021.13.issue-26/20210707/aamick.2021.13.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-13/accacs.2021.11.issue-13/20210702/accacs.2021.11.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-13/acncdm.2021.12.issue-13/20210707/acncdm.2021.12.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-27/acsodf.2021.6.issue-27/20210713/acsodf.2021.6.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-27/ascecg.2021.9.issue-27/20210712/ascecg.2021.9.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-27/ancham.2021.93.issue-27/20210713/ancham.2021.93.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-27/bichaw.2021.60.issue-27/20210713/bichaw.2021.60.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-13/cmatex.2021.33.issue-13/20210713/cmatex.2021.33.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-13/enfuem.2021.35.issue-13/20210701/enfuem.2021.35.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-13/esthag.2021.55.issue-13/20210706/esthag.2021.55.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-26/iecred.2021.60.issue-26/20210707/iecred.2021.60.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-13/inocaj.2021.60.issue-13/20210705/inocaj.2021.60.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-26/jafcau.2021.69.issue-26/20210707/jafcau.2021.69.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-13/joceah.2021.86.issue-13/20210702/joceah.2021.86.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-26/jpcafh.2021.125.issue-26/20210708/jpcafh.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-26/jpcbfk.2021.125.issue-26/20210708/jpcbfk.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-26/jpccck.2021.125.issue-26/20210708/jpccck.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-26/jpclcd.2021.12.issue-26/20210708/jpclcd.2021.12.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-26/jacsat.2021.143.issue-26/20210707/jacsat.2021.143.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-27/langd5.2021.37.issue-27/20210713/langd5.2021.37.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-13/mamobx.2021.54.issue-13/20210713/mamobx.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-13/orlef7.2021.23.issue-13/20210702/orlef7.2021.23.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-13/orgnd7.2021.40.issue-13/20210712/orgnd7.2021.40.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c02111&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c02111&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c02111&amp;href=/doi/10.1021/acs.jmedchem.0c02111" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, XXXX</span><span class="cit-fg-issue">, XXX</span><span class="cit-fg-pageRange">, XXX-XXX</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/0/0" title="Return to Articles ASAP" id="returnToASAP" class="content-navigation__btn--return"><span>RETURN TO ARTICLES ASAP</span></a><a href="/doi/10.1021/acs.jmedchem.0c02118" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01467" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Novel Pyrrolo[2,3-<i>d</i>]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Xuewu Liang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xuewu Liang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xuewu++Liang">Xuewu Liang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shuai Tang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shuai Tang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shuai++Tang">Shuai Tang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xuyi Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xuyi Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xuyi++Liu">Xuyi Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yingluo Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yingluo Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yingluo++Liu">Yingluo Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qifu Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qifu Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Shandong University, Ji’nan, Shandong 250012, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qifu++Xu">Qifu Xu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiaomin Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaomin Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaomin++Wang">Xiaomin Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Abdusaid Saidahmatov</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Abdusaid Saidahmatov</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Abdusaid++Saidahmatov">Abdusaid Saidahmatov</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chunpu Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chunpu Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chunpu++Li">Chunpu Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jiang Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jiang Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jiang++Wang">Jiang Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yu Zhou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yu Zhou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yu++Zhou">Yu Zhou</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7684-2939" title="Orcid link">http://orcid.org/0000-0002-7684-2939</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yingjie Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yingjie Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Shandong University, Ji’nan, Shandong 250012, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yingjie++Zhang">Yingjie Zhang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6118-6695" title="Orcid link">http://orcid.org/0000-0001-6118-6695</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Meiyu Geng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Meiyu Geng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Meiyu++Geng">Meiyu Geng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Min Huang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Min Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</div></div><span class="conrtib-corresp"><strong>*</strong>M.H.: email. <a href="/cdn-cgi/l/email-protection#3f52574a5e51587f4c565252115e5c115c51"><span class="__cf_email__" data-cfemail="f29f9a87939c95b2819b9f9fdc9391dc919c">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Min++Huang">Min Huang</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Hong Liu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hong Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</div></div><span class="conrtib-corresp"><strong>*</strong>L.H.: phone, +86 21 50807042; email, <a href="/cdn-cgi/l/email-protection#640c080d112409050d084a170c070a074a05074a070a"><span class="__cf_email__" data-cfemail="f99195908cb994989095d78a919a979ad7989ad79a97">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hong++Liu">Hong Liu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3685-6268" title="Orcid link">http://orcid.org/0000-0003-3685-6268</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02111&amp;href=/doi/10.1021%2Facs.jmedchem.0c02111" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, XXXX</span><span class="cit-issue">, XXX</span><span class="cit-pageRange">, XXX-XXX</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 15, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>7 December 2020</li><li><span class="item_label"><b>Published</b> online</span>15 February 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c02111" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02111</a></div><div class="article_header-article-copyright"><strong>© 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1%26pageCount%3D22%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DXuewu%2BLiang%252C%2BShuai%2BTang%252C%2BXuyi%2BLiu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D0%26issueNum%3D0%26contentID%3Dacs.jmedchem.0c02111%26title%3DDiscovery%2Bof%2BNovel%2BPyrrolo%255B2%252C3-d%255Dpyrimidine-based%2BDerivatives%2Bas%2BPotent%2BJAK%252FHDAC%2BDual%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BRefractory%2BSolid%2BTumors%26numPages%3D22%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D22%26publicationDate%3DFebruary%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c02111"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1742</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c02111" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Novel Pyrrolo[2,3-d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Xuewu&quot;,&quot;last_name&quot;:&quot;Liang&quot;},{&quot;first_name&quot;:&quot;Shuai&quot;,&quot;last_name&quot;:&quot;Tang&quot;},{&quot;first_name&quot;:&quot;Xuyi&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Yingluo&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Qifu&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Xiaomin&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Abdusaid&quot;,&quot;last_name&quot;:&quot;Saidahmatov&quot;},{&quot;first_name&quot;:&quot;Chunpu&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Jiang&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Yu&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Yingjie&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Meiyu&quot;,&quot;last_name&quot;:&quot;Geng&quot;},{&quot;first_name&quot;:&quot;Min&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;Liu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;15&quot;,&quot;issue&quot;:&quot;0&quot;,&quot;volume&quot;:&quot;0&quot;,&quot;pages&quot;:&quot;&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c02111&quot;},&quot;abstract&quot;:&quot;It remains a big challenge to develop HDAC inhibitors effective for solid tumors. Previous studies have suggested that the feedback activation of JAK-STAT3 pathway represents a key mechanism leading to resistance to HDAC inhibitors in breast cancer, suggesting the therapeutic promise of JAK/HDAC dual inhibitors. In this work, we discovered a series of pyrrolo[2,3-d]pyrimidine-based derivatives as potent JAK and HDAC dual inhibitors. Especially, compounds 15d and 15h potently inhibited JAK1/2/3 and HDAC1/6 and displayed antiproliferative and proapoptotic activities in triple-negative breast cancer cell lines. Besides, compounds 15d and 15h also diminished the activation of LIFR-JAK-STAT signaling triggered by tumor-associated fibroblasts, which suggests that these compounds could potentially overcome the drug resistance caused by the tumor microenvironment. More importantly, compound 15d effectively inhibited the tumor growth in MDA-MB-231 xenograft tumor model. Overall, this work provides valuable leads and n&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02111&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02111" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02111&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02111" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02111&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02111" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02111&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02111&amp;href=/doi/10.1021/acs.jmedchem.0c02111" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c02111" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c02111" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (12 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c02111%26sid%3Dliteratum%253Aachs%26pmid%3D33586434%26genre%3Darticle%26aulast%3DLiang%26date%3D2021%26atitle%3DDiscovery%2Bof%2BNovel%2BPyrrolo%255B2%252C3-d%255Dpyrimidine-based%2BDerivatives%2Bas%2BPotent%2BJAK%252FHDAC%2BDual%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BRefractory%2BSolid%2BTumors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D0%26issue%3D0%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (8)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/0/0" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02111&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">It remains a big challenge to develop HDAC inhibitors effective for solid tumors. Previous studies have suggested that the feedback activation of JAK-STAT3 pathway represents a key mechanism leading to resistance to HDAC inhibitors in breast cancer, suggesting the therapeutic promise of JAK/HDAC dual inhibitors. In this work, we discovered a series of pyrrolo[2,3-<i>d</i>]pyrimidine-based derivatives as potent JAK and HDAC dual inhibitors. Especially, compounds <b>15d</b> and <b>15h</b> potently inhibited JAK1/2/3 and HDAC1/6 and displayed antiproliferative and proapoptotic activities in triple-negative breast cancer cell lines. Besides, compounds <b>15d</b> and <b>15h</b> also diminished the activation of LIFR-JAK-STAT signaling triggered by tumor-associated fibroblasts, which suggests that these compounds could potentially overcome the drug resistance caused by the tumor microenvironment. More importantly, compound <b>15d</b> effectively inhibited the tumor growth in MDA-MB-231 xenograft tumor model. Overall, this work provides valuable leads and novel antitumor mechanisms for the treatment of the SAHA-resistant triple-negative breast cancers.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="specialIssueNotice" class="extra-info-sec articleNote"><h4>SPECIAL ISSUE</h4><p class="last">This article is part of the <a href="/toc/jmcmar"><issue-title>New Horizons in Drug Discovery - Understanding and Advancing Kinase Inhibitors</issue-title></a> special issue.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58162" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58162" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Simultaneous intervention of two or even multiple targets in the complex pathogenesis may be beneficial to the treatment of patients suffered from complex diseases like malignant tumors and central nervous system diseases.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> To tackle complex diseases like cancer, modulating the activity of multiple targets could possibly achieve better therapeutic benefit, which provides a reasonable scientific basis for multitargeted drug design.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> In clinical applications, multitargeted drugs possess advantages such as optimal therapeutic efficacy (like sorafenib and dasatinib), slowing down drug resistance, as well as predictable pharmacokinetic (PK) profile and avoiding drug–drug interactions compared with combinational therapies.<a onclick="showRef(event, 'ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6">(4−6)</a> However, it is undeniable that multitargeted effects are also a very important cause of drug side effects. Nevertheless, multitarget drug design strategies are widely used in antitumor drugs.</div><div class="NLM_p">Histone deacetylases (HDACs), a family of epigenetic enzymes, regulate the deacetylation of a variety of their substrates including histone and nonhistone proteins, then further control the expression level of many oncogenes and apoptotic genes and hence impact many cancer cellular processes such as cell proliferation, cell migration, cell apoptosis, and angiogenesis.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> Up to now, five HDAC inhibitors, namely vorinostat (SAHA), romidepsin, belinostat, panobinostat, and chidamide (approved in China) have been approved for the treatment of hematological malignancies, including refractory cutaneous T cell lymphoma (CTCL), peripheral T cell lymphoma, and multiple myeloma.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> Despite the great success achieved in treatment of hematological malignancies, most of the known HDAC inhibitors used as a single agent failed to show clinical benefits in nearly all types of solid tumors,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> including breast cancer, renal cancer,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> prostate cancer,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and head and neck cancer.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Simultaneously inhibiting HDAC and other targets involved in the pathogenesis of solid tumors may solve the dilemma.</div><div class="NLM_p">Actually, chimeric HDAC inhibitors, which simultaneously modulate HDAC and other targets in feedback or compensatory pathways, could provide a potential treatment for relapsing and drug-resistant cancers. Thus far, a dozen different types of chimeric HDAC inhibitors have been developed,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> including chimeric EGFR/HDAC inhibitors,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> chimeric VEGFR/HDAC inhibitors,<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> dual c-Src/HDAC inhibitors,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> dual Janus kinase (JAK)/HDAC inhibitors,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and so on.</div><div class="NLM_p">Invasive solid tumors, such as triple-negative breast cancer, possess strong aggression, high mortality, and poor prognosis, which lack effective clinical treatment.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> Development of more effective therapy for treatment of such human malignancies is very urgent. Interestingly, recent research showed that HDAC inhibitors promoted BRD4-mediated activation of leukemia inhibitory factor receptor (LIFR), which in turn activated JAK1-STAT3 signaling and restrained the efficacy of HDAC inhibitors in breast cancer.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Concurrent inhibition of JAK sensitized breast cancer, including the triple-negative subset, to HDAC inhibitors.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Thus, the development of JAK/HDAC dual inhibitors may be a reasonable and effective treatment for triple-negative breast cancer. Of note, JAKs are a family of intracellular tyrosine kinases comprising JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2) that play a critical role in both tumor cells and in the tumor microenvironment.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> JAKs, activated by different cytokines, lead to phosphorylation and dimerization of the signal transducers and activators of transcription (STAT) family of proteins that translocate to the nucleus and stimulate gene expression.<a onclick="showRef(event, 'ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26">(24−26)</a> Inhibition of JAKs is promising to block the biological crosstalk between tumor cells and the surrounding cells in the tumor microenvironment. As such, combining JAK and HDAC is expected to overcome the limitations of HDAC inhibitors and bring clinical benefits to solid tumors. We have previously discovered that LIFR-JAK1-STAT3 signaling limits response to HDAC inhibition in the solid tumors.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Given JAK1 and JAK2 share the same downstream molecules in cancer cells, dual inhibition of JAK1 and JAK2 may avoid compensatory activation and ensure the blockage of the feedback activation of STAT3 signaling. Co-inhibition of HDACs with JAK1/JAK2 may be more suitable for treating solid tumors.</div><div class="NLM_p">So far, a few JAK/HDAC dual inhibitors have been developed (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Dymock’s group first reported JAK/HDAC dual inhibitors <b>1</b>, <b>2</b>, and <b>3</b> based on the structure of JAK inhibitor templates pacritinib, ruxolitinib, and XL019, respectively.<a onclick="showRef(event, 'ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29">(27−29)</a> Compound <b>1</b> was selective for JAK2 and HDAC6 against other JAK and HDAC isoforms with IC<sub>50</sub> values at 1.4 and 2.1 nM. Further detailed studies in acute myelocytic leukemia (AML), multiple myeloma (MM), and erythroleukemia cell lines (EL) showed that compound <b>1</b> could effectively block both the JAK-STAT and HDAC pathways.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Compound <b>2</b> broadly inhibited JAK1 and HDACs 1, 2, 3, 6, and 10, with IC<sub>50</sub> values of less than 20 nM. Broad cellular antiproliferative potency of compound <b>2</b> was supported by demonstration of JAK-STAT and HDAC pathway blockade in hematological cell lines.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> It is worth mentioning that compound <b>3</b> with strong JAK2 potency (IC<sub>50</sub> = 3.1 nM) and HDAC6 potency (IC<sub>50</sub> = 1.2 nM) showed 16–25-fold selectivity against the other three JAK isoforms. It also showed submicromolar potencies against a panel of four solid tumor cell lines.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> In 2018, Sheng’s group reported a novel JAK/HDAC dual inhibitor <b>4</b>. Compound <b>4</b> possessed potent inhibitory activities against JAK2 and HDAC6 with IC<sub>50</sub> values at 8 and 46 nM, respectively. Further studies in vivo showed that compound <b>4</b> possessed excellent antitumor efficacy in several AML models and synergized with fluconazole for the treatment of resistant <i>Candida albicans</i> infections.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> In 2019, our group reported a novel series of pyrimidin-2-amino-pyrazol hydroxamate derivatives as JAK and HDAC dual inhibitors, among which compound <b>5a</b> possessed potent and balanced activities against both JAK2 and HDAC6 with IC<sub>50</sub> values at 4.3 and 14.4 nM, respectively. Compound <b>5a</b> exhibited improved antiproliferative and proapoptotic activities over SAHA and ruxolitinib in several hematological cell lines.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> It is worth mentioning that the studies of these JAK/HDAC dual inhibitors are more likely to focus on hematological malignancies rather than solid tumors which are insensitive to JAK inhibitors or HDAC inhibitors.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0001.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of representative JAK/HDAC dual inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02111&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">It remains a big challenge to develop HDAC inhibitors effective for solid tumors. Combining JAK and HDAC is expected to overcome the limitations of HDAC inhibitors and bring clinical benefits to solid tumors. Therefore, we developed a novel series of pyrrolo[2,3-<i>d</i>]pyrimidine-based derivatives as potent JAK/HDAC dual inhibitors and explore the advantages of multitarget drugs for the treatment of relapsing and drug-resistant cancers, in particular the triple-negative breast cancers in this work.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57833" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57833" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Rational Design of Novel JAK and HDAC Dual Inhibitors</h3><div class="NLM_p">In our previous research, a potent JAK/HDAC dual inhibitor <b>5b</b> with notable antiproliferative and proapoptotic activities was identified.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> However, this series of compounds showed a very potent in vitro but a mild in vivo anticancer activities against hematological malignancies. In this work, we carried out further structural modifications based on compound <b>5b</b> in the hope of obtaining desired in vivo efficacy on the solid tumors, which are not sensitive to JAK inhibitors or HDAC inhibitors. Through analyzing the binding mode between compound <b>5b</b> and JAK2 protein using molecular docking study, we found a hydrophobic pocket in the ATP pocket of JAK2 protein that had not yet been occupied (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). Thus, we tried to fill this hydrophobic pocket with an aromatic ring on the ligand molecule to improve the binding of ligand to protein. In addition, considering the large cavity in the surface recognition cap (SRC) of HDAC protein, the introduction of an aromatic ring on the ligand molecule would not affect the binding of the ligand to HDAC protein. To improve the biological activity, fused ring strategy in the ligand molecule was frequently applied in the design of JAK inhibitors.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a> On the basis of the above analysis, we introduced different aromatic rings to the pyrimidine ring on the compound <b>5b</b>, including phenyl ring, biphenyl ring, and pyrrole ring (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). By preliminary inhibitory activity against JAK2, compounds containing quinazoline and phenylpyrimidine scaffolds showed weaker JAK2 inhibition than the compound containing pyrrolo[2,3-<i>d</i>]pyrimidine scaffold. Therefore, we selected pyrrole ring as the optimal fused ring to design the novel pyrrolo[2,3-<i>d</i>]pyrimidine-based derivatives as novel and potent JAK/HDAC dual inhibitors.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Rational design of novel JAK and HDAC dual inhibitors. (A) Predicted binding mode of compound <b>5b</b> in the ATP pocket of JAK2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>). The unoccupied pocket is indicated by arrow. (B) Design strategy of JAK and HDAC dual inhibitors based on compound <b>5b</b>. The three parts of HDAC inhibitor pharmacophore are indicated in three colors (ZBG, zinc-binding group). In addition, the structure of compound <b>6a</b> is shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02111&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>6a</b>, one of the representative pyrrolo[2,3-<i>d</i>]pyrimidine derivatives which showed the most similar structure with compound <b>5b</b>, was analyzed for its proposed binding modes in the active sites of JAK2 and HDAC6 using molecular docking study. The docking results in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>(A,C) showed the binding mode of compound <b>6a</b> in the ATP active pocket of JAK2. It can be seen that aminopyrimidine moiety of compound <b>6a</b> forms dual hydrogen bonds with Leu932, which is the same as compound <b>5b</b>. As we predicted, the pyrrole ring introduced to the pyrimidine moiety perfectly fills this unoccupied hydrophobic pocket and fixes the orientation of the phenyl group. In addition, alkyl hydroxamate part of compound <b>6a</b> is projected toward the solvent region and forms hydrogen bonds with the amino acid residues Arg980 and Lys857 at the entrance of the ATP active pocket in JAK2. The docking results in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B,D showed the binding mode of compound <b>6a</b> in the active site of HDAC6. It can be seen that the hydroxamic acid group of compound <b>6a</b> chelates the Zn<sup>2+</sup> in a bidentate manner and forms multiple hydrogen bonds with Tyr745, His573, and His574 residues in the deep active pocket of HDAC6 protein, which contribute to its high inhibition potency against HDAC6. The aliphatic chain occupies the hydrophobic channel, which perfectly connect hydroxamic acid group with terminal cap group. The above docking results strongly support the rationality of the design strategy of the novel pyrrolo[2,3-<i>d</i>]pyrimidine-based derivatives as potent JAK/HDAC dual inhibitors.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) The predicted binding mode of compound <b>6a</b> in the ATP pocket of JAK2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>). (B) The predicted binding mode of compound <b>6a</b> in the active site of HDAC6 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI">5EEI</a>). (C) Surface representation of compound <b>6a</b> in the ATP pocket of JAK2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>). (D) Surface representation of compound <b>6a</b> in the active site of HDAC6 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI">5EEI</a>). Yellow dashed lines represent the hydrogen bonds. In the ligand, oxygen, nitrogen, carbon, and polar hydrogen atoms are shown in red, blue, green, and white, respectively. The figures were generated using PyMol (<a href="http://www.pymol.org/" class="extLink">http://www.pymol.org/</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02111&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">On the basis of the structure of compound <b>6a</b>, we further introduced some substituents on the phenyl group to investigate the influence of substituents on the biological activities and designed compounds <b>6b</b>–<b>e</b>. Meanwhile, we reduced the length of aliphatic linker from 6 to 5 and designed compounds <b>6f</b>,<b>g</b>. Considering the relatively strong rigidity of the compounds <b>6a</b>–<b>g</b>, we replaced the phenyl groups with different substituted benzyl groups, phenethyl groups, and cycloalkyl groups to increase their structural flexibility and designed the other target compounds (<b>15a</b>–<b>l</b>, <b>16a</b>–<b>j</b>, and <b>17a</b>–<b>c</b>).</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Chemistry</h3><div class="NLM_p">Chemical synthesis of JAK/HDAC dual inhibitors are depicted in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>–<a class="ref internalNav" href="#sch3" aria-label="3">3</a>. 4-Nitro-1<i>H</i>-pyrazole <b>7</b>, as the starting material is reduced by hydrogen to produce 1<i>H</i>-pyrazol-4-amine <b>8</b>. Intemediate <b>8</b> is protected by Boc group to obtain intemediate <b>9</b>, which reacted with commercially available bromoalkanes under basic condition of cesium carbonate to produce intermediates <b>10a</b>,<b>b</b>. Boc deprotection of intermediates <b>10a</b>,<b>b</b> under strong acid condition gave intermediates <b>11a,</b><b>b</b>, respectively (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Intermediates <b>13a</b>–<b>s</b> were obtained by the reaction of 2-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine <b>12</b> as the starting material with different aryl bromides under different conditions (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Intermediates <b>14a</b>–<b>z</b> and <b>14A</b>–<b>F</b> were prepared by the reaction of the key intermediates <b>13a</b>–<b>s</b> and the key intermediates <b>11a</b>,<b>b</b> under the conditions of high temperature and acid catalyst in microwave apparatus. Intermediates <b>14a</b>–<b>z</b> and <b>14A</b>–<b>F</b> were subsequently reacted with NH<sub>2</sub>OK/methanol solution to give target compounds <b>6a</b>–<b>g</b>, <b>15a</b>–<b>l</b>, <b>16a</b>–<b>j</b>, and <b>17a</b>–<b>c</b>, respectively (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0012.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Intermediate Compounds <b>11a</b>,<b>b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02111&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Conditions and reagents: (a) Pd/C, H<sub>2</sub>, EtOH, rt, 2 days, 90%; (b) (Boc)<sub>2</sub>O, NaHCO<sub>3</sub>/H<sub>2</sub>O, THF, rt, 2 days, 75%; (c) Cs<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, 40–50 °C, 10 h, 76–78%; (d) HCl/EtOAc, rt, 10 h, 63–75%.</p></p></figure><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0013.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Intermediate Compounds <b>13a</b>–<b>s</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02111&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Conditions and reagents: (e) for <b>13a</b>–<b>e</b>. CuI, <i>trans</i>-1,2-cyclohexanediamine, K<sub>3</sub>PO<sub>4</sub>, dioxane, 130 °C, microwave 1 h, 20–50%; For <b>13f</b>–<b>s</b>, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, 40–50 °C, 5 h, 67–96%.</p></p></figure><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0014.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Target Compounds <b>6a</b>–<b>g</b>, <b>15a</b>–<b>l</b>, <b>16a</b>–<b>j</b>, and <b>17a</b>–<b>c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02111&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Conditions and reagents: (f) EtOH, 130 °C, microwave 2 h, 18–41%; (g) NH<sub>2</sub>OK, CH<sub>3</sub>OH, rt, 0.5–1 h, 70–95%.</p></p></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> In Vitro JAK and HDAC Inhibition Assay</h3><div class="NLM_p">The inhibitory activities of these novel pyrrolo[2,3-<i>d</i>]pyrimidine-based derivatives against JAK2 and HDAC6 were evaluated by determining their IC<sub>50</sub> values, with the approved JAK inhibitor ruxolitinib (INCB) and approved hydroxamic acid-based HDAC inhibitor SAHA as positive controls. The results in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> showed that <b>6a</b> exhibited potent JAK2 and HDAC6 inhibitory activities with IC<sub>50</sub> values at 16.8 and 13.1 nM, validating the rationality of our JAK and HDAC dual inhibitor design strategy shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>. It is worth noting that compound <b>6a</b> showed much more potent HDAC6 inhibitory activity than that of SAHA (IC<sub>50</sub> value: 75.9 nM) and slightly weaker JAK2 inhibitory activity than that of ruxolitnib (IC<sub>50</sub> value: 2.9 nM). Simultaneously inhibiting JAK2 and HDAC6 with nanomolar level is acceptable. Next, different <i>para</i>-substituents were introduced to the phenyl moiety of compound <b>6a</b>, leading to the compounds <b>6b</b>–<b>e</b>. Comparing JAK2 and HDAC6 inhibitory activities data of compounds <b>6b</b>–<b>e</b> with that of compound <b>6a</b>, it is obvious to figure out that the introduction of different <i>para</i>-substituents to the phenyl moiety will slightly reduce the JAK2 and HDAC6 inhibitory activities, excluding compound <b>6e</b>. Compound <b>6e</b> exhibited comparable JAK2 inhibitory activity to <b>6a</b> (IC<sub>50</sub> values: 15.7 vs 16.8 nM) and a little more potent HDAC6 inhibitory activity than <b>6a</b> (IC<sub>50</sub> values: 5.9 vs 13.1 nM). To investigate the effects of the linker on JAK2 and HDAC6 inhibition, we reduced the length of aliphatic linker from 6 to 5 and obtained compounds <b>6f</b>,<b>g</b>. Comparing their JAK2 and HDAC6 inhibitory activities data, we found that aliphatic linker length of 5 or 6 methylenes had no dramatic influence on the JAK2 and HDAC6 inhibition. All the compounds (<b>6a</b>–<b>g</b>) containing 5 or 6 methylenes showed high potencies on the JAK2 and HDAC6 inhibition. Linker length of 5 or 6 methylenes is both accepted in the structural modification of these JAK/HDAC dual inhibitors.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Structures and in Vitro Enzymes Inhibitory Activities Comparison of the Target Compounds <b>6a</b>–<b>g</b> and Compounds <b>15a</b>–<b>l</b><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0015.gif" alt="" id="fx1fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0016.gif" alt="" id="GRAPHIC-d7e1044-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Assays were performed in replicate (<i>n</i> ≥ 3), IC<sub>50</sub> values are shown as mean ± SD.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Not active at 10 μM.</p></div></div><div></div></div><div class="NLM_p">To reduce the rigidity of compounds <b>6a</b>–<b>g</b> and considering the aliphatic linker length of 5 or 6 methylenes both accepted, compounds <b>15a</b>–<b>l</b> and compounds <b>16a</b>–<b>j</b> were synthesized and evaluated. Compounds <b>15a</b>–<b>j</b> exhibited potent JAK2 and HDAC6 inhibition with IC<sub>50</sub> values lower than 50 nM (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), validating that <i>ortho</i>- and <i>meta</i>- halogen substituents on the phenyl moiety were well tolerated both in the JAK2 and HDAC6 inhibition. However, compounds <b>15k</b>–<b>l</b> exhibited poor JAK2 inhibition (IC<sub>50</sub> > 100 nM) and potent HDAC6 inhibition (IC<sub>50</sub> lower than 50 nM), validating that <i>meta</i>- methoxyl substituent on the phenyl moiety was not tolerated in the JAK2 inhibition. Note that through this round of compound screening, we obtained many potent JAK/HDAC dual inhibitors with IC<sub>50</sub> at nanomolar level, including <b>15a</b>, <b>15c</b>–<b>e</b>, and <b>15g</b>–<b>i</b>. Among these compounds, <b>15g</b> potently inhibited JAK2 and HDAC6 with the IC<sub>50</sub> values at 4.1 and 13.7 nM, respectively.</div><div class="NLM_p">Next, <i>para-</i>substituents were introduced to the phenyl moiety on the structures of JAK/HDAC dual inhibitors <b>15a</b> and <b>15b</b>. The enzyme inhibition results in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> showed that <i>para</i>-substituents (no matter halogen or methoxyl group) on the phenyl moiety were not beneficial for JAK2 inhibition but tolerated in HDAC6 inhibition. All compounds <b>16a</b>–<b>h</b> exhibited very poor JAK2 inhibition (IC<sub>50</sub> > 100 nM), which is not what we expected. In addition, both compounds <b>16i</b>,<b>j</b> exhibited very poor JAK2 inhibition (IC<sub>50</sub> > 100 nM), validating that phenethyl group in R substituent were also not beneficial for JAK2 inhibition but tolerated in HDAC6 inhibition.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Structures and in Vitro Enzymes Inhibitory Activities Comparison of the Target Compounds <b>16a</b>–<b>j</b> and Compounds <b>17a</b>–<b>c</b><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0017.gif" alt="" id="fx3fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0018.gif" alt="" id="GRAPHIC-d7e1200-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Assays were performed in replicate (<i>n</i> ≥ 3).</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">@10 nM means HDAC6 inhibition rate at 10 nM.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">The IC<sub>50</sub> (nM) values of compounds <b>17a</b>, <b>17b</b>, <b>17c</b>, and SAHA against HDAC6.</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">Not active at 10 μM.</p></div></div><div></div></div><div class="NLM_p">Finally, we also introduced some cycloalkyl substituents instead of aromatic substituents as R group to the pyrrolo moiety of the JAK/HDAC dual inhibitors, leading to the compounds <b>17a</b>–<b>c</b>. The enzyme inhibition results in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> showed that compounds <b>17a</b> and <b>17b</b> possessed very potent inhibitory activities against HDAC6 (IC<sub>50</sub>: 22 and 16 nM, respectively) but very low inhibitory activities against JAK2 (IC<sub>50</sub> > 100 nM). However, compound <b>17c</b> possessed a balanced but mild JAK2 and HDAC6 inhibition with the IC<sub>50</sub> values at 69 and 88 nM, respectively.</div><div class="NLM_p">The inhibitory activities of the corresponding compounds <b>16a</b>–<b>h</b> against JAK2 were greatly decreased when the <i>para</i>- substituents were present on the phenyl moiety. To explain the phenomenon, we analyzed the binding modes of compound <b>15d</b> and compound <b>16b</b> in the ATP pocket of JAK2 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). The docking results in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A showed that, like compound <b>6a</b>, compound <b>15d</b> showed a similar binding mode with JAK2 protein. Aminopyrimidine moiety of compound <b>15d</b> forms dual hydrogen bonds with Leu932 and alkyl hydroxamate moiety forms multiple hydrogen bonds with the amino acid residues Ser936, Arg938, and Asp939. Therefore, compound <b>15d</b> exhibited comparable and potent JAK2 inhibitory activity to <b>6a</b> (IC<sub>50</sub> values: 32.9 vs 16.8 nM). It is worth noting that the <i>para-</i>site of the phenyl moiety in the ligand molecule <b>15d</b> was very close (3.7 Å, indicated by a red dashed line) to the Lys857 residue at the P-loop region. The introduction of a substituent in the <i>para-</i> site of the phenyl moiety may aggravate the repulsion force between the ligand molecule with the Lys857 residue of JAK2 protein. Therefore, in the binding mode of compound <b>16b</b> with JAK2 protein (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B), the dominant conformation of the phenyl moiety in the ligand molecule <b>16b</b> has undergone a huge change. The disadvantageous conformation change led to a sharp decrease in the JAK2 inhibitory activity of the ligand molecules (IC<sub>50</sub> > 100 nM). In addition, compound <b>15d</b> showed a similar binding mode with <b>16b</b> in the active site of HDAC6 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C,D), which rationally confirmed the comparable and potent HDAC6 inhibitory activity of compounds <b>15d</b> (IC<sub>50</sub> = 8.4 nM) and <b>16b</b> (62% inhibition at 10 nM).</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Predicted binding mode of compound <b>15d</b> in the ATP pocket of JAK2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>). (B) Predicted binding mode of compound <b>16b</b> in the ATP pocket of JAK2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>). (C) Predicted binding mode of compound <b>15d</b> in the active site of HDAC6 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI">5EEI</a>). (D) Predicted binding mode of compound <b>16b</b> in the active site of HDAC6 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI">5EEI</a>). Yellow dashed lines represent the hydrogen bonds. In the ligand, oxygen, nitrogen, carbon, fluoro, and in polar hydrogen atoms are shown in red, blue, green, pale cyan, and white, respectively. The repulsion force between the ligand molecule with the Lys857 residue of JAK2 protein was shown in a red dashed line. The figures were generated using PyMol (<a href="http://www.pymol.org/" class="extLink">http://www.pymol.org/</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02111&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In summary, we did a relatively comprehensive structure–activity relationship (SAR) study based on the linker length and R group. Aliphatic linker length of 5 or 6 methylenes, <i>para</i>-substituted phenyl, <i>ortho</i>-, and <i>meta</i>- halogen substituted benzyl groups were accepted in this series of potent JAK/HDAC dual inhibitors.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> JAK and HDAC Selectivity Profile</h3><div class="NLM_p">Because of their significant JAK2 and HDAC6 inhibitory activities, Compounds <b>6a</b>, <b>15c</b>, <b>15d</b>, <b>15g</b>, and <b>15h</b> were evaluated against JAK isoforms and HDAC isoforms to perform the JAK and HDAC selectivity profile. As depicted in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, this series of compounds exhibited potent but undifferentiated inhibitory activities against JAK1, JAK2, JAK3, and TYK2 with the IC<sub>50</sub> values between 4 and 40 nM (except that compound <b>6a</b> showed a mild inhibitory activity against JAK3 with the IC<sub>50</sub> value of 81.2 nM). Therefore, from the experimental results, these compounds tend to be pan-JAKs inhibitors. A comprehensive HDAC selectivity study on the representative compounds was also conducted. Results in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Tables <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> showed that compounds <b>6a</b>, <b>15c</b>, <b>15d</b>, <b>15g</b>, and <b>15h</b> all exhibited potent inhibitory activities against HDAC1 and HDAC6. Especially, compound <b>15d</b> broadly inhibited HDAC class I (HDACs 1, 3, 8), and HDAC class IIb (HDACs 6, 10), with IC<sub>50</sub> values of less than 50 nM. However, compound <b>15d</b> possessed very poor inhibitory activities against HDAC class IIa (HDACs 4, 7), with IC<sub>50</sub> values of larger than 10 μM (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. JAK Isoform and HDAC Selectivity Profiles of Representative Compounds<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" align="center">JAK2</th><th class="rowsep1 colsep0" align="center">JAK1</th><th class="rowsep1 colsep0" align="center">JAK3</th><th class="rowsep1 colsep0" align="center">TYK2</th><th class="rowsep1 colsep0" align="center">HDAC1</th><th class="rowsep1 colsep0" align="center">HDAC6</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>6a</b></td><td class="colsep0 rowsep0" align="center">16.8 ± 2.0</td><td class="colsep0 rowsep0" align="center">19.6 ± 3.2</td><td class="colsep0 rowsep0" align="center">81.2 ± 4.8</td><td class="colsep0 rowsep0" align="center">23.5 ± 0.2</td><td class="colsep0 rowsep0" align="center">52.1 ± 0.9</td><td class="colsep0 rowsep0" align="center">13.1 ± 2.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>15c</b></td><td class="colsep0 rowsep0" align="center">10.0 ± 0.3</td><td class="colsep0 rowsep0" align="center">32.3 ± 8.6</td><td class="colsep0 rowsep0" align="center">18.4 ± 3.1</td><td class="colsep0 rowsep0" align="center">13.3 ± 4.3</td><td class="colsep0 rowsep0" align="center">144.7 ± 23.7</td><td class="colsep0 rowsep0" align="center">15.3 ± 0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>15d</b></td><td class="colsep0 rowsep0" align="center">32.9 ± 8.2</td><td class="colsep0 rowsep0" align="center">33.4 ± 4.0</td><td class="colsep0 rowsep0" align="center">25.1 ± 0.2</td><td class="colsep0 rowsep0" align="center">40.9 ± 3.3</td><td class="colsep0 rowsep0" align="center">34.2 ± 1.3</td><td class="colsep0 rowsep0" align="center">8.4 ± 0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>15g</b></td><td class="colsep0 rowsep0" align="center">4.1 ± 0.7</td><td class="colsep0 rowsep0" align="center">8.7 ± 1.0</td><td class="colsep0 rowsep0" align="center">12.6 ± 1.9</td><td class="colsep0 rowsep0" align="center">15.0 ± 3.3</td><td class="colsep0 rowsep0" align="center">172.9 ± 11.0</td><td class="colsep0 rowsep0" align="center">13.7 ± 1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>15h</b></td><td class="colsep0 rowsep0" align="center">15.7 ± 3.7</td><td class="colsep0 rowsep0" align="center">19.9 ± 2.4</td><td class="colsep0 rowsep0" align="center">16.1 ± 0.1</td><td class="colsep0 rowsep0" align="center">21.7 ± 1.8</td><td class="colsep0 rowsep0" align="center">92.1 ± 19.1</td><td class="colsep0 rowsep0" align="center">14.7 ± 2.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>Ruxolitinib</b></td><td class="colsep0 rowsep0" align="center">2.9 ± 0.3</td><td class="colsep0 rowsep0" align="center">1.1 ± 0.1</td><td class="colsep0 rowsep0" align="center">20.7 ± 0.9</td><td class="colsep0 rowsep0" align="center">10.3 ± 5.1</td><td class="colsep0 rowsep0" align="center">ND<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>SAHA</b></td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">180.3 ± 10.9</td><td class="colsep0 rowsep0" align="center">75.9 ± 5.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Assays were performed in replicate (<i>n</i> ≥ 3), IC<sub>50</sub> values are shown as mean ± SD.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Not determined.</p></div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Further HDAC Selectivity Data for Representative Lead <b>15d</b><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char="±">HDAC class I</th><th class="rowsep1 colsep0" colspan="2" align="center">HDAC class IIa</th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">HDAC class IIb</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" align="center" char="±">HDAC1</th><th class="rowsep1 colsep0" align="center" char="±">HDAC3</th><th class="rowsep1 colsep0" align="center" char="±">HDAC8</th><th class="rowsep1 colsep0" align="center">HDAC4</th><th class="rowsep1 colsep0" align="center">HDAC7</th><th class="rowsep1 colsep0" align="center" char="±">HDAC6</th><th class="rowsep1 colsep0" align="center" char="±">HDAC10</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15d</b></td><td class="colsep0 rowsep0" align="char" char="±">34.2 ± 1.3</td><td class="colsep0 rowsep0" align="char" char="±">3.8 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">9.2 ± 0.8</td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="char" char="±">8.4 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">3.6 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SAHA</td><td class="colsep0 rowsep0" align="char" char="±">180.3 ± 10.9</td><td class="colsep0 rowsep0" align="char" char="±">28.1 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">191.5 ± 24.7</td><td class="colsep0 rowsep0" align="center">63.2 ± 7.7</td><td class="colsep0 rowsep0" align="center">75.2 ± 10.9</td><td class="colsep0 rowsep0" align="char" char="±">75.9 ± 5.2</td><td class="colsep0 rowsep0" align="char" char="±">47.5 ± 3.5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Assays were performed in replicate (<i>n</i> ≥ 3), IC<sub>50</sub> values are shown as mean ± SD.</p></div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Concurrent Inhibition of Intracellular JAK and HDAC</h3><div class="NLM_p">To confirm the intracellular dual actions of this series of JAK/HDAC dual inhibitors, Western blot analysis was performed. As the previous literature reported that concurrent inhibition of BRD4 or JAK sensitized breast cancer to HDAC inhibitors, we selected triple-negative breast cancer cell line MDA-MB-231 to perform the Western blot. Consistent with our previous findings, HDAC inhibitor SAHA at the concentration of 10 and 3 μM could cause the upregulation of phosphorylated STAT3, suggesting the restrained efficacy in breast cancer. Cotreatment of HDAC inhibitor SAHA with JAK inhibitor ruxolitinib (INCB) successfully suppressed the JAK-STAT pathway. To our delight, at the concentration of 10 μM, our designed compounds <b>15c</b>, <b>15d</b>, <b>15g</b>, and <b>15h</b> obviously increased the HDAC substrates acetyl-α-tubulin and acetyl-histone H3, suggesting the effective  of HDACs activity and meanwhile prevented the feedback activation of phosphorylated STAT3 in a dose-dependent manner compared to the control group, which validated that this series of newly designed compounds simultaneously inhibited JAKs and HDACs in MDA-MB-231 cells (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). At the low concentration of 3 μM, compounds <b>15c</b>, <b>15d</b>, <b>15g</b>, and <b>15h</b> also effectively simultaneously inhibited JAK and HDAC proteins in the MDA-MB-231 cell lines (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B). In this celluar assay, the inhibitory activities against JAK and HDAC proteins of compounds <b>15d</b> and <b>15h</b> were more potent than that of compounds <b>15c</b> and <b>15g</b>.</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) MDA-MB-231 cells were treated with DMSO or compounds at 10 μM for 12 h. (B) MDA-MB-231 cells were treated with DMSO or compounds at 3 μM for 12 h. The levels of phosphorylated STAT3 (<i>p</i>-STAT3-Tyr705), STAT3, acetyl-α-tubulin (Ac-tubulin), acetyl-H3K9/14 (Ac-H3K9/14) were determined by immunoblotting. β-Actin was used as a loading control. Ruxolitinib was indicated by INCB in the combined treatment group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02111&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Considering their potent inhibitory activities against JAK and HDAC proteins in MDA-MB-231 cell lines, we further verified the effect of the compounds <b>15d</b> and <b>15h</b> on the inhibition of the two target proteins JAK and HDAC in the triple-negative breast cancer cell line BT-549. The results in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> showed that similarly to results obtained in MDA-MB-231 cells, compounds <b>15d</b> and <b>15h</b> increased the levels of HDAC substrates, Ac-tubulin, and Ac-H3K9/14 yet did not cause the feedback activation of of p-STAT3 at the concentration of 3 μM, which further confirmed the JAK and HDAC dual inhibitory activity of the newly designed compounds at the cellular level.</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0006.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. BT-549 cells were treated with DMSO or compounds at 3 μM for 12 h. The levels of phosphorylated STAT3 (<i>p</i>-STAT3-Tyr705), acetyl-α-tubulin (Ac-tubulin), and acetyl-H3K9/14 (Ac-H3K9/14) were determined by immunoblotting. GAPDH was used as a loading control. Ruxolitinib was indicated by INCB in the combined treatment group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02111&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> In Vitro Antiproliferation Assay</h3><div class="NLM_p">JAK/HDAC dual inhibitors reported before tended to focus on hematological malignancies rather than solid tumors which were insensitive to JAK inhibitors or HDAC inhibitors. To further investigate the antiproliferative effect of these JAK/HDAC dual inhibitors on solid tumors, we selected hepatoma, renal cell adenocarcinoma, nonsmall cell lung carcinomas, colon cancer, and other three breast cancer cell lines as the research objects. The results in Supporting Information, <a class="ref internalNav" href="#notes-1" aria-label="Table S1">Table S1</a>, showed that most of our dual inhibitors, especially the compounds <b>6a</b>, <b>15d</b>, and <b>15h</b>, exhibited better antiproliferative activities against 4T1 and MDA-MB-231 breast cancer cell lines than other solid cancer cell lines. The antiproliferative results preliminarily validated that our designed compounds may provide an effective treatment for intractable breast cancers.</div><div class="NLM_p">Encouraged by the cell-based anticancer activity in breast cancer cells, we continue to select several breast cancer cells for further antiproliferative activity test. Results in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> showed that compounds <b>15d</b> and <b>15h</b> not only showed potent antiproliferative activities against the breast cancers 4T1 and MDA-MB-231, with the IC<sub>50</sub> values at the low digit micromolar level, but also inhibited the growth of BT-549, MDA-MB-468, and Cal-51 breast cancer cells. Meanwhile, in the BT-549 (IC<sub>50</sub> values: 2.41 vs 2.96 μM), MDA-MB-468 (IC<sub>50</sub> values: 2.08 vs 2.75 μM), and Cal-51 breast cancer cells (IC<sub>50</sub> values: 0.79 vs 1.04 μM), the antiproliferative activity of compound <b>15d</b> is slightly better than that of SAHA.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. In Vitro Antiproliferative Activities of Representative Compounds on the Breast Cancer Cells<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center" char=".">antiproliferative effect on breast cancer cells (IC<sub>50</sub>, μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">4T1</th><th class="colsep0 rowsep0" align="center" char=".">MDA-MB −231</th><th class="colsep0 rowsep0" align="center" char=".">BT-549</th><th class="colsep0 rowsep0" align="center" char=".">MDA-MB-468</th><th class="colsep0 rowsep0" align="center" char=".">Cal-51</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15d</b></td><td class="colsep0 rowsep0" align="char" char=".">2.87</td><td class="colsep0 rowsep0" align="char" char=".">3.83</td><td class="colsep0 rowsep0" align="char" char=".">2.41</td><td class="colsep0 rowsep0" align="char" char=".">2.08</td><td class="colsep0 rowsep0" align="char" char=".">0.79</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15h</b></td><td class="colsep0 rowsep0" align="char" char=".">3.72</td><td class="colsep0 rowsep0" align="char" char=".">3.94</td><td class="colsep0 rowsep0" align="char" char=".">3.02</td><td class="colsep0 rowsep0" align="char" char=".">2.45</td><td class="colsep0 rowsep0" align="char" char=".">1.28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SAHA</td><td class="colsep0 rowsep0" align="char" char=".">1.59</td><td class="colsep0 rowsep0" align="char" char=".">1.09</td><td class="colsep0 rowsep0" align="char" char=".">2.96</td><td class="colsep0 rowsep0" align="char" char=".">2.75</td><td class="colsep0 rowsep0" align="char" char=".">1.04</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Assays were performed in replicate (<i>n</i> ≥ 3).</p></div></div></div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Apoptosis Assay</h3><div class="NLM_p">Because compound <b>15d</b> exhibited excellent antiproliferative activity in breast cancer cells, we continue to select this compound for further studies on its pro-apoptotic activity via flow cytometry. Results in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a> showed that at the concentration of 2.5 μM, SAHA induced about 39% MDA-MB-231 cell apoptosis and possessed synergistic pro-apoptotic activity in combination with ruxolitinib (SAHA+ ruxolinib, about 72% MDA-MB-231 cell apoptosis). To our delight, compound <b>15d</b> induced MDA-MB-231 cell apoptosis in a dose-dependent manner. At the concentrations of 10 and 5 μM, compound <b>15d</b> could induce about 75% and 62% MDA-MB-231 cell apoptosis, suggesting a potent pro-apoptotic activity in MDA-MB-231 cells.</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0007.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Induction of apoptosis in MDA-MB-231 cells after 48 h of treatment. (B) Efficacy of compound <b>15d</b> at different concentrations to induce apoptosis in MDA-MB-231 cells after 48 h of treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02111&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Next, we further investigate the potency of compound <b>15d</b> in inducing cell apoptosis in the 4T1 cell lines. Results in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a> showed that compound <b>15d</b> induced 4T1 cell apoptosis in a dose-dependent manner. At the concentration of 5 μM, SAHA showed a very low pro-apoptotic potency on the 4T1 cell lines (about 20% 4T1 cell apoptosis). To our delight, at the same concentration of 5 μM, compound <b>15d</b> could induce about 90% 4T1 cell apoptosis, which is higher than that of SAHA and ruxolitinib combination group (about 35% 4T1 cell apoptosis). Therefore, it can be seen that for 4T1 solid tumor, compound <b>15d</b> as a JAK and HDAC dual inhibitor exhibited higher pro-apoptotic activity than the drugs combination group.</div><figure id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0008.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Induction of apoptosis in 4T1 cells after 48 h of treatment. (B) Efficacy of compound <b>15d</b> at different concentrations to induce apoptosis in 4T1 cells after 48 h of treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02111&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Blockage of LIFR-JAK-STAT Signaling Pathway Stimulated by the Crosstalk between Tumor Cells and Tumor Associated Fibroblasts</h3><div class="NLM_p">In addition to tumor cells, other cell components in the tumor microenvironment could also contribute to JAK-STAT signaling activation via secreting of IL-6 family of cytokines, such as LIF, leading to the activation of JAK-STAT signaling, which also contributes to the limited efficacy of HDAC inhibitors in breast cancer. Tumor associated fibroblast cells could secrete cytokines like LIF to activate JAK-STAT pathway. To investigate the effect of tumor microenvironment on HDAC inhibitor resistance in MDA-MB-231 cancer cells, we treated MDA-MB-231 cancer cells with the conditioned medium derived from tumor-associated Wl-38 fibroblasts. The results in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A,B showed that cytokines secreted by fibroblasts Wl-38 could upregulate the LIFR-JAK-STAT signaling pathway in MDA-MB-231 cancer cells. In the represence of conditioned medium, HDAC inhibitor SAHA further substantially amplified LIFR-JAK-STAT signaling pathway, presumably rendering tumors more resistant to drug. To our delight, at 3 μM, compounds <b>15d</b> and <b>15h</b> effectively diminished the LIFR-JAK-STAT signaling pathway, which demonstrated the potential therapeutic benefits of JAK and HDAC dual inhibitors in triple-negative breast cancer and provided a reasonable basis for the advantages in the in vivo experiment.</div><figure id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0009.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) Compounds <b>15d</b> and <b>15h</b> inhibited LIFR-JAK-STAT signaling in MDA-MB-231 stimulated by the  conditioned medium (CM) of Wl-38 cells. The concentrations of compounds <b>15d</b>, <b>15h</b>, and SAHA were all 3 μM in this Western blot. (B) Compounds <b>15d</b> and <b>15h</b> could diminish the activation of LIFR-JAK-STAT signaling triggered by tumor-associated fibroblasts, which suggests that JAK/HDAC dual inhibitors could potentially overcome the drug resistance caused by the tumor microenvironment and improve the in vivo anticancer activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02111&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Preliminary in Vivo Antitumor Activity Evaluation</h3><div class="NLM_p">Considering its potent antiproliferative and proapoptotic capacities in MDA-MB-231 breast cancer cell lines, compound <b>15d</b> was progressed into a preliminary in vivo antitumor activity study in a MDA-MB-231 xenograft model. Mice were randomly separated into six groups (<i>n</i> = 6/group) and treated with compound <b>15d</b> (30 or 100 mg/kg/day, IP), SAHA (100 mg/kg/day, PO), ruxolitinib (100 mg/kg/day, PO), combination of SAHA and ruxolitinib (100 + 100 mg/kg/day, PO) and saline for 14 consecutive days. Tumor growth inhibition (TGI) was calculated at the end of treatment. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a> and <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>, compound <b>15d</b> showed significant antitumor potency with TGI of 37% at the low dose of 30 mg/kg/day and 49% at the large dose of 100 mg/kg/day. The antitumor activity of compound <b>15d</b> is comparable to or slightly better than that of the combination group SAHA and Ruxolitinib. In addition, the body weight of mice in the low-dose administration (30 mg/kg/d, IP) group of compound <b>15d</b> did not change significantly, but the mice in the high-dose administration group (100 mg/kg/d, IP) showed some weight loss (about 15%). Nevertheless, the result indicated that compound <b>15d</b> as a potent JAK and HDAC dual inhibitor exhibited effective antitumor activity in vivo against triple-negative breast cancer.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. In Vivo Antitumor Efficacy in MDA-MB-231 Xenograft Model</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="left">administration</th><th class="colsep0 rowsep0" align="left">TGI (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SAHA</td><td class="colsep0 rowsep0" align="center">100 mg/kg/d, po</td><td class="colsep0 rowsep0" align="center">26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ruxolitinib</td><td class="colsep0 rowsep0" align="center">100 mg/kg/d, po</td><td class="colsep0 rowsep0" align="center">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SAHA + ruxolitinib</td><td class="colsep0 rowsep0" align="center">100 + 100 mg/kg/d, po</td><td class="colsep0 rowsep0" align="center">33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15d</b></td><td class="colsep0 rowsep0" align="center">30 mg/kg/d, ip</td><td class="colsep0 rowsep0" align="center">37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15d</b></td><td class="colsep0 rowsep0" align="center">100 mg/kg/d, ip</td><td class="colsep0 rowsep0" align="center">49<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Compared with the control group, the treated group showed statistically significant (<i>P</i> < 0.05) TGI by Student’s two-tailed <i>t</i> test.</p></div></div></div><figure id="fig10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0010.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Growth curve of the implanted MDA-MB-231 xenograft in mice (RTV ± SEM). Ruxolitinib was indicated by INCB.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02111&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Protein Kinase Selectivity Profile</h3><div class="NLM_p">Because of its potent JAK/HDAC dual inhibitory activities and anticancer capacities, compound <b>15d</b> was further tested against 134 kinases to characterize its protein kinase selective profiles at 50 and 500 nM, respectively. As depicted in Supporting Information, <a class="ref internalNav" href="#notes-1" aria-label="Table S2">Table S2</a> and <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>, at the concentration of 50 nM, compound <b>15d</b> exhibited over 75% inhibition of JAK1, JAK2, JAK3, and TYK2, which further confirmed that compound <b>15d</b> is a pan-JAK inhibitor. In addition, compound <b>15d</b> exhibited 65% inhibition of FMS-like receptor tyrosine kinase 3 (Flt3), which plays important roles in the progress of tumors. Although compound <b>15d</b> possessed strong inhibitory activities against other kinases, such as VEGFR-2, Met, FGFR at 500 nM, overall, compound <b>15d</b> was relatively selective to the inhibition of JAK.</div><figure id="fig11" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0011.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Kinome selectivity profiles for compound <b>15d</b>. Percent inhibition of phosphorylation of substrates at the indicated test compound concentration using a LANCE or HTRF detection method supplied by Eurofins Cerep Corporation. In these heat maps, inhibition <50% is assigned as green, inhibition >90% inhibition is assigned as red, and 50% < inhibition < 90% is assigned as yellow. In the kinome selectivity profiles, ATP concentration is close to the <i>K</i><sub>m</sub> of each tested kinase.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02111&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37572" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37572" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">It is urgent to develop a more effective therapy for the treatment of invasive solid tumors, especially triple-negative breast cancer. In the present work, a novel series of pyrrolo[2,3-<i>d</i>]pyrimidine-based derivatives simultaneously inhibiting JAKs and HDACs were rationally designed, synthesized, and evaluated. Most of these compounds possessed JAK/HDAC dual inhibitory activities with IC<sub>50</sub> values at nanomolar levels. Lead <b>15d</b>, as the representative compound, showed the potent antiproliferative and proapoptotic activities in several breast cancer cell lines. Western blot analysis confirmed that the newly designed compounds effectively and simultaneously inhibited JAK and HDAC proteins in the breast cancer cell lines. Besides, compounds <b>15d</b> and <b>15h</b> effectively downregulated the LIFR-JAK-STAT signaling pathway via the inhibition of phosphorylated STAT3, which implies that JAK/HDAC dual inhibitors can effectively overcome the drug resistance caused by the tumor microenvironment. More importantly, <b>15d</b> effectively inhibits tumor growth in MDA-MB-231-bearing mice. In summary, this work confirms the therapeutic potency of JAK and HDAC dual inhibitors and proposes a novel constructive antitumor mechanism for solid tumors.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70543" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70543" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Chemistry</h3><div class="NLM_p">Unless otherwise noted, all solvents and reagents were commercially available (Sinopharm, Bide, Adamas-beta, SigmaAldrich, TCI, J&K, etc.) and used without further purification. All reactions were monitored by thin-layer chromatography on 0.25 mm silica gel plates (60 GF-254) and visualized with UV light, or iodine vapor. <sup>1</sup>H NMR and <sup>13</sup>C NMR were generated in CDCl<sub>3</sub>, DMSO-<i>d</i><sub>6</sub>, or CD<sub>3</sub>OD on Varian Mercury 300, 400, or 500 NMR spectrometers. Chemical shifts were reported in parts per million (ppm). Multiplicity of <sup>1</sup>H NMR signals was reported as single (s), double (d), triplet (t), quarter (q), and multiplet (m). ESI (Low resolution mass spectra) were recorded on a Thermo Fisher LCQ-DECA spectrometer; ESI (high resolution mass spectra) were determined on an Agilent G6520 Q-TOF spectrometer. Melting points were determined on an electrothermal melting point apparatus and were uncorrected. All the final compounds achieved a minimum of 95% purity determined by HPLC analysis, which was carried out on an Agilent 1200 coupled with a diode array detector (DAD) and an extended C18 column (4.6 mm × 250 mm, 5 μm).</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> General Procedure for the Preparation of <b>6a</b>–<b>6g</b></h4><div id="sec4_1_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> <i>N</i>-Hydroxy-7-(4-((7-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanamide (<b>6a</b>)</h5><div class="NLM_p last">A mixture of ethyl 7-(4-((7-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14a</b>, 0.20 g, 0.46 mmol) in NH<sub>2</sub>OK/CH<sub>3</sub>OH (20 mL) was stirred at room temperature for 0.5 h. When TLC showed the reaction was completed, evaporation of the solvent under reduced pressure gave a residue, which was dissolved in water (20 mL). the mixture was neutralized by adding a 1 M HCl solution. The white precipitate was filtered and dried in cabinet drier to give the crude material. MeOH (3–5 mL) was added and the slurry was sonicated and then stirred at 40 °C for 4 h. The solids were collected by suction filtration and allowed to air-dry overnight to give the pure compound <b>6a</b> (0.15 g, 78% yield) as a white solid, mp 148–150 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.33 (s, 1H), 9.35 (s, 1H), 8.72 (s, 1H), 8.65 (s, 1H), 7.91 (s, 1H), 7.89–7.83 (m, 2H), 7.58 (dd, <i>J</i> = 9.7, 5.7 Hz, 3H), 7.47 (s, 1H), 7.40 (t, <i>J</i> = 7.4 Hz, 1H), 6.62 (d, <i>J</i> = 3.7 Hz, 1H), 3.98 (t, <i>J</i> = 7.0 Hz, 2H), 1.91 (t, <i>J</i> = 7.3 Hz, 2H), 1.70 (p, <i>J</i> = 7.0 Hz, 2H), 1.44 (p, <i>J</i> = 7.3 Hz, 2H), 1.22 (h, <i>J</i> = 6.9, 6.4 Hz, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.5, 156.2, 152.2, 151.4, 137.9, 129.7, 126.8, 126.0, 123.8, 119.2, 112.2, 102.4, 51.9, 32.6, 30.2, 28.6, 26.2, 25.4. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>26</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 420.2142, found 420.2151. Retention time: 7.6 min, eluted with 23% acetonitrile/77% water (containing 0.4% formic acid).</div></div><div id="sec4_1_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> 7-(4-((7-(4-Bromophenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyheptanamide (<b>6b</b>)</h5><div class="NLM_p last">Ethyl 7-(4-((7-(4-bromophenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14b</b>, 0.10 g, 0.19 mmol) was reacted using a procedure similar to the synthesis of <b>6a</b>, affording compound <b>6b</b> (0.08 g, 83% yield) as a white solid, mp 182–184 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.31 (s, 1H), 9.39 (s, 1H), 8.73 (d, <i>J</i> = 3.2 Hz, 1H), 8.65 (s, 1H), 7.96–7.69 (m, 5H), 7.58 (dd, <i>J</i> = 7.6, 3.8 Hz, 1H), 7.47 (d, <i>J</i> = 2.9 Hz, 1H), 6.65 (t, <i>J</i> = 3.5 Hz, 1H), 4.02 (t, <i>J</i> = 7.2 Hz, 2H), 2.03–1.87 (m, 2H), 1.72 (q, <i>J</i> = 7.2 Hz, 2H), 1.45 (p, <i>J</i> = 7.3 Hz, 2H), 1.39–1.12 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.5, 156.6, 138.3, 137.2, 132.5, 129.6, 125.8, 125.6, 123.9, 119.2, 102.7, 51.9, 32.6, 30.3, 28.6, 26.3, 25.5. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>24</sub>BrN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 498.1248, found 498.1248. Retention time: 28.7 min, eluted with 23% acetonitrile/77% water (containing 0.4% formic acid).</div></div><div id="sec4_1_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> 7-(4-((7-(4-Chlorophenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyheptanamide (<b>6c</b>)</h5><div class="NLM_p last">Ethyl 7-(4-((7-(4-chlorophenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14c</b>, 0.08 g, 0.17 mmol) was reacted using a procedure similar to the synthesis of <b>6a</b>, affording compound <b>6c</b> (0.06 g, 77% yield) as a white solid, mp 185–187 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.30 (s, 1H), 9.37 (s, 1H), 8.72 (s, 1H), 8.63 (s, 1H), 7.95–7.84 (m, 3H), 7.66–7.61 (m, 2H), 7.57 (d, <i>J</i> = 3.7 Hz, 1H), 7.46 (s, 1H), 6.64 (d, <i>J</i> = 3.7 Hz, 1H), 4.00 (t, <i>J</i> = 7.1 Hz, 2H), 1.90 (t, <i>J</i> = 7.4 Hz, 2H), 1.70 (p, <i>J</i> = 7.2 Hz, 2H), 1.44 (p, <i>J</i> = 7.4 Hz, 2H), 1.22 (p, <i>J</i> = 8.6 Hz, 4H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 169.4, 156.4, 152.2, 151.8, 136.8, 130.9, 129.7, 129.6, 125.6, 125.3, 123.8, 119.2, 112.2, 102.7, 51.9, 32.6, 30.3, 28.6, 26.3, 25.5. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>25</sub>ClN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 454.1753 found 454.1751. Retention time: 22.5 min, eluted with 23% acetonitrile/77% water (containing 0.4% formic acid).</div></div><div id="sec4_1_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> 7-(4-((7-(4-Fluorophenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyheptanamide (<b>6d</b>)</h5><div class="NLM_p last">Ethyl 7-(4-((7-(4-fluorophenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14d</b>, 0.08 g, 0.17 mmol) was reacted using a procedure similar to the synthesis of <b>6a</b>, affording compound <b>6d</b> (0.06 g, 77% yield) as a white solid, mp 173–175 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.30 (s, 1H), 9.35 (s, 1H), 8.72 (s, 1H), 8.63 (d, <i>J</i> = 1.8 Hz, 1H), 7.96–7.81 (m, 3H), 7.53 (d, <i>J</i> = 3.7 Hz, 1H), 7.49–7.38 (m, 3H), 6.62 (d, <i>J</i> = 3.7 Hz, 1H), 3.99 (t, <i>J</i> = 7.1 Hz, 2H), 1.89 (t, <i>J</i> = 7.4 Hz, 2H), 1.69 (t, <i>J</i> = 7.2 Hz, 2H), 1.43 (t, <i>J</i> = 7.3 Hz, 2H), 1.27–1.09 (m, 4H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.5, 161.6, 159.7, 152.3, 134.2, 129.8, 126.0, 123.7, 119.3, 116.5, 116.3, 102.3, 51.8, 32.6, 30.2, 28.6, 26.2, 25.4. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>25</sub>FN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 438.2048, found 438.2055. Retention time: 9.4 min, eluted with 23% acetonitrile/77% water (containing 0.4% formic acid).</div></div><div id="sec4_1_1_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> 7-(4-((7-(4-(Methylsulfonyl)phenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyheptanamide (<b>6e</b>)</h5><div class="NLM_p last">Ethyl 7-(4-((7-(4-(methylsulfonyl)phenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14e</b>, 0.10 g, 0.19 mmol) was reacted using a procedure similar to the synthesis of <b>6a</b>, affording compound <b>6e</b> (0.08 g, 83% yield) as a white solid, mp 198–200 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.32 (s, 1H), 9.44 (s, 1H), 8.77 (s, 1H), 8.65 (s, 1H), 8.26 (d, <i>J</i> = 8.5 Hz, 2H), 8.12 (d, <i>J</i> = 8.5 Hz, 2H), 7.92 (s, 1H), 7.73 (d, <i>J</i> = 3.8 Hz, 1H), 7.53 (s, 1H), 6.72 (d, <i>J</i> = 3.8 Hz, 1H), 4.04 (t, <i>J</i> = 7.1 Hz, 2H), 3.30 (s, 3H), 1.91 (t, <i>J</i> = 7.4 Hz, 2H), 1.79–1.67 (m, 2H), 1.52–1.38 (m, 2H), 1.24 (d, <i>J</i> = 6.1 Hz, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.5, 156.7, 142.1, 129.9, 128.7, 123.7, 123.5, 51.9, 44.1, 32.6, 30.4, 28.6, 26.2, 25.5. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>27</sub>N<sub>7</sub>O<sub>4</sub>S [M + H]<sup>+</sup> 498.1918, found 498.1917. Retention time: 8.5 min, eluted with 23% acetonitrile/77% water (containing 0.4% formic acid).</div></div><div id="sec4_1_1_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> 6-(4-((7-(4-(Methylsulfonyl)phenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyhexanamide (<b>6f</b>)</h5><div class="NLM_p last">Ethyl 6-(4-((7-(4-(methylsulfonyl)phenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>16f</b>, 0.10 g, 0.20 mmol) was reacted using a procedure similar to the synthesis of <b>6a</b>, affording compound <b>6f</b> (0.08 g, 83% yield) as a white solid, mp 208–210 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.36 (s, 1H), 9.46 (s, 1H), 8.77 (s, 2H), 8.26 (d, <i>J</i> = 8.7 Hz, 2H), 8.13 (d, <i>J</i> = 8.6 Hz, 2H), 7.91 (s, 1H), 7.73 (d, <i>J</i> = 3.7 Hz, 1H), 7.54 (s, 1H), 6.73 (d, <i>J</i> = 3.8 Hz, 1H), 4.04 (t, <i>J</i> = 6.9 Hz, 2H), 3.37 (s, 3H), 1.92 (t, <i>J</i> = 7.3 Hz, 2H), 1.80–1.67 (m, 2H), 1.60–1.43 (m, 2H), 1.21 (dt, <i>J</i> = 15.1, 7.6 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.4, 156.7, 152.6, 152.2, 142.1, 138.1, 129.9, 128.7, 125.1, 123.8, 123.5, 119.5, 103.6, 51.8, 44.1, 32.5, 30.2, 26.1, 25.1. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>25</sub>N<sub>7</sub>O<sub>4</sub>S [M + H]<sup>+</sup> 484.1761, found 484.1762. Retention time: 3.8 min, eluted with 23% acetonitrile/77% water (containing 0.4% formic acid).</div></div><div id="sec4_1_1_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> 6-(4-((7-(4-Bromophenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyhexanamide (<b>6g</b>)</h5><div class="NLM_p last">Ethyl 6-(4-((7-(4-bromophenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl) amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>14g</b>, 0.10 g, 0.20 mmol) was reacted using a procedure similar to the synthesis of <b>6a</b>, affording compound <b>6g</b> (0.09 g, 93% yield) as a white solid, mp 174–176 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.30 (s, 1H), 9.37 (s, 1H), 8.72 (d, <i>J</i> = 3.0 Hz, 1H), 8.64 (s, 1H), 7.94–7.68 (m, 5H), 7.57 (dd, <i>J</i> = 7.6, 3.7 Hz, 1H), 7.47 (s, 1H), 6.63 (t, <i>J</i> = 3.5 Hz, 1H), 4.00 (t, <i>J</i> = 7.1 Hz, 2H), 1.91 (td, <i>J</i> = 7.5, 5.2 Hz, 2H), 1.71 (p, <i>J</i> = 7.2 Hz, 2H), 1.50 (h, <i>J</i> = 7.2 Hz, 2H), 1.25–1.13 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 169.3, 156.6, 152.0, 138.3, 137.3, 132.5, 129.7, 125.8, 125.7, 123.9, 119.2, 119.1, 102.7, 51.8, 32.6, 30.2, 26.2, 25.2. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>22</sub>BrN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 484.1091, found 484.1112. Retention time: 17.9 min, eluted with 23% acetonitrile/77% water (containing 0.4% formic acid).</div></div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> The Procedures for the Preparation of Compounds <b>8</b>, <b>9</b>, <b>10a</b>,<b>b</b>, and <b>11a</b>,<b>b</b> Were Described in Our Previous Paper.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></h4><div id="sec4_1_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> General Procedure for the Preparation of <b>13a</b>–<b>13e</b>; 2-Chloro-7-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13a</b>)</h5><div class="NLM_p last">To a solution of 2-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (1.0 g, 6.51 mmol) and iodobenzene (2.66 g, 13.02 mmol) in dioxane (20 mL) was added CuI (0.5 g, 7.24 mmol), K<sub>3</sub>PO<sub>4</sub> (2.0 g, 9.46 mmol), and <i>trans</i>-1,2-cyclohexanediamine (0.20 g, 1.94 mmol). The resulting mixture was irradiated in a microwave (150 W) at 130 °C for 1 h. The resulting mixture was filtered through Celite and concentrated under reduced pressure to give a residue, which was dissolved in DCM (300 mL). The organic layer was washed with water (100 mL) and brine (100 mL), dried over sodium sulfate, filtered, and concentrated to give the crude product, which was purified by silica gel chromatography (CH<sub>2</sub>Cl<sub>2</sub>/EtOAc, 20:1 V/V) to give compound <b>13a</b> (0.3 g, 20% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.08 (s, 1H), 8.08 (d, <i>J</i> = 3.7 Hz, 1H), 7.87–7.79 (m, 2H), 7.69–7.59 (m, 2H), 7.49 (ddt, <i>J</i> = 7.9, 6.9, 1.1 Hz, 1H), 6.95 (d, <i>J</i> = 3.7 Hz, 1H). ESI-MS <i>m</i>/<i>z</i> = 230.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> 7-(4-Bromophenyl)-2-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13b</b>)</h5><div class="NLM_p last">2-Chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (0.5 g, 3.26 mmol) and 1-bromo-4-iodobenzene (0.65 g, 2.30 mmol) were reacted using a procedure similar to the synthesis of <b>13a</b>, affording compound <b>13b</b> (0.5 g, 50% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.10 (s, 1H), 8.20 (d, <i>J</i> = 3.8 Hz, 1H), 8.16 (s, 4H), 7.01 (d, <i>J</i> = 3.8 Hz, 1H), 3.31 (s, 3H). ESI-MS <i>m</i>/<i>z</i> = 308.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> 2-Chloro-7-(4-chlorophenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13c</b>)</h5><div class="NLM_p last">2-Chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (0.68 g, 4.43 mmol) and 1-chloro-4-iodobenzene (2.11 g, 8.86 mmol) were reacted using a procedure similar to the synthesis of <b>13a</b>, affording compound <b>13c</b> (0.45 g, 39% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.04 (s, 1H), 8.05 (d, <i>J</i> = 3.7 Hz, 1H), 7.91–7.78 (m, 2H), 7.74–7.61 (m, 2H), 6.92 (d, <i>J</i> = 3.7 Hz, 1H). ESI-MS <i>m</i>/<i>z</i> = 265.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_2_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> 2-Chloro-7-(4-fluorophenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13d</b>)</h5><div class="NLM_p last">2-Chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (0.50 g, 3.26 mmol) and 1-fluoro-4-iodobenzene (1.45 g, 6.51 mmol) were reacted using a procedure similar to the synthesis of <b>13a</b>, affording compound <b>13d</b> (0.20 g, 25% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 9.04 (s, 1H), 8.02 (d, <i>J</i> = 3.7 Hz, 1H), 7.87–7.77 (m, 2H), 7.50–7.39 (m, 2H), 6.91 (dd, <i>J</i> = 3.7, 0.7 Hz, 1H). ESI-MS <i>m</i>/<i>z</i> = 248.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_2_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> 2-Chloro-7-(4-(methylsulfonyl)phenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13e</b>)</h5><div class="NLM_p last">2-Chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (0.5 g, 3.26 mmol) and 1-bromo-4-(methylsulfonyl)benzene (0.65 g, 2.66 mmol) were reacted using a procedure similar to the synthesis of <b>13a</b>, affording compound <b>13e</b> (0.5 g, 50% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 9.10 (s, 1H), 8.20 (d, <i>J</i> = 3.8 Hz, 1H), 8.16 (s, 4H), 7.01 (d, <i>J</i> = 3.8 Hz, 1H), 3.31 (s, 3H). ESI-MS <i>m</i>/<i>z</i> = 308.2 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> General Procedure for the Preparation of <b>13f</b>–<b>13s</b></h4><div id="sec4_1_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> 7-Benzyl-2-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13f</b>)</h5><div class="NLM_p last">To a solution of 2-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (0.8 g, 5.22 mmol) and (bromomethyl)benzene (0.97 g, 5.75 mmol) in acetonitrile (80 mL) was added K<sub>2</sub>CO<sub>3</sub> (1.4 g, 10.44 mmol). The resulting mixture was heated at 40–50 °C for 5 h. The resulting mixture was filtered through Celite and concentrated under reduced pressure to give a residue, which was dissolved in DCM (150 mL). The organic layer was washed with citric acid (100 mL), water (100 mL), and brine (100 mL), dried over sodium sulfate, filtered, and concentrated to give the crude product, which was purified by silica gel chromatography (petroleum ether/EtOAc, 8:1 v/v) to give compound <b>13f</b> (1.0 g, 78% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.96 (s, 1H), 7.75 (d, <i>J</i> = 3.6 Hz, 1H), 7.39–7.19 (m, 5H), 6.73 (d, <i>J</i> = 3.6 Hz, 1H), 5.45 (s, 2H). ESI-MS <i>m</i>/<i>z</i> = 244.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> 2-Chloro-7-(2-fluorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13g</b>)</h5><div class="NLM_p last">2-Chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (0.5 g, 3.26 mmol) and 1-(bromomethyl)-2-fluorobenzene (0.70 g, 3.74 mmol) were reacted using a procedure similar to the synthesis of <b>13f</b>, affording compound <b>13g</b> (0.78 g, 92% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.96 (s, 1H), 7.77–7.61 (m, 1H), 7.37 (td, <i>J</i> = 7.6, 1.8 Hz, 1H), 7.28–7.20 (m, 1H), 7.20–7.08 (m, 2H), 6.74 (d, <i>J</i> = 3.6 Hz, 1H), 5.49 (d, <i>J</i> = 13.4 Hz, 2H). ESI-MS <i>m</i>/<i>z</i> = 262.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> 2-Chloro-7-(2-chlorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13h</b>)</h5><div class="NLM_p last">2-Chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (0.6 g, 3.91 mmol) and 1-(bromomethyl)-2-chlorobenzene (0.88 g, 4.30 mmol) were reacted using a procedure similar to the synthesis of <b>13f</b>, affording compound <b>13h</b> (0.87 g, 80% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.96 (s, 1H), 7.65 (d, <i>J</i> = 3.6 Hz, 1H), 7.51 (dd, <i>J</i> = 7.9, 1.3 Hz, 1H), 7.30 (dtd, <i>J</i> = 29.3, 7.5, 1.5 Hz, 2H), 6.82 (dd, <i>J</i> = 7.7, 1.7 Hz, 1H), 6.75 (d, <i>J</i> = 3.7 Hz, 1H), 5.52 (s, 2H). ESI-MS <i>m</i>/<i>z</i> = 279.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_3_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> 2-Chloro-7-(3-fluorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13i</b>)</h5><div class="NLM_p last">2-Chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (0.5 g, 3.26 mmol) and 1-(bromomethyl)-3-fluorobenzene (0.64 g, 2.78 mmol) were reacted using a procedure similar to the synthesis of <b>13f</b>, affording compound <b>13i</b> (0.80 g, 96% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.96 (s, 1H), 7.77 (d, <i>J</i> = 3.6 Hz, 1H), 7.39 (td, <i>J</i> = 7.9, 6.0 Hz, 1H), 7.25–6.96 (m, 3H), 6.75 (d, <i>J</i> = 3.6 Hz, 1H), 5.48 (s, 2H). ESI-MS <i>m</i>/<i>z</i> = 262.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_3_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> 2-Chloro-7-(3-chlorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13j</b>)</h5><div class="NLM_p last">2-Chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (0.5 g, 3.26 mmol) and 1-(bromomethyl)-3-chlorobenzene (0.73 g, 3.58 mmol) were reacted using a procedure similar to the synthesis of <b>13f</b>, affording compound <b>13j</b> (0.78 g, 86% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.96 (s, 1H), 7.77 (d, <i>J</i> = 3.6 Hz, 1H), 7.41–7.31 (m, 3H), 7.16 (ddd, <i>J</i> = 5.5, 3.1, 1.8 Hz, 1H), 6.74 (d, <i>J</i> = 3.6 Hz, 1H), 5.46 (s, 2H). ESI-MS <i>m</i>/<i>z</i> = 279.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_3_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> 2-Chloro-7-(3-methoxybenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13k</b>)</h5><div class="NLM_p last">2-Chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (0.5 g, 3.26 mmol) and 1-(chloromethyl)-3-methoxybenzene (0.56 g, 3.58 mmol) were reacted using a procedure similar to the synthesis of <b>13f</b>, affording compound <b>13k</b> (0.70 g, 78% yield) as a white solid. ESI-MS <i>m</i>/<i>z</i> = 273.9 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_3_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> 2-Chloro-7-(4-fluorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13l</b>)</h5><div class="NLM_p last">2-Chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (0.5 g, 3.26 mmol) and 1-(bromomethyl)-4-fluorobenzene (0.64 g, 2.78 mmol) were reacted using a procedure similar to the synthesis of <b>13f</b>, affording compound <b>13l</b> (0.70 g, 82% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.95 (s, 1H), 7.74 (d, <i>J</i> = 3.6 Hz, 1H), 7.37–7.28 (m, 2H), 7.22–7.13 (m, 2H), 6.73 (d, <i>J</i> = 3.6 Hz, 1H), 5.44 (s, 2H). ESI-MS <i>m</i>/<i>z</i> = 262.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_3_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> 2-Chloro-7-(4-chlorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13m</b>)</h5><div class="NLM_p last">2-Chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (0.50 g, 3.26 mmol) and 1-(bromomethyl)-4-chlorobenzene (0.75 g, 3.27 mmol) were reacted using a procedure similar to the synthesis of <b>13f</b>, affording compound <b>13m</b> (0.70 g, 78% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.96 (s, 1H), 7.75 (d, <i>J</i> = 3.6 Hz, 1H), 7.45–7.37 (m, 2H), 7.30–7.22 (m, 2H), 6.74 (d, <i>J</i> = 3.6 Hz, 1H), 5.45 (s, 2H). ESI-MS <i>m</i>/<i>z</i> = 278.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_3_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> 2-Chloro-7-(4-methylbenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13n</b>)</h5><div class="NLM_p last">2-Chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (0.50 g, 3.26 mmol) and 1-(bromomethyl)-4-methylbenzene (0.60 g, 3.27 mmol) were reacted using a procedure similar to the synthesis of <b>13f</b>, affording compound <b>13n</b> (0.70 g, 83% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.94 (s, 1H), 7.71 (d, <i>J</i> = 3.6 Hz, 1H), 7.15 (s, 4H), 6.71 (d, <i>J</i> = 3.6 Hz, 1H), 5.40 (s, 2H), 2.26 (s, 3H). ESI-MS <i>m</i>/<i>z</i> = 258.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_3_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> 2-Chloro-7-(4-methoxybenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13o</b>)</h5><div class="NLM_p last">2-Chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (0.50 g, 3.26 mmol) and 1-(bromomethyl)-4-methoxybenzene (0.65 g, 3.27 mmol) were reacted using a procedure similar to the synthesis of <b>13f</b>, affording compound <b>13o</b> (0.70 g, 79% yield) as a white solid. ESI-MS <i>m</i>/<i>z</i> = 274.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_3_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> 2-Chloro-7-phenethyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13p</b>)</h5><div class="NLM_p last">2-Chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (0.50 g, 3.26 mmol) and (2-bromoethyl)benzene (0.60 g, 3.27 mmol) were reacted using a procedure similar to the synthesis of <b>13f</b>, affording compound <b>13p</b> (0.70 g, 83% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.88 (s, 1H), 7.58 (d, <i>J</i> = 3.6 Hz, 1H), 7.28–7.08 (m, 5H), 6.62 (d, <i>J</i> = 3.6 Hz, 1H), 4.46 (dd, <i>J</i> = 7.7, 6.7 Hz, 2H), 3.11 (t, <i>J</i> = 7.2 Hz, 2H). ESI-MS <i>m</i>/<i>z</i> = 258.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_3_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> 2-Chloro-7-cyclopentyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13q</b>)</h5><div class="NLM_p last">2-Chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (0.7 g, 4.56 mmol) and bromocyclopentane (1.36 g, 9.12 mmol) were reacted using a procedure similar to the synthesis of <b>13f</b>, affording compound <b>13q</b> (0.70 g, 69% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.91 (s, 1H), 7.79 (d, <i>J</i> = 3.7 Hz, 1H), 6.71 (d, <i>J</i> = 3.7 Hz, 1H), 5.12–5.04 (m, 1H), 2.14 (ddt, <i>J</i> = 10.9, 5.3, 2.8 Hz, 2H), 1.93–1.83 (m, 4H), 1.76–1.67 (m, 2H). ESI-MS <i>m</i>/<i>z</i> = 222.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_3_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> 2-Chloro-7-(cyclopropylmethyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13r</b>)</h5><div class="NLM_p last">2-Chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (1.0 g, 6.51 mmol) and (bromomethyl)cyclopropane (1.05 g, 7.81 mmol) were reacted using a procedure similar to the synthesis of <b>13f</b>, affording compound <b>13r</b> (0.90 g, 67% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.92 (s, 1H), 7.76 (d, <i>J</i> = 3.6 Hz, 1H), 6.69 (d, <i>J</i> = 3.6 Hz, 1H), 4.08 (d, <i>J</i> = 7.2 Hz, 2H), 1.31–1.22 (m, 1H), 0.51 (dt, <i>J</i> = 8.0, 3.0 Hz, 2H), 0.47–0.38 (m, 2H). ESI-MS <i>m</i>/<i>z</i> = 208.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_3_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> 2-Chloro-7-(cyclohexylmethyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13s</b>)</h5><div class="NLM_p last">2-Chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (1.0 g, 6.51 mmol) and (bromomethyl)cyclohexane (1.38 g, 7.81 mmol) were reacted using a procedure similar to the synthesis of <b>13f</b>, affording compound <b>13s</b> (1.20 g, 74% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.92 (s, 1H), 7.67 (d, <i>J</i> = 3.5 Hz, 1H), 6.69 (d, <i>J</i> = 3.5 Hz, 1H), 4.06 (d, <i>J</i> = 7.4 Hz, 2H), 1.85 (dqd, <i>J</i> = 11.1, 7.5, 3.8 Hz, 1H), 1.65 (h, <i>J</i> = 4.2, 3.4 Hz, 2H), 1.59 (s, 1H), 1.48–1.43 (m, 2H), 1.20–1.10 (m, 3H), 0.97 (qd, <i>J</i> = 11.5, 3.5 Hz, 2H). ESI-MS <i>m</i>/<i>z</i> = 250.1 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> General Procedure for the Preparation of <b>14a</b>–<b>14z</b> and <b>14A</b>–<b>14F</b></h4><div id="sec4_1_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> Ethyl 7-(4-((7-Phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14a</b>)</h5><div class="NLM_p last">2-Chloro-7-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13a</b>, 0.23 g, 1.00 mmol) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate (hydrochloride) (<b>11b</b>, 0.20 g, 0.83 mmol) were suspended in ethanol (16 mL). The mixture was irradiated in a microwave (150 W) at 125 °C for 2–3 h. Evaporation of the solvent under reduced pressure gave a residue, which was preliminarily purified by silica gel chromatography (CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>3</sub>OH/Et<sub>3</sub>N, 100:1:0.25 v/v/v) to give the product <b>14a</b> (0.10 g, yield 27%) as a white solid. ESI-MS <i>m</i>/<i>z</i> = 433.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> Ethyl 7-(4-((7-(4-Bromophenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14b</b>)</h5><div class="NLM_p last">7-(4-Bromophenyl)-2-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13b</b>, 0.3 g, 0.97 mmol) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate (hydrochloride) (<b>11b</b>, 0.25 g, 0.91 mmol) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14b</b> (0.10 g, yield 22%) as a white solid. ESI-MS <i>m</i>/<i>z</i> = 511.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> Ethyl 7-(4-((7-(4-Chlorophenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14c</b>)</h5><div class="NLM_p last">2-Chloro-7-(4-chlorophenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13c</b>, 0.26 g, 1.00 mmol) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate (hydrochloride) (<b>11b</b>, 0.20 g, 0.83 mmol) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14c</b> (0.08 g, yield 20%) as a white solid. ESI-MS <i>m</i>/<i>z</i> = 467.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> Ethyl 7-(4-((7-(4-Fluorophenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14d</b>)</h5><div class="NLM_p last">2-Chloro-7-(4-fluorophenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13d</b>, 0.22 g, 0.90 mmol) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate (hydrochloride) (<b>11b</b>, 0.18 g, 0.75 mmol) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14d</b> (0.08 g, yield 20%) as a white solid. ESI-MS <i>m</i>/<i>z</i> = 451.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> Ethyl 7-(4-((7-(4-(Methylsulfonyl)phenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl) amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14e</b>)</h5><div class="NLM_p last">2-Chloro-7-(4-(methylsulfonyl)phenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13e</b>, 0.30 g, 0.97 mmol) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate (hydrochloride) (<b>11b</b>, 0.25 g, 0.91 mmol) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14e</b> (0.10 g, yield 20%) as a white solid. ESI-MS <i>m</i>/<i>z</i> = 511.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> Ethyl 6-(4-((7-(4-(Methylsulfonyl)phenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl) amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>14f</b>)</h5><div class="NLM_p last">2-Chloro-7-(4-(methylsulfonyl)phenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13e</b>, 0.30 g, 0.97 mmol) and ethyl 6-(4-amino-1<i>H</i>-pyrazol-1-yl)hexanoate (hydrochloride) (<b>11a</b>, 0.25 g, 0.95 mmol) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14f</b> (0.10 g, 22% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.45 (s, 1H), 8.77 (s, 1H), 8.25 (d, <i>J</i> = 8.8 Hz, 2H), 8.12 (d, <i>J</i> = 8.6 Hz, 2H), 7.92 (s, 1H), 7.73 (d, <i>J</i> = 3.8 Hz, 1H), 7.52 (s, 1H), 6.72 (d, <i>J</i> = 3.8 Hz, 1H), 4.04 (q, <i>J</i> = 6.3, 5.7 Hz, 2H), 3.95 (t, <i>J</i> = 6.6 Hz, 2H), 3.30 (s, 3H), 2.25 (t, <i>J</i> = 7.3 Hz, 2H), 1.80–1.68 (m, 2H), 1.52–1.47 (m, 2H), 1.26–1.21 (m, 2H), 0.84 (t, <i>J</i> = 7.4 Hz, 3H). ESI-MS <i>m</i>/<i>z</i> = 497.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> Ethyl 6-(4-((7-(4-Bromophenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>14g</b>)</h5><div class="NLM_p last">7-(4-Bromophenyl)-2-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13b</b>, 0.3 g, 0.97 mmol) and ethyl 6-(4-amino-1<i>H</i>-pyrazol-1-yl)hexanoate (hydrochloride) (<b>11a</b>, 0.25 g, 0.95 mmol) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14g</b> (0.15 g, 32% yield) as a white solid. ESI-MS <i>m</i>/<i>z</i> = 497.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> Ethyl 6-(4-((7-Benzyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>14h</b>)</h5><div class="NLM_p last">7-Benzyl-2-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13f</b>, 0.35 g, 1.44 mmol) and ethyl 6-(4-amino-1<i>H</i>-pyrazol-1-yl)hexanoate (hydrochloride) (<b>11a</b>, 0.25 g, 0.95 mmol) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14h</b> (0.18 g, 45% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 9.23 (s, 1H), 8.63 (s, 1H), 8.02–7.84 (m, 1H), 7.49 (d, <i>J</i> = 0.9 Hz, 1H), 7.30 (dtd, <i>J</i> = 12.0, 8.3, 7.7, 5.8 Hz, 6H), 6.43 (d, <i>J</i> = 3.5 Hz, 1H), 5.38 (s, 2H), 4.02 (tt, <i>J</i> = 7.1, 3.8 Hz, 4H), 2.23 (dt, <i>J</i> = 14.6, 7.3 Hz, 2H), 1.71 (h, <i>J</i> = 8.3, 7.7 Hz, 2H), 1.60–1.43 (m, 2H), 1.28–1.17 (m, 2H), 1.15 (d, <i>J</i> = 6.9 Hz, 3H). ESI-MS <i>m</i>/<i>z</i> = 433.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> Ethyl 7-(4-((7-Benzyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14i</b>)</h5><div class="NLM_p last">7-Benzyl-2-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13f</b>, 0.35 g, 1.44 mmol) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate (hydrochloride) (<b>11b</b>, 0.25 g, 0.91 mmol) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14i</b> (0.15 g, yield 38%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.23 (s, 1H), 8.63 (s, 1H), 7.93 (s, 1H), 7.48 (s, 1H), 7.34–7.22 (m, 6H), 6.43 (d, <i>J</i> = 3.5 Hz, 1H), 5.38 (s, 2H), 4.10–3.95 (m, 4H), 2.29–2.16 (m, 2H), 1.71 (p, <i>J</i> = 7.0 Hz, 2H), 1.48 (pd, <i>J</i> = 7.2, 2.4 Hz, 2H), 1.26 (ddd, <i>J</i> = 23.4, 11.8, 7.5 Hz, 4H), 1.18–1.05 (m, 3H). ESI-MS <i>m</i>/<i>z</i> = 447.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> Ethyl 6-(4-((7-(2-Fluorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>14j</b>)</h5><div class="NLM_p last">2-Chloro-7-(2-fluorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13g</b>, 0.35 g, 1.34 mmol) and ethyl 6-(4-amino-1<i>H</i>-pyrazol-1-yl)hexanoate (hydrochloride) (<b>11a</b>, 0.25 g, 0.95 mmol) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14j</b> (0.15 g, 35% yield) as a white solid. ESI-MS <i>m</i>/<i>z</i> = 451.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> Ethyl 7-(4-((7-(2-Fluorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14k</b>)</h5><div class="NLM_p last">2-Chloro-7-(2-fluorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13g</b>, 0.35 g, 1.34 mmol) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate (hydrochloride) (<b>11b</b>, 0.25 g, 0.91 mmol) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14k</b> (0.16 g, yield 38%) as a white solid. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.73 (s, 1H), 8.73 (s, 1H), 7.98 (s, 1H), 7.54 (s, 1H), 7.42 (d, <i>J</i> = 3.7 Hz, 1H), 7.39–7.34 (m, 1H), 7.25 (dd, <i>J</i> = 10.4, 8.2 Hz, 1H), 7.19 (t, <i>J</i> = 7.4 Hz, 1H), 7.14 (t, <i>J</i> = 7.4 Hz, 1H), 6.58 (d, <i>J</i> = 3.7 Hz, 1H), 5.46 (s, 2H), 4.07–4.00 (m, 4H), 2.24 (t, <i>J</i> = 7.4 Hz, 2H), 1.78–1.69 (m, 2H), 1.48 (q, <i>J</i> = 7.5 Hz, 2H), 1.25 (dq, <i>J</i> = 26.2, 7.8 Hz, 4H), 1.15 (t, <i>J</i> = 7.1 Hz, 3H). ESI-MS <i>m</i>/<i>z</i> = 465.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> Ethyl 6-(4-((7-(2-Chlorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>14l</b>)</h5><div class="NLM_p last">2-Chloro-7-(2-chlorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13h</b>, 0.37 g, 1.33 mmol) and ethyl 6-(4-amino-1<i>H</i>-pyrazol-1-yl)hexanoate (hydrochloride) (<b>11a</b>, 0.25 g, 0.95 mmol) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14l</b> (0.15 g, 30% yield) as a white solid. ESI-MS <i>m</i>/<i>z</i> = 467.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> Ethyl 7-(4-((7-(2-Chlorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14m</b>)</h5><div class="NLM_p last">2-Chloro-7-(2-<i>chloro</i>benzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13h</b>, 0.35 g, 1.25 mmol) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate (hydrochloride) (<b>11b</b>, 0.25 g, 0.91 mmol) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14m</b> (0.10 g, yield 20%) as a white solid. ESI-MS <i>m</i>/<i>z</i> = 481.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> Ethyl 6-(4-((7-(3-Fluorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>14n</b>)</h5><div class="NLM_p last">2-Chloro-7-(3-fluorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13i</b>, 0.35 g, 1.34 mmol) and ethyl 6-(4-amino-1<i>H</i>-pyrazol-1-yl)hexanoate (hydrochloride) (<b>11a</b>, 0.25 g, 0.95 mmol) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14n</b> (0.15 g, yield 35%) as a white solid. ESI-MS <i>m</i>/<i>z</i> = 451.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> Ethyl 7-(4-((7-(3-Fluorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14o</b>)</h5><div class="NLM_p last">2-Chloro-7-(3-fluorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13i</b>, 0.35 g, 1.34 mmol) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate (hydrochloride) (<b>11b</b>, 0.25 g, 0.91 mmol) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14o</b> (0.16 g, yield 38%) as a white solid. ESI-MS <i>m</i>/<i>z</i> = 465.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> Ethyl 6-(4-((7-(3-Chlorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>14p</b>)</h5><div class="NLM_p last">2-Chloro-7-(3-chlorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13j</b>, 0.37 g, 1.34 mmol) and ethyl 6-(4-amino-1<i>H</i>-pyrazol-1-yl)hexanoate (hydrochloride) (<b>11a</b>, 0.25 g, 0.95 mmol) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14p</b> (0.10 g, yield 20%) as a white solid. ESI-MS <i>m</i>/<i>z</i> = 467.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> Ethyl 7-(4-((7-(3-Chlorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14q</b>)</h5><div class="NLM_p last">2-Chloro-7-(3-chlorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13j</b>, 0.37 g, 1.34 mmol) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate (hydrochloride) (<b>11b</b>, 0.25 g, 0.91 mmol) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14q</b> (0.10 g, yield 20%) as a white solid. ESI-MS <i>m</i>/<i>z</i> = 481.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> Ethyl 6-(4-((7-(3-Methoxybenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>14r</b>)</h5><div class="NLM_p last">2-Chloro-7-(3-methoxybenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13k</b>, 0.37 g, 1.34 mmol) and ethyl 6-(4-amino-1<i>H</i>-pyrazol-1-yl)hexanoate (hydrochloride) (<b>11a</b>, 0.25 g, 0.95 mmol) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14r</b> (0.12 g, yield 27%) as a white solid. ESI-MS <i>m</i>/<i>z</i> = 463.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74"> Ethyl 7-(4-((7-(3-Methoxybenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14s</b>)</h5><div class="NLM_p last">2-Chloro-7-(3-methoxybenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13k</b>, 0.29 g, 1.09 mmol) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate (hydrochloride) (<b>11b</b>, 0.25 g, 0.91 mmol) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14s</b> (0.10 g, yield 20%) as a white solid. ESI-MS <i>m</i>/<i>z</i> = 477.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75"> Ethyl 6-(4-((7-(4-Fluorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1H-pyrazol-1-yl)hexanoate (<b>14t</b>)</h5><div class="NLM_p last">2-Chloro-7-(4-fluorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13l</b>, 0.35 g, 1.34 mmol) and ethyl 6-(4-amino-1<i>H</i>-pyrazol-1-yl)hexanoate (hydrochloride) (<b>11a</b>, 0.25 g, 0.95 mmol) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14t</b> (0.15 g, 35% yield) as a white solid. ESI-MS <i>m</i>/<i>z</i> = 451.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> Ethyl 7-(4-((7-(4-Fluorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14u</b>)</h5><div class="NLM_p last">2-Chloro-7-(4-fluorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13l</b>, 0.35 g, 1.34 mmol) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate (hydrochloride) (<b>11b</b>, 0.25 g, 0.91 mmol) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14u</b> (0.16 g, yield 38%) as a white solid. ESI-MS <i>m</i>/<i>z</i> = 465.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77"> Ethyl 6-(4-((7-(4-Chlorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>14v</b>)</h5><div class="NLM_p last">2-Chloro-7-(4-chlorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13m</b>, 0.35 g, 1.25 mmol) and ethyl 6-(4-amino-1<i>H</i>-pyrazol-1-yl)hexanoate (hydrochloride) (<b>11a</b>, 0.25 g, 0.95 mmol) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14v</b> (0.15 g, 34% yield) as a white solid. ESI-MS <i>m</i>/<i>z</i> = 467.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78"> Ethyl 7-(4-((7-(4-Chlorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14w</b>)</h5><div class="NLM_p last">2-Chloro-7-(4-chlorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13m</b>, 0.35 g, 1.25 mmol) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate (hydrochloride) (<b>11b</b>, 0.25 g, 0.91 mmol) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14w</b> (0.15 g, yield 34%) as a white solid. ESI-MS <i>m</i>/<i>z</i> = 481.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i79" class="anchor-spacer"></div><h5 class="article-section__title" id="_i79"> Ethyl 6-(4-((7-(4-Methylbenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>14x</b>)</h5><div class="NLM_p last">2-Chloro-7-(4-methylbenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13n</b>, 0.35 g, 1.36 mmol) and ethyl 6-(4-amino-1<i>H</i>-pyrazol-1-yl)hexanoate (hydrochloride) (<b>11a</b>, 0.25 g, 0.95 mmol) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14x</b> (0.20 g, 47% yield) as a white solid. ESI-MS <i>m</i>/<i>z</i> = 447.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4_25" class="NLM_sec NLM_sec_level_4"><div id="ac_i80" class="anchor-spacer"></div><h5 class="article-section__title" id="_i80"> Ethyl 7-(4-((7-(4-Methylbenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14y</b>)</h5><div class="NLM_p last">2-Chloro-7-(4-methylbenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13n</b>, 0.35 g, 1.36 mmol) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate (hydrochloride) (<b>11b</b>, 0.25 g, 0.91 mmol) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14y</b> (0.20 g, yield 47%) as a white solid. ESI-MS <i>m</i>/<i>z</i> = 461.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4_26" class="NLM_sec NLM_sec_level_4"><div id="ac_i81" class="anchor-spacer"></div><h5 class="article-section__title" id="_i81"> Ethyl 6-(4-((7-(4-Methoxybenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>14z</b>)</h5><div class="NLM_p last">2-Chloro-7-(4-methoxybenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine <b>(13o</b>, 0.35 g, 1.28 mmol) and ethyl 6-(4-amino-1<i>H</i>-pyrazol-1-yl)hexanoate (hydrochloride) (<b>11a</b>, 0.25 g, 0.95 mmol) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14z</b> (0.18 g, 41% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.23 (s, 1H), 8.61 (s, 1H), 8.04–7.95 (m, 1H), 7.51 (t, <i>J</i> = 0.7 Hz, 1H), 7.31–7.20 (m, 3H), 6.98–6.82 (m, 2H), 6.40 (d, <i>J</i> = 3.5 Hz, 1H), 5.30 (s, 2H), 4.09–3.95 (m, 4H), 3.70 (s, 3H), 2.23 (dt, <i>J</i> = 14.5, 7.4 Hz, 2H), 1.80–1.68 (m, 2H), 1.53 (td, <i>J</i> = 7.8, 3.0 Hz, 2H), 1.30–1.18 (m, 2H), 1.13 (d, <i>J</i> = 6.3 Hz, 3H). ESI-MS <i>m</i>/<i>z</i> = 463.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4_27" class="NLM_sec NLM_sec_level_4"><div id="ac_i82" class="anchor-spacer"></div><h5 class="article-section__title" id="_i82"> Ethyl 7-(4-((7-(4-Methoxybenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14A</b>)</h5><div class="NLM_p last">2-Chloro-7-(4-methoxybenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13o</b>, 0.35 g, 1.28 mmol) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate (hydrochloride) (<b>11b</b>, 0.25 g, 0.91 mmol) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14A</b> (0.18 g, yield 41%) as a white solid. ESI-MS <i>m</i>/<i>z</i> = 477.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4_28" class="NLM_sec NLM_sec_level_4"><div id="ac_i83" class="anchor-spacer"></div><h5 class="article-section__title" id="_i83"> Ethyl 6-(4-((7-Phenethyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>14B</b>)</h5><div class="NLM_p last">2-Chloro-7-phenethyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13p</b>, 0.35 g, 1.36 mmol) and ethyl 6-(4-amino-1<i>H</i>-pyrazol-1-yl)hexanoate (hydrochloride) (<b>11a</b>, 0.25 g, 0.95 mmol) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14B</b> (0.16 g, yield 38%) as a white solid. ESI-MS <i>m</i>/<i>z</i> = 447.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4_29" class="NLM_sec NLM_sec_level_4"><div id="ac_i84" class="anchor-spacer"></div><h5 class="article-section__title" id="_i84"> Ethyl 7-(4-((7-Phenethyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14C</b>)</h5><div class="NLM_p last">2-Chloro-7-phenethyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13p</b>, 0.35 g, 1.36 mmol) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate (hydrochloride) (<b>11b</b>, 0.25 g, 0.91 mmol) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14C</b> (0.16 g, yield 38%) as a white solid. ESI-MS <i>m</i>/<i>z</i> = 461.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4_30" class="NLM_sec NLM_sec_level_4"><div id="ac_i85" class="anchor-spacer"></div><h5 class="article-section__title" id="_i85"> Ethyl 7-(4-((7-Cyclopentyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14D</b>)</h5><div class="NLM_p last">2-Chloro-7-cyclopentyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13q</b>, 0.30 g, 1.35 mmol) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate (hydrochloride) (<b>11b</b>, 0.25 g, 0.91 mmol) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14D</b> (0.12 g, yield 21%) as a colorless oil. ESI-MS <i>m</i>/<i>z</i> = 425.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4_31" class="NLM_sec NLM_sec_level_4"><div id="ac_i86" class="anchor-spacer"></div><h5 class="article-section__title" id="_i86"> Ethyl 7-(4-((7-(Cyclopropylmethyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14E</b>)</h5><div class="NLM_p last">2-Chloro-7-(cyclopropylmethyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13r</b>, 0.28 g, 1.35 mmol) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate (hydrochloride) (<b>11b</b>, 0.25 g, 0.91 mmol) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14E</b> (0.10 g, 18% yield) as a colorless oil. ESI-MS <i>m</i>/<i>z</i> = 425.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4_32" class="NLM_sec NLM_sec_level_4"><div id="ac_i87" class="anchor-spacer"></div><h5 class="article-section__title" id="_i87"> Ethyl 7-(4-((7-(Cyclohexylmethyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14F</b>)</h5><div class="NLM_p last">2-Chloro-7-(cyclohexylmethyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13s</b>, 0.32 g, 1.35 mmol) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate (hydrochloride) (<b>11b</b>, 0.25 g, 0.91 mmol) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14F</b> (0.15 g, 25% yield) as a white solid. ESI-MS <i>m</i>/<i>z</i> = 453.3 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> General Procedure for the Preparation of <b>15a</b>–<b>l</b>, <b>16a</b>–<b>j</b>, and <b>17a</b>–<b>c</b></h4><div id="sec4_1_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i89" class="anchor-spacer"></div><h5 class="article-section__title" id="_i89"> 6-(4-((7-Benzyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyhexanamide (<b>15a</b>)</h5><div class="NLM_p last">Ethyl 6-(4-((7-benzyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl) hexanoate (<b>14h</b>, 0.16 g, 0.37 mmol) was reacted using a procedure similar to the synthesis of <b>6a</b>, affording compound <b>15a</b> (0.12 g, 80% yield) as a white solid, mp 160–162 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.39 (s, 1H), 9.24 (s, 1H), 8.70 (s, 1H), 8.63 (s, 1H), 7.92 (s, 1H), 7.50 (s, 1H), 7.29 (td, <i>J</i> = 12.0, 9.8, 5.7 Hz, 6H), 6.43 (d, <i>J</i> = 3.6 Hz, 1H), 5.39 (s, 2H), 4.02 (t, <i>J</i> = 6.9 Hz, 2H), 1.93 (t, <i>J</i> = 7.3 Hz, 2H), 1.72 (p, <i>J</i> = 7.2 Hz, 2H), 1.50 (p, <i>J</i> = 7.5 Hz, 2H), 1.20 (p, <i>J</i> = 7.7 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 169.4, 156.3, 152.3, 151.1, 138.6, 129.6, 129.0, 127.8, 127.5, 126.8, 124.2, 119.1, 111.5, 100.1, 51.6, 47.5, 32.6, 30.2, 26.1, 25.2. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>25</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 420.2142, found 420.2147. Retention time: 3.7 min, eluted with 23% acetonitrile/77% water (containing 0.4% formic acid).</div></div><div id="sec4_1_5_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i90" class="anchor-spacer"></div><h5 class="article-section__title" id="_i90"> 7-(4-((7-Benzyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyheptanamide (<b>15b</b>)</h5><div class="NLM_p last">Ethyl 7-(4-((7-benzyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl) heptanoate (<b>14i</b>, 0.12 g, 0.26 mmol) was reacted using a procedure similar to the synthesis of <b>6a</b>, affording compound <b>15b</b> (0.12 g, 95% yield) as a white solid, mp 150–152 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.35 (s, 1H) 9.23 (s, 1H), 8.67 (d, <i>J</i> = 1.8 Hz, 1H), 8.63 (s, 1H), 7.97–7.88 (m, 1H), 7.48 (d, <i>J</i> = 0.7 Hz, 1H), 7.36–7.22 (m, 6H), 6.43 (d, <i>J</i> = 3.6 Hz, 1H), 5.38 (s, 2H), 4.02 (t, <i>J</i> = 7.0 Hz, 2H), 1.92 (t, <i>J</i> = 7.3 Hz, 2H), 1.71 (q, <i>J</i> = 7.1 Hz, 2H), 1.44 (q, <i>J</i> = 7.2 Hz, 2H), 1.22 (d, <i>J</i> = 6.8 Hz, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.5, 156.3, 151.1, 138.6, 129.6, 129.0, 127.8, 127.5, 124.2, 119.1, 100.2, 51.7, 47.4, 32.6, 30.4, 28.6, 26.2, 25.4. ESI-MS <i>m</i>/<i>z</i> = 434 [M + H]<sup>+</sup>. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>27</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 434.2299, found 434.2304. Retention time: 5.5 min, eluted with 23% acetonitrile/77% water (containing 0.4% formic acid).</div></div><div id="sec4_1_5_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i91" class="anchor-spacer"></div><h5 class="article-section__title" id="_i91"> 6-(4-((7-(2-Fluorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyhexanamide (<b>15c</b>)</h5><div class="NLM_p last">Ethyl 6-(4-((7-(2-fluorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl) amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>14j</b>, 0.12 g, 0.26 mmol) was reacted using a procedure similar to the synthesis of <b>6a</b>, affording compound <b>15c</b> (0.08 g, 73% yield) as a white solid, mp 156–158 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.36 (s, 1H), 9.23 (s, 1H), 8.76 (s, 1H), 8.63 (s, 1H), 7.94 (s, 1H), 7.48 (s, 1H), 7.34 (dtd, <i>J</i> = 8.7, 5.6, 2.7 Hz, 1H), 7.29–7.21 (m, 2H), 7.12 (d, <i>J</i> = 6.2 Hz, 2H), 6.45 (d, <i>J</i> = 3.5 Hz, 1H), 5.44 (s, 2H), 4.02 (t, <i>J</i> = 7.0 Hz, 2H), 1.93 (t, <i>J</i> = 7.4 Hz, 2H), 1.80–1.63 (m, 2H), 1.59–1.41 (m, 2H), 1.21 (tt, <i>J</i> = 9.6, 6.3 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.4, 161.4, 159.0, 156.3, 152.3, 151.2, 130.1, 130.1, 129.8, 129.6, 126.7, 125.2, 125.1, 125.1, 124.2, 119.1, 115.9, 115.7, 111.4, 100.4, 51.7, 41.3, 32.6, 30.2, 26.1, 25.2. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>24</sub>FN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 438.2048, found 438.2053. Retention time: 4.6 min, eluted with 23% acetonitrile/77% water (containing 0.4% formic acid).</div></div><div id="sec4_1_5_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i92" class="anchor-spacer"></div><h5 class="article-section__title" id="_i92"> 7-(4-((7-(2-Fluorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyheptanamide (<b>15d</b>)</h5><div class="NLM_p last">Ethyl 7-(4-((7-(2-fluorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl) amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14k</b>, 0.15 g, 0.32 mmol) was reacted using a procedure similar to the synthesis of <b>6a</b>, affording compound <b>15d</b> (0.10 g, 70% yield) as a white solid, mp 158–160 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.31 (s, 1H), 9.22 (s, 1H), 8.63 (d, <i>J</i> = 16.2 Hz, 2H), 7.92 (s, 1H), 7.45 (s, 1H), 7.35–7.29 (m, 1H), 7.26–7.19 (m, 2H), 7.13–7.04 (m, 2H), 6.43 (d, <i>J</i> = 3.6 Hz, 1H), 5.42 (s, 2H), 4.00 (t, <i>J</i> = 7.0 Hz, 2H), 1.90 (t, <i>J</i> = 7.4 Hz, 2H), 1.70 (t, <i>J</i> = 7.2 Hz, 2H), 1.49–1.37 (m, 2H), 1.21 (q, <i>J</i> = 12.7, 8.3 Hz, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.5, 161.4, 159.0, 156.3, 152.3, 151.2, 130.1, 130.1, 129.8, 129.6, 126.7, 125.2, 125.1, 125.0, 124.2, 119.1, 115.9, 115.7, 111.4, 100.4, 51.7, 41.3, 32.6, 30.4, 28.6, 26.2, 25.5. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>26</sub>FN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 452.2205, found 452.2209. Retention time: 6.2 min, eluted with 25% acetonitrile/75% water (containing 0.4% formic acid).</div></div><div id="sec4_1_5_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i93" class="anchor-spacer"></div><h5 class="article-section__title" id="_i93"> 6-(4-((7-(2-Chlorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyhexanamide (<b>15e</b>)</h5><div class="NLM_p last">Ethyl 6-(4-((7-(2-chlorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>14l</b>, 0.12 g, 0.25 mmol) was reacted using a procedure similar to the synthesis of <b>6a</b>, affording compound <b>15e</b> (0.08 g, 68% yield) as a white solid, mp 172–174 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.35 (s, 1H), 9.25 (s, 1H), 8.67 (s, 2H), 7.82 (s, 1H), 7.54 (dd, <i>J</i> = 8.0, 1.3 Hz, 1H), 7.43 (s, 1H), 7.33 (td, <i>J</i> = 7.7, 1.8 Hz, 1H), 7.27–7.23 (m, 2H), 6.79 (s, 1H), 6.49 (d, <i>J</i> = 3.6 Hz, 1H), 5.48 (s, 2H), 3.97 (t, <i>J</i> = 7.0 Hz, 2H), 1.92 (t, <i>J</i> = 7.4 Hz, 2H), 1.69 (p, <i>J</i> = 7.4 Hz, 2H), 1.49 (p, <i>J</i> = 7.4 Hz, 2H), 1.18 (p, <i>J</i> = 7.7 Hz, 2H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.4, 156.3, 151.2, 135.7, 131.9, 129.8, 129.6, 128.7, 128.0, 126.8, 124.2, 100.4, 51.7, 45.2, 32.6, 30.2, 26.1, 25.1. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>25</sub>ClN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 454.1753, found 454.1749. Retention time: 8.7 min, eluted with 23% acetonitrile/77% water (containing 0.4% formic acid).</div></div><div id="sec4_1_5_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i94" class="anchor-spacer"></div><h5 class="article-section__title" id="_i94"> 7-(4-((7-(2-Chlorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyheptanamide (<b>15f</b>)</h5><div class="NLM_p last">Ethyl 7-(4-((7-(2-chlorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14m</b>, 0.10 g, 0.20 mmol) was reacted using a procedure similar to the synthesis of <b>6a</b>, affording compound <b>15f</b> (0.08 g, 82% yield) as a white solid, mp 168–170 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.35 (s, 1H), 9.25 (s, 1H), 8.71–8.64 (m, 2H), 7.83 (s, 1H), 7.54 (dd, <i>J</i> = 8.0, 1.2 Hz, 1H), 7.42 (s, 1H), 7.33 (td, <i>J</i> = 7.7, 1.7 Hz, 1H), 7.27–7.22 (m, 2H), 6.78 (d, <i>J</i> = 7.7 Hz, 1H), 6.49 (d, <i>J</i> = 3.6 Hz, 1H), 5.48 (s, 2H), 3.98 (t, <i>J</i> = 7.0 Hz, 2H), 1.92 (t, <i>J</i> = 7.4 Hz, 2H), 1.68 (p, <i>J</i> = 7.2 Hz, 2H), 1.45 (p, <i>J</i> = 7.4 Hz, 2H), 1.22 (dp, <i>J</i> = 22.3, 7.4 Hz, 4H). <sup>13</sup>C NMR (124 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.5, 156.3, 152.5, 151.2, 131.9, 129.8, 129.6, 128.7, 128.0, 126.8, 124.2, 118.9, 100.5, 51.8, 45.2, 32.6, 30.4, 28.6, 26.2, 25.4. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>27</sub>ClN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 468.1909, found 468.1900. Retention time: 11.7 min, eluted with 23% acetonitrile/77% water (containing 0.4% formic acid).</div></div><div id="sec4_1_5_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i95" class="anchor-spacer"></div><h5 class="article-section__title" id="_i95"> 6-(4-((7-(3-Fluorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyhexanamide (<b>15g</b>)</h5><div class="NLM_p last">Ethyl 6-(4-((7-(3-fluorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>14n</b>, 0.16 g, 0.35 mmol) was reacted using a procedure similar to the synthesis of <b>6a</b>, affording compound <b>15g</b> (0.10 g, 67% yield) as a white solid, mp 156–158 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.35 (s, 1H), 9.23 (s, 1H), 8.64 (s, 2H), 7.91 (s, 1H), 7.48 (s, 1H), 7.41–7.33 (m, 1H), 7.31 (d, <i>J</i> = 3.6 Hz, 1H), 7.14–7.04 (m, 3H), 6.45 (d, <i>J</i> = 3.6 Hz, 1H), 5.41 (s, 2H), 4.02 (t, <i>J</i> = 7.0 Hz, 2H), 1.92 (t, <i>J</i> = 7.4 Hz, 2H), 1.72 (p, <i>J</i> = 7.2 Hz, 2H), 1.49 (h, <i>J</i> = 7.2 Hz, 2H), 1.29–1.12 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.4, 163.8, 161.4, 156.3, 152.3, 151.2, 141.6, 141.5, 131.1, 131.0, 129.6, 126.7, 124.2, 123.5, 123.5, 119.1, 114.7, 114.5, 114.4, 114.2, 100.3, 51.6, 46.9, 32.6, 30.2, 26.1, 25.1. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>24</sub>FN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 438.2048, found 438.2049. Retention time: 4.7 min, eluted with 23% acetonitrile/77% water (containing 0.4% formic acid).</div></div><div id="sec4_1_5_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i96" class="anchor-spacer"></div><h5 class="article-section__title" id="_i96"> 7-(4-((7-(3-Fluorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyheptanamide (<b>15h</b>)</h5><div class="NLM_p last">Ethyl 7-(4-((7-(3-fluorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl) amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14o</b>, 0.15 g, 0.32 mmol) was reacted using a procedure similar to the synthesis of <b>6a</b>, affording compound <b>15h</b> (0.10 g, 70% yield) as a white solid, mp 158–160 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.33 (s, 1H), 9.23 (s, 1H), 8.63 (s, 2H), 7.91 (s, 1H), 7.47 (s, 1H), 7.41–7.32 (m, 1H), 7.30 (d, <i>J</i> = 3.6 Hz, 1H), 7.13–7.06 (m, 3H), 6.44 (d, <i>J</i> = 3.6 Hz, 1H), 5.40 (s, 2H), 4.02 (t, <i>J</i> = 7.0 Hz, 2H), 1.92 (t, <i>J</i> = 7.4 Hz, 2H), 1.71 (t, <i>J</i> = 7.1 Hz, 2H), 1.51–1.40 (m, 2H), 1.21 (dd, <i>J</i> = 8.1, 4.5 Hz, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.5, 163.8, 161.4, 156.3, 152.3, 151.2, 141.6, 141.5, 131.1, 131.0, 129.6, 126.7, 124.1, 123.5, 123.5, 119.1, 114.7, 114.5, 114.4, 114.2, 100.3, 51.7, 46.9, 32.6, 30.4, 28.6, 26.2, 25.4. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>26</sub>FN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 452.2205, found 452.2205. Retention time:6.7 min, eluted with 23% acetonitrile/77% water (containing 0.4% formic acid).</div></div><div id="sec4_1_5_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i97" class="anchor-spacer"></div><h5 class="article-section__title" id="_i97"> 6-(4-((7-(3-Chlorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyhexanamide (<b>15i</b>)</h5><div class="NLM_p last">Ethyl 6-(4-((7-(3-fluorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>14p</b>, 0.06 g, 0.13 mmol) was reacted using a procedure similar to the synthesis of <b>6a</b>, affording compound <b>15i</b> (0.05 g, 86% yield) as a white solid, mp 160–162 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.32 (s, 1H), 9.46 (s, 1H), 9.23 (s, 1H), 8.64 (s, 1H), 8.62 (s, 1H), 7.89 (s, 1H), 7.46 (s, 1H), 7.36–7.29 (m, 3H), 7.20 (dd, <i>J</i> = 6.8, 2.1 Hz, 1H), 6.43 (d, <i>J</i> = 3.6 Hz, 1H), 5.38 (s, 2H), 4.00 (t, <i>J</i> = 7.0 Hz, 2H), 1.90 (t, <i>J</i> = 7.4 Hz, 2H), 1.76–1.63 (m, 2H), 1.54–1.43 (m, 2H), 1.19 (q, <i>J</i> = 7.8 Hz, 2H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.4, 141.0, 133.6, 131.0, 129.8, 127.8, 127.4, 126.2, 123.8, 119.4, 111.5, 100.6, 51.7, 46.9, 32.6, 30.2, 26.1, 25.1. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>25</sub>ClN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 454.1753, found 454.1755. Retention time: 8.2 min, eluted with 23% acetonitrile/77% water (containing 0.4% formic acid).</div></div><div id="sec4_1_5_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i98" class="anchor-spacer"></div><h5 class="article-section__title" id="_i98"> 7-(4-((7-(3-Chlorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyheptanamide (<b>15j</b>)</h5><div class="NLM_p last">Ethyl 7-(4-((7-(3-chlorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14q</b>, 0.09 g, 0.18 mmol) was reacted using a procedure similar to the synthesis of <b>6a</b>, affording compound <b>15j</b> (0.08 g, 91% yield) as a white solid, mp 150–152 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.33 (s, 1H), 9.24 (s, 1H), 8.63 (d, <i>J</i> = 12.3 Hz, 2H), 7.90 (s, 1H), 7.46 (s, 1H), 7.35–7.27 (m, 4H), 7.19 (d, <i>J</i> = 7.0 Hz, 1H), 6.43 (d, <i>J</i> = 3.5 Hz, 1H), 5.38 (s, 2H), 4.00 (t, <i>J</i> = 7.0 Hz, 2H), 1.89 (t, <i>J</i> = 7.4 Hz, 2H), 1.69 (t, <i>J</i> = 7.1 Hz, 2H), 1.43 (t, <i>J</i> = 7.3 Hz, 2H), 1.20 (h, <i>J</i> = 7.3 Hz, 4H).<sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 169.4, 140.8, 133.6, 131.0, 127.9, 127.5, 126.3, 51.8, 47.0, 32.6, 30.3, 28.6, 26.2, 25.4. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>27</sub>ClN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 468.1909, found 468.1917. Retention time: 11.3 min, eluted with 23% acetonitrile/77% water (containing 0.4% formic acid).</div></div><div id="sec4_1_5_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i99" class="anchor-spacer"></div><h5 class="article-section__title" id="_i99"> <i>N</i>-Hydroxy-6-(4-((7-(3-methoxybenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)hexanamide (<b>15k</b>)</h5><div class="NLM_p last">Ethyl 6-(4-((7-(3-methoxybenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>14r</b>, 0.10 g, 0.21 mmol) was reacted using a procedure similar to the synthesis of <b>6a</b>, affording compound <b>15k</b> (0.07 g, 72% yield) as a white solid, mp 148–150 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.34 (s, 1H), 9.27 (s, 1H), 8.64 (s, 2H), 7.93 (s, 1H), 7.51 (s, 1H), 7.30 (d, <i>J</i> = 3.6 Hz, 1H), 7.24 (t, <i>J</i> = 7.9 Hz, 1H), 6.88 (s, 1H), 6.83 (dt, <i>J</i> = 8.3, 2.5 Hz, 2H), 6.44 (d, <i>J</i> = 3.6 Hz, 1H), 5.35 (s, 2H), 4.02 (t, <i>J</i> = 7.0 Hz, 2H), 3.68 (s, 3H), 1.92 (t, <i>J</i> = 7.4 Hz, 2H), 1.78–1.68 (m, 2H), 1.55–1.46 (m, 2H), 1.29–1.14 (m, 2H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.4, 159.8, 140.1, 130.1, 129.7, 119.7, 119.2, 113.6, 112.9, 100.2, 55.4, 51.6, 47.4, 32.6, 30.2, 26.1, 25.1. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>28</sub>N<sub>7</sub>O<sub>3</sub> [M + H]<sup>+</sup> 450.2248, found 450.2259. Retention time: 4.4 min, eluted with 23% acetonitrile/77% water (containing 0.4% formic acid).</div></div><div id="sec4_1_5_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i100" class="anchor-spacer"></div><h5 class="article-section__title" id="_i100"> <i>N</i>-Hydroxy-7-(4-((7-(3-methoxybenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanamide (<b>15l</b>)</h5><div class="NLM_p last">Ethyl 7-(4-((7-(3-methoxybenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14s</b>, 0.09 g, 0.18 mmol) was reacted using a procedure similar to the synthesis of <b>6a</b>, affording compound <b>15l</b> (0.07 g, 80% yield) as a white solid, mp 145–147 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.31 (s, 1H), 9.22 (s, 1H), 8.62 (d, <i>J</i> = 20.4 Hz, 2H), 7.91 (s, 1H), 7.48 (s, 1H), 7.31–7.15 (m, 2H), 6.93–6.70 (m, 3H), 6.52–6.31 (m, 1H), 5.32 (s, 2H), 3.99 (d, <i>J</i> = 7.2 Hz, 2H), 3.66 (s, 3H), 1.90 (t, <i>J</i> = 7.3 Hz, 2H), 1.69 (t, <i>J</i> = 7.7 Hz, 2H), 1.53–1.38 (m, 2H), 1.20 (s, 4H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.5, 159.8, 152.3, 140.1, 130.1, 129.7, 119.7, 119.2, 113.6, 112.9, 100.3, 55.4, 51.7, 47.4, 32.6, 30.4, 28.6, 26.2, 25.4. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>30</sub>N<sub>7</sub>O<sub>3</sub> [M + H]<sup>+</sup> 464.2405, found 464.2405. Retention time: 5.8 min, eluted with 23% acetonitrile/77% water (containing 0.4% formic acid).</div></div><div id="sec4_1_5_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i101" class="anchor-spacer"></div><h5 class="article-section__title" id="_i101"> 6-(4-((7-(4-Fluorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyhexanamide (<b>16a</b>)</h5><div class="NLM_p last">Ethyl 6-(4-((7-(4-fluorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl) amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>14t</b>, 0.12 g, 0.26 mmol) was reacted using a procedure similar to the synthesis of <b>6a</b>, affording compound <b>16a</b> (0.08 g, 73% yield) as a white solid, mp 176–178 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.34 (s, 1H), 9.22 (s, 1H), 8.64 (d, <i>J</i> = 12.3 Hz, 2H), 7.92 (s, 1H), 7.50 (s, 1H), 7.40–7.29 (m, 2H), 7.27 (d, <i>J</i> = 3.6 Hz, 1H), 7.20–7.09 (m, 2H), 6.42 (d, <i>J</i> = 3.6 Hz, 1H), 5.37 (s, 2H), 4.02 (t, <i>J</i> = 7.0 Hz, 2H), 1.92 (t, <i>J</i> = 7.4 Hz, 2H), 1.72 (t, <i>J</i> = 7.5 Hz, 2H), 1.49 (q, <i>J</i> = 7.5 Hz, 2H), 1.30–1.14 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.4, 163.1, 160.6, 156.3, 152.2, 151.1, 134.8, 134.8, 129.7, 129.7, 129.6, 126.6, 124.2, 119.1, 115.9, 115.7, 111.5, 100.3, 51.6, 46.7, 32.6, 30.2, 26.1, 25.1. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>24</sub>FN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 438.2048, found 438.2043. Retention time: 5.1 min, eluted with 23% acetonitrile/77% water (containing 0.4% formic acid).</div></div><div id="sec4_1_5_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i102" class="anchor-spacer"></div><h5 class="article-section__title" id="_i102"> 7-(4-((7-(4-Fluorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyheptanamide (<b>16b</b>)</h5><div class="NLM_p last">Ethyl 7-(4-((7-(4-fluorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl) amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14u</b>, 0.15 g, 0.32 mmol) was reacted using a procedure similar to the synthesis of <b>6a</b>, affording compound <b>16b</b> (0.12 g, 83% yield) as a white solid, mp 160–162 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.34 (s, 1H), 9.22 (s, 1H), 8.63 (s, 2H), 7.91 (s, 1H), 7.50 (s, 1H), 7.37–7.30 (m, 2H), 7.26 (d, <i>J</i> = 3.6 Hz, 1H), 7.15 (t, <i>J</i> = 8.9 Hz, 2H), 6.42 (d, <i>J</i> = 3.5 Hz, 1H), 5.37 (s, 2H), 4.02 (t, <i>J</i> = 7.0 Hz, 2H), 1.92 (t, <i>J</i> = 7.4 Hz, 2H), 1.71 (t, <i>J</i> = 7.1 Hz, 2H), 1.50–1.41 (m, 2H), 1.28–1.19 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.5, 160.6, 156.3, 152.2, 151.1, 134.8, 134.8, 129.7, 129.6, 126.6, 124.2, 119.1, 115.9, 115.7, 100.3, 51.7, 46.7, 32.6, 30.4, 28.6, 26.2, 25.4. ESI-MS <i>m</i>/<i>z</i> = 452 [M + H]<sup>+</sup>. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>26</sub>FN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 452.2202, found 452.2201. Retention time: 7.5 min, eluted with 23% acetonitrile/77% water (containing 0.4% formic acid).</div></div><div id="sec4_1_5_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i103" class="anchor-spacer"></div><h5 class="article-section__title" id="_i103"> 6-(4-((7-(4-Chlorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyhexanamide (<b>16c</b>)</h5><div class="NLM_p last">Ethyl 6-(4-((7-(4-chlorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>14v</b>, 0.15 g, 0.32 mmol) was reacted using a procedure similar to the synthesis of <b>6a</b>, affording compound <b>16c</b> (0.10 g, 70% yield) as a white solid, mp 158–160 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.34 (s, 1H), 9.23 (s, 1H), 8.65 (d, <i>J</i> = 10.2 Hz, 2H), 7.88 (s, 1H), 7.49 (s, 1H), 7.44–7.35 (m, 2H), 7.28 (dd, <i>J</i> = 6.1, 2.5 Hz, 3H), 6.44 (d, <i>J</i> = 3.6 Hz, 1H), 5.39 (s, 2H), 4.02 (t, <i>J</i> = 7.0 Hz, 2H), 1.93 (t, <i>J</i> = 7.4 Hz, 2H), 1.72 (p, <i>J</i> = 7.2 Hz, 2H), 1.51 (p, <i>J</i> = 7.5 Hz, 2H), 1.20 (qd, <i>J</i> = 9.3, 8.7, 6.1 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.4, 156.3, 152.3, 151.2, 137.6, 132.4, 129.6, 129.4, 129.0, 126.7, 124.2, 119.1, 100.3, 51.6, 46.8, 32.6, 30.2, 26.1, 25.2. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>24</sub>ClN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 454.1753, found 454.1757. Retention time: 9.6 min, eluted with 23% acetonitrile/77% water (containing 0.4% formic acid).</div></div><div id="sec4_1_5_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i104" class="anchor-spacer"></div><h5 class="article-section__title" id="_i104"> 7-(4-((7-(4-Chlorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyheptanamide (<b>16d</b>)</h5><div class="NLM_p last">Ethyl 7-(4-((7-(4-chlorobenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14w</b>, 0.15 g, 0.31 mmol) was reacted using a procedure similar to the synthesis of <b>6a</b>, affording compound <b>16d</b> (0.10 g, 70% yield) as a white solid, mp 174–176 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.33 (s, 1H), 9.27 (s, 1H), 8.63 (s, 2H), 7.87 (s, 1H), 7.47 (d, <i>J</i> = 3.0 Hz, 1H), 7.39–7.24 (m, 5H), 6.44 (d, <i>J</i> = 3.6 Hz, 1H), 5.37 (s, 2H), 4.01 (t, <i>J</i> = 7.0 Hz, 2H), 1.91 (t, <i>J</i> = 7.4 Hz, 2H), 1.69 (p, <i>J</i> = 7.1 Hz, 2H), 1.45 (p, <i>J</i> = 7.3 Hz, 2H), 1.31–1.18 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.5, 156.3, 152.3, 151.2, 137.6, 132.4, 129.6, 129.3, 129.0, 126.7, 124.2, 119.1, 111.5, 100.3, 51.7, 46.8, 32.6, 30.4, 28.6, 26.2, 25.4. ESI-MS <i>m</i>/<i>z</i> = 468 [M + H]<sup>+</sup>. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>26</sub>ClN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 468.1909, found 468.1905. Retention time: 15.6 min, eluted with 23% acetonitrile/77% water (containing 0.4% formic acid).</div></div><div id="sec4_1_5_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i105" class="anchor-spacer"></div><h5 class="article-section__title" id="_i105"> 6-(4-((7-(4-Methylbenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyhexanamide (<b>16e</b>)</h5><div class="NLM_p last">Ethyl 6-(4-((7-(4-methylbenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>14x</b>, 0.15 g, 0.33 mmol) was reacted using a procedure similar to the synthesis of <b>6a</b>, affording compound <b>16e</b> (0.10 g, 70% yield) as a white solid, mp 140–142 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.34 (s, 1H), 9.21 (s, 1H), 8.64 (d, <i>J</i> = 17.4 Hz, 2H), 7.93 (s, 1H), 7.50 (s, 1H), 7.26 (d, <i>J</i> = 3.5 Hz, 1H), 7.22–7.09 (m, 4H), 6.41 (d, <i>J</i> = 3.6 Hz, 1H), 5.33 (s, 2H), 4.03 (t, <i>J</i> = 7.0 Hz, 2H), 2.25 (s, 3H), 1.93 (t, <i>J</i> = 7.4 Hz, 2H), 1.80–1.67 (m, 2H), 1.51 (p, <i>J</i> = 7.5 Hz, 2H), 1.21 (tt, <i>J</i> = 9.8, 6.4 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.4, 156.2, 152.2, 151.0, 137.0, 135.6, 129.6, 129.5, 127.6, 126.7, 124.2, 119.1, 111.5, 100.1, 51.7, 47.2, 32.6, 30.3, 26.1, 25.2, 21.1. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>27</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 434.2299, found 434,2294. Retention time: 7.6 min, eluted with 23% acetonitrile/77% water (containing 0.4% formic acid).</div></div><div id="sec4_1_5_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i106" class="anchor-spacer"></div><h5 class="article-section__title" id="_i106"> 7-(4-((7-(4-Methylbenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyheptanamide (<b>16f</b>)</h5><div class="NLM_p last">Ethyl 7-(4-((7-(4-methylbenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14y</b>, 0.15 g, 0.32 mmol) was reacted using a procedure similar to the synthesis of <b>6a</b>, affording compound <b>16f</b> (0.11 g, 70% yield) as a white solid, mp 166–168 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.35 (s, 1H), 9.20 (s, 1H), 8.62 (s, 2H), 7.94 (s, 1H), 7.50 (s, 1H), 7.25 (d, <i>J</i> = 3.5 Hz, 1H), 7.21–7.09 (m, 4H), 6.41 (d, <i>J</i> = 3.5 Hz, 1H), 5.33 (s, 2H), 4.03 (t, <i>J</i> = 7.0 Hz, 2H), 2.25 (s, 3H), 1.92 (t, <i>J</i> = 7.4 Hz, 2H), 1.72 (t, <i>J</i> = 7.0 Hz, 2H), 1.46 (t, <i>J</i> = 7.2 Hz, 2H), 1.31–1.17 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.5, 156.2, 152.2, 151.1, 137.0, 135.6, 129.6, 129.5, 127.6, 126.7, 124.2, 119.1, 111.5, 100.1, 51.7, 47.2, 32.6, 30.4, 28.6, 26.2, 25.5, 21.1. ESI-MS <i>m</i>/<i>z</i> = 448 [M + H]<sup>+</sup>. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>29</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 448.2455, found 448.2457. Retention time: 10.4 min, eluted with 23% acetonitrile/77% water (containing 0.4% formic acid).</div></div><div id="sec4_1_5_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i107" class="anchor-spacer"></div><h5 class="article-section__title" id="_i107"> 6-(4-((7-(4-Methoxybenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyhexanamide (<b>16g</b>)</h5><div class="NLM_p last">Ethyl 6-(4-((7-(4-methoxybenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>14z</b>, 0.10 g, 0.21 mmol) was reacted using a procedure similar to the synthesis of <b>6a</b>, affording compound <b>16g</b> (0.08 g, 95% yield) as a white solid, mp 118–120 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.36 (s, 1H), 9.23 (s, 1H), 8.70 (s, 1H), 8.62 (s, 1H), 7.97 (s, 1H), 7.52 (s, 1H), 7.29–7.22 (m, 3H), 6.91–6.84 (m, 2H), 6.40 (d, <i>J</i> = 3.5 Hz, 1H), 5.30 (s, 2H), 4.04 (t, <i>J</i> = 6.9 Hz, 2H), 3.70 (s, 3H), 1.93 (t, <i>J</i> = 7.4 Hz, 2H), 1.74 (t, <i>J</i> = 7.5 Hz, 2H), 1.51 (t, <i>J</i> = 7.5 Hz, 2H), 1.28–1.15 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.4, 159.0, 156.2, 152.2, 151.0, 130.5, 129.6, 129.1, 126.6, 124.3, 119.1, 114.4, 111.6, 100.1, 55.5, 51.7, 46.9, 32.6, 30.3, 26.1, 25.2. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>27</sub>N<sub>7</sub>O<sub>3</sub> [M + H]<sup>+</sup> 450.2248, found 450.2249. Retention time: 4.0 min, eluted with 23% acetonitrile/77% water (containing 0.4% formic acid).</div></div><div id="sec4_1_5_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i108" class="anchor-spacer"></div><h5 class="article-section__title" id="_i108"> 7-(4-((7-(4-Methoxybenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyheptanamide (<b>16h</b>)</h5><div class="NLM_p last">Ethyl 7-(4-((7-(4-methoxybenzyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14A</b>, 0.10 g, 0.21 mmol) was reacted using a procedure similar to the synthesis of <b>6a</b>, affording compound <b>16h</b> (0.08 g, 95% yield) as a white solid, mp 138–140 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.34 (s, 1H), 9.38 (s, 1H), 8.64 (s, 2H), 7.97 (s, 1H), 7.53 (s, 1H), 7.29 (d, <i>J</i> = 3.5 Hz, 1H), 7.25 (d, <i>J</i> = 8.6 Hz, 2H), 6.89–6.85 (m, 2H), 6.43 (d, <i>J</i> = 3.6 Hz, 1H), 5.30 (s, 2H), 4.04 (t, <i>J</i> = 7.0 Hz, 2H), 3.69 (s, 3H), 1.91 (t, <i>J</i> = 7.4 Hz, 2H), 1.72 (t, <i>J</i> = 7.1 Hz, 2H), 1.44 (q, <i>J</i> = 7.2 Hz, 2H), 1.22 (dq, <i>J</i> = 13.5, 6.9 Hz, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.5, 159.0, 156.2, 152.2, 151.0, 130.5, 129.6, 129.1, 126.5, 124.2, 119.1, 114.3, 114.2, 111.5, 100.1, 55.5, 51.7, 46.9, 32.6, 30.4, 28.6, 26.2, 25.5. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>29</sub>N<sub>7</sub>O<sub>3</sub> [M + H]<sup>+</sup> 464.2405, found 464.2408. Retention time: 5.9 min, eluted with 23% acetonitrile/77% water (containing 0.4% formic acid).</div></div><div id="sec4_1_5_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i109" class="anchor-spacer"></div><h5 class="article-section__title" id="_i109"> 6-(4-((7-Phenethyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyhexanamide (<b>16i</b>)</h5><div class="NLM_p last">Ethyl 6-(4-((7-phenethyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl) hexanoate (<b>14B</b>, 0.10 g, 0.22 mmol) was reacted using a procedure similar to the synthesis of <b>6a</b>, affording compound <b>16i</b> (0.08 g, 95% yield) as a white solid, mp 168–170 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.35 (s, 1H), 9.19 (s, 1H), 8.67 (s, 1H), 8.59 (s, 1H), 7.98 (s, 1H), 7.55 (s, 1H), 7.32–7.19 (m, 5H), 7.19–7.10 (m, 1H), 6.34 (d, <i>J</i> = 3.5 Hz, 1H), 4.38 (dd, <i>J</i> = 8.4, 6.6 Hz, 2H), 4.05 (t, <i>J</i> = 7.0 Hz, 2H), 3.12 (t, <i>J</i> = 7.5 Hz, 2H), 1.93 (t, <i>J</i> = 7.4 Hz, 2H), 1.80–1.71 (m, 2H), 1.55–1.46 (m, 2H), 1.29–1.16 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.4, 156.1, 152.2, 150.9, 139.0, 129.7, 129.0, 128.8, 126.8, 126.5, 124.4, 119.0, 99.6, 51.7, 45.4, 35.9, 32.6, 30.2, 26.1, 25.1. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>27</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 434.2299, found 434.2302. Retention time: 5.9 min, eluted with 25% acetonitrile/75% water (containing 0.4% formic acid).</div></div><div id="sec4_1_5_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i110" class="anchor-spacer"></div><h5 class="article-section__title" id="_i110"> 7-(4-((7-Phenethyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyheptanamide (<b>16j</b>)</h5><div class="NLM_p last">Ethyl 7-(4-((7-phenethyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl) heptanoate (<b>14C</b>, 0.15 g, 0.32 mmol) was reacted using a procedure similar to the synthesis of <b>6a</b>, affording compound <b>16j</b> (0.10 g, 70% yield) as a white solid, mp 158–160 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.36 (s, 1H), 9.41 (s, 1H), 9.18 (s, 1H), 8.59 (s, 1H), 7.99 (s, 1H), 7.55 (s, 1H), 7.32–7.18 (m, 5H), 7.13 (d, <i>J</i> = 3.6 Hz, 1H), 6.34 (d, <i>J</i> = 3.5 Hz, 1H), 4.38 (dd, <i>J</i> = 8.4, 6.5 Hz, 2H), 4.05 (t, <i>J</i> = 7.0 Hz, 2H), 3.12 (dd, <i>J</i> = 8.3, 6.6 Hz, 2H), 1.92 (t, <i>J</i> = 7.4 Hz, 2H), 1.74 (s, 2H), 1.46 (t, <i>J</i> = 7.3 Hz, 2H), 1.24 (p, <i>J</i> = 3.6 Hz, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.5, 156.1, 152.2, 150.9, 139.0, 129.7, 129.0, 128.8, 126.8, 126.5, 124.4, 119.1, 111.5, 99.6, 51.8, 45.4, 35.9, 32.6, 30.4, 28.6, 26.2, 25.5. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>29</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 448.2455, found 448.2454. Retention time: 7.0 min, eluted with 23% acetonitrile/77% water (containing 0.4% formic acid).</div></div><div id="sec4_1_5_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i111" class="anchor-spacer"></div><h5 class="article-section__title" id="_i111"> 7-(4-((7-Cyclopentyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyheptanamide (<b>17a</b>)</h5><div class="NLM_p last">Ethyl 7-(4-((7-cyclopentyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14D</b>, 0.12 g, 0.28 mmol) was reacted using a procedure similar to the synthesis of <b>6a</b>, affording compound <b>17a</b> (0.10 g, 86% yield) as a white solid, mp 159–161 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.30 (s, 1H), 9.13 (s, 1H), 8.63 (s, 1H), 8.57 (s, 1H), 7.92 (s, 1H), 7.54 (s, 1H), 7.24 (d, <i>J</i> = 3.7 Hz, 1H), 6.37 (d, <i>J</i> = 3.6 Hz, 1H), 4.96 (q, <i>J</i> = 7.5 Hz, 1H), 4.03 (t, <i>J</i> = 7.0 Hz, 2H), 2.11 (d, <i>J</i> = 7.9 Hz, 2H), 1.89 (q, <i>J</i> = 6.8, 6.4 Hz, 6H), 1.72 (q, <i>J</i> = 8.4, 7.3 Hz, 4H), 1.50–1.40 (m, 2H), 1.23 (s, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.4, 156.0, 150.9, 129.8, 124.4, 124.0, 119.1, 112.0, 99.9, 55.2, 51.7, 32.6, 32.1, 30.3, 28.6, 26.2, 25.4, 24.1. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>30</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 412.2455, found 412.2444. Retention time: 4.8 min, eluted with 23% acetonitrile/77% water (containing 0.4% formic acid).</div></div><div id="sec4_1_5_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i112" class="anchor-spacer"></div><h5 class="article-section__title" id="_i112"> 7-(4-((7-(Cyclopropylmethyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyheptanamide (<b>17b</b>)</h5><div class="NLM_p last">Ethyl 7-(4-((7-(cyclopropylmethyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14E</b>, 0.08 g, 0.19 mmol) was reacted using a procedure similar to the synthesis of <b>6a</b>, affording compound <b>17b</b> (0.06 g, 77% yield) as a white solid, mp 135–137 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.30 (s, 1H), 9.14 (s, 1H), 8.64 (d, <i>J</i> = 1.7 Hz, 1H), 8.59 (s, 1H), 7.95 (s, 1H), 7.53 (s, 1H), 7.23 (d, <i>J</i> = 3.6 Hz, 1H), 6.36 (d, <i>J</i> = 3.6 Hz, 1H), 4.08–3.95 (m, 4H), 1.91 (t, <i>J</i> = 7.4 Hz, 2H), 1.79–1.67 (m, 2H), 1.44 (q, <i>J</i> = 7.2 Hz, 2H), 1.23 (q, <i>J</i> = 8.1, 4.7 Hz, 5H), 0.48 (dtd, <i>J</i> = 7.8, 6.1, 5.5, 2.7 Hz, 2H), 0.42 (tt, <i>J</i> = 5.1, 2.6 Hz, 2H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.5, 156.2, 152.2, 150.9, 129.7, 126.5, 124.4, 119.1, 99.6, 51.7, 48.2, 32.6, 30.3, 28.6, 26.2, 25.4. 11.9. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>28</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 398.2299, found 398.2308. Retention time: 2.7 min, eluted with 23% acetonitrile/77% water (containing 0.4% formic acid).</div></div><div id="sec4_1_5_25" class="NLM_sec NLM_sec_level_4"><div id="ac_i113" class="anchor-spacer"></div><h5 class="article-section__title" id="_i113"> 7-(4-((7-(Cyclohexylmethyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyheptanamide (<b>17c</b>)</h5><div class="NLM_p last">Ethyl 7-(4-((7-(cyclohexylmethyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14F</b>, 0.10 g, 0.22 mmol) was reacted using a procedure similar to the synthesis of <b>6a</b>, affording compound <b>17c</b> (0.08 g, 82% yield) as a white solid, mp 142–144 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.32 (s, 1H), 9.17 (s, 1H), 8.63 (s, 1H), 8.58 (s, 1H), 7.99 (s, 1H), 7.50 (s, 1H), 7.14 (d, <i>J</i> = 3.6 Hz, 1H), 6.35 (d, <i>J</i> = 3.5 Hz, 1H), 4.03 (t, <i>J</i> = 7.0 Hz, 2H), 3.97 (d, <i>J</i> = 7.1 Hz, 2H), 1.90 (t, <i>J</i> = 7.4 Hz, 3H), 1.73 (s, 2H), 1.64 (s, 2H), 1.61–1.51 (m, 3H), 1.49–1.41 (m, 2H), 1.23 (s, 4H), 1.17–1.07 (m, 3H), 0.99 (d, <i>J</i> = 12.1 Hz, 2H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.4, 156.1, 152.5, 150.9, 129.5, 127.1, 124.5, 118.9, 111.4, 99.4, 51.8, 50.1, 38.4, 32.6, 30.8, 30.4, 28.6, 26.4, 26.3, 25.6, 25.4. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>34</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 440.2768, found 440.2766. Retention time: 16.7 min, eluted with 23% acetonitrile/77% water (containing 0.4% formic acid).</div></div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i114" class="anchor-spacer"></div><h3 class="article-section__title" id="_i114"> Molecular Docking Study</h3><div class="NLM_p last">The crystal structures of JAK2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>) and HDAC6 (PDB 5EEI) were obtained from the Protein Data Bank. Before the docking process, the structure of protein was treated by adding hydrogen atoms, deleting water molecules, assigning AMBER7 FF99 charges, and a 100-step minimization process using Sybyl X_2.1. The molecular structure was generated with the Sybyl/Sketch module and optimized using Powell’s method with the Tripos force field with convergence criterion set at 0.005 kcal/(Å mol) and assigned charges with the Gasteiger–Hückel method. Other docking parameters were kept to the default values. Molecular docking was carried out via the Sybyl/Surflex-Dock module.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i115" class="anchor-spacer"></div><h3 class="article-section__title" id="_i115"> Janus Kinase Inhibition Assay</h3><div class="NLM_p last">(1) Janus kinase 1/2/3 inhibition assay. Target compounds were dissolved in DMSO and centrifuged for 5 min to obtain 10<sup>–2</sup> M solution. The 10<sup>–2</sup> M target compound solutions were kept at 4 °C. The final concentration of DMSO in the assay was no more than 1%. In 384-well plates, a 5 μL enzyme system (50 mM HEPES pH 7.5, 1 mM EGTA, 10 mM MgCl<sub>2</sub>, 0.01% brij-35, 4 μM substrate, 0.4–5 ng/μL enzymes) was added with 2.5 μL of target compound solution, 2.5 μL of 200 μM ATP. The mixture was incubated at room temperature and away from light for 60 min. Subsequently, 5 μL of reagent A diluted with development buffer was added to each well and incubated at room temperature and away from light for 60 min. Then, 5 μL of stop solution was added to each well to terminate the reaction and incubated at room temperature and away from light for 10 min. Fluorescence intensity was measured using a microplate reader at excitation and emission wavelengths of 400 and 445/520 nm, respectively. Origin data analysis software were used to calculate the IC<sub>50</sub> data by the nonlinear curve fitting method (allowed to float and fitted as a parameter). (2) TYK2 kinase inhibition assay. Target compounds were dissolved in DMSO and centrifuged for 5 min to obtain 10<sup>–2</sup> M solution. The 10<sup>–2</sup> M target compound solutions were kept at 4 °C. The final concentration of DMSO in the assay was no more than 1%. In 384-well plates, 3 μL of enzyme system (5 mM MgCl<sub>2</sub>, 1 mM MnCl<sub>2</sub>, 1 mM DTT, 12.5 nM SEB, 0.8 ng/μL enzyme) was added with 4 μL of target compound solution, 3 μL of substrate mixture (33.3 μM ATP and 3.3 μM substrate) and incubated at room temperature for 40 min. Subsequently, 10 μL of premix of SA-XL665 and TK Ab was added to stop the reaction and incubated the plate at room temperature for 1 h and then read in a microplate reader using HTRF settings. GraphPad software were used to calculate the IC<sub>50</sub> data by the nonlinear curve fitting method (allowed to float and fitted as a parameter).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i116" class="anchor-spacer"></div><h3 class="article-section__title" id="_i116"> Protein Kinase Selectivity Profile</h3><div class="NLM_p last">The kinase inhibition assays were performed by Eurofins Cerep Corporation in France. In brief, evaluation of the effects of compounds on the activity of the kinases was quantified by measuring the phosphorylation of their substrates using human recombinant enzymes and the LANCE detection method. For example, evaluation of the effects of compounds on the activity of the human ALK quantified by measuring the phosphorylation of the substrate Ulight-CKKSRGDYMTMQIG (IRS-1) using a human recombinant enzyme and the LANCE detection method. The test compound, reference compound or water (control) were mixed with the enzyme (about 0.25 ng) in a buffer containing 40 mM Hepes/Tris (pH 7.4), 0.8 mM EGTA/Tris, 8 mM MgCl<sub>2</sub>, 1.6 mM DTT, and 0.008% Tween 20. Thereafter, the reaction is initiated by adding 250 nM of the substrate Ulight-CKKSRGDYMTMQIG (IRS-1) and 30 μM ATP, and the mixture is incubated for 60 min at room temperature. For control basal measurements, the enzyme is omitted from the reaction mixture. Following incubation, the reaction is stopped by adding 13 mM EDTA. After 5 min, the antiphopho-PT66 antibody labeled with europium chelate is added. After 60 more min, the fluorescence transfer is measured at excitation and emission wavelengths of 337 and 620/665 nm, using a microplate reader (Envision, PerkinElmer). The enzyme activity is determined by dividing the signal measured at 665 nm by that measured at 620 nm (ratio). The results are expressed as a percent inhibition of the control enzyme activity. Other kinase inhibition assays were performed as above method.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i117" class="anchor-spacer"></div><h3 class="article-section__title" id="_i117"> In Vitro HDAC1/6 Inhibition Fluorescence Assay</h3><div class="NLM_p last">In 384-well plates, 5 μL of enzyme system (15 mM Tris-HCl pH 8.1, 250 μM EDTA, 250 mM NaCl, 10% glycerol, 0.7–12.5 ng/μL enzymes) was added with 2.5 μL of target compound solution and 2.5 μL of substrate. The mixture was incubated at room temperature protected from light for 60 min. Subsequently, 10 μL of trypsin diluted with trypsin buffer was added to each well and incubated at room temperature and away from light for 10 min. Fluorescence intensity was measured using a microplate reader at excitation and emission wavelengths of 390 and 460 nm, respectively. The inhibition ratios were calculated from the fluorescence intensity readout of tested wells relative to those of control wells, and the IC<sub>50</sub> values were calculated using Prism nonlinear curve fitting method (allowed to float and fitted as a parameter).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i118" class="anchor-spacer"></div><h3 class="article-section__title" id="_i118"> In Vitro HDAC3 Enzymic Assay</h3><div class="NLM_p last">A 10 μL reactive system (50 mM Tris-HCl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl<sub>2</sub>, 0.01% Tween20) containing HDAC3 enzyme, H3(1–21)K9Ac substrate, and the tested compounds was added in 384-well plates and incubated at room temperature for 1 h. Subsequently, 10 μL of premix of SA-XL665 and anti-H3K9me0-Eu(K) was added to stop the reaction and incubated the plate at room temperature for 1 h and then read in a microplate reader using HTRF settings. GraphPad software were used to calculate the IC<sub>50</sub> data by the nonlinear curve fitting method (allowed to float and fitted as a parameter).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i119" class="anchor-spacer"></div><h3 class="article-section__title" id="_i119"> In Vitro HDAC4, HDAC7, HDAC8, and HDAC10 Enzymic Assay</h3><div class="NLM_p last">The assays were carried out by Sundia MediTech Company, Ltd. Briefly, different concentrations of compounds were incubated with recombinant HDAC4, HDAC7, HDAC8 (Active Motif, USA), and HDAC10 (BPS Biosciences, USA) at room temperature for 15 min, which was followed by adding mixture of Ac-peptide-AMC substrates to initiate the coupled reaction in Tris-based assay buffer. For HDAC4 and HDAC7, fluorescent AMC released from substrate was measured in Synergy2 (BioTek, US) using filter sets as excitation = 355 nm and emission = 460 nm kinetically. For HDAC8 and HDAC10, reaction mixtures were incubated at room temperature for 240 min. Then stop solution containing trypsin was added. The coupled reaction was incubated for another 90 min at 37 °C. Fluorescent AMC released from substrate was measured in Synergy2 using filter sets as excitation = 355 nm and emission = 460 nm. IC<sub>50</sub> values were calculated by GraphPad Prism software (California, US).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i120" class="anchor-spacer"></div><h3 class="article-section__title" id="_i120"> Western Blot Analysis</h3><div class="NLM_p last">Cells in the logarithmic growth stage were inoculated into 6-well culture plates at an appropriate density overnight before exposed to compounds of different concentrations. After treatment, cells were collected and lysed using 1× SDS sample buffer (50 mM Tris pH 6.8, 100 mM DTT, 2% SDS, 0.1% bromophenol blue, 10% glycerol). The cell lysate was collected, heated in a boiling water bath for 10 min, and centrifuged at 10 000 rpm for 10 min. The supernatant was taken for SDS-page electrophoresis. After the electrophoresis, the proteins were transferred to the cellulose nitrate membrane. The membrane was incubated in sealing solution containing 5% skim milk powder (5% skim milk, 20 mM tris-HCl PH 7.2–7.4, 150 mM NaCl, 0.1% Tween-20) for 60 min at room temperature. and then placed in a primary antibody diluted in 5% skim milk at 4 °C overnight. After washing with 100 mM tris-HCl (PH. 7.2–7.4, 0.9% NaCl, 0.2% Tween-20) at room temperature for 3 times, 10 min each, horseradish peroxidase-labeled secondary antibody was added and incubated at room temperature for 1 h. After three-time washing, and the blots were visualized with an enhanced chemiluminescence assay.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i121" class="anchor-spacer"></div><h3 class="article-section__title" id="_i121"> In Vitro Antiproliferative Assay</h3><div class="NLM_p last">SRB assay was used to determine the growth inhibition of cancer cells. The specific steps were as follows: 100 μL cells in the logarithmic growth stage were seeded to the 96-well culture plate according to the appropriate density and incubated overnight. Different concentrations of compounds were added and coincubated for 72 h. After the coincubation, pour the culture solution and add 10% (w/v) trichloroacetic acid (100 μL/well) at 4 °C for 1 h. Then the adherent cells were washed with distilled water five times. After drying by air, to each well was added 100 μL of SRB solution (Sigma, st. Louis, MO, U.S.A) (4 mg/mL, soluble in 1% acetic acid). After incubation for 15 min, it was washed with 1% acetic acid for five times. After drying by air, 10 mM Tris solution (100 μL) was added to each well, and the optical density (OD value) at the wavelength of 560 nm was determined by SPECTRA max PLUS.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i122" class="anchor-spacer"></div><h3 class="article-section__title" id="_i122"> Apoptosis Assay</h3><div class="NLM_p last">For flow cytometry assay, annexin V-FITC/propidium iodide (PI) staining assay (A211-02, Vazyme) was employed to detect cells in early apoptotic and late apoptotic stages. Cells were seeded in 6-well plates and incubated overnight, then treated with DMSO or compounds for 48 h, and harvested and washed in cold PBS. Cells were resuspended in 100 μL of annexin V-FITC/PI staining solution and incubated for 10–15 min at room temperature. After incubation, the cells were collected and analyzed by FACSCalibur (BD, USA), and data were analyzed using FlowJo 7.6 Software.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i123" class="anchor-spacer"></div><h3 class="article-section__title" id="_i123"> In Vivo Antitumor Activity Assay</h3><div class="NLM_p last">The female BALB/c nude mice (IACUC no. 2019-04-GMY-12) were purchased from Beijing Vital River Laboratory Animal Technology Co. Ltd. MDA-MB-231 cells were suspended in serum-free medium and injected with 0.2 mL containing 2 × 10<sup>6</sup> cells into the right flank of BALB/c-nude mice. When the tumor reached a mean volume of 100–150 mm<sup>3</sup>, the tumor-bearing nude mice were randomly divided into control and treatment groups (6 mice/group) and received the vehicle, SAHA (100 mg/kg/d, PO), ruxolintinib (100 mg/kg/d, PO), and <b>15d</b> (30 and 100 mg/kg/d, IP) at indicated doses. The size of tumors was measured individually twice per week. Tumor volume (TV) was calculated as <i>V</i> = (length × width<sup>2</sup>)/2. All experiments were performed according to the institutional ethical guidelines on animal care and approved by the Institute Animal Care and Use Committee at Shanghai Institute of Materia Medica.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i124"><a href="/doi/suppl/10.1021/acs.jmedchem.0c02111" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48831" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48831" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c02111?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02111</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Supporting tables; <sup>1</sup>H NMR, and <sup>13</sup>C NMR of all target compounds; HPLC spectra and HRMS of the representative compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula stings (CSV) (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Predicted binding mode of <b>6a</b> in the ATP pocket of JAK2; surface representation of <b>6a</b> in the ATP pocket of JAK2 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>) (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_003.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Predicted binding mode of <b>15d</b> in the ATP pocket of JAK2 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>) (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_004.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Predicted binding mode of <b>16b</b> in the ATP pocket of JAK2 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>)  (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_005.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Predicted binding mode of <b>6a</b> in the active site of HDAC6; surface representation of <b>6a</b> in the active site of HDAC6 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI">5EEI</a>) (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_006.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Predicted binding mode of <b>15d</b> in the active site of HDAC6 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI">5EEI</a>) (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_007.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Predicted binding mode of <b>16b</b> in the active site of HDAC6 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI">5EEI</a>) (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_008.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_001.pdf">jm0c02111_si_001.pdf (4.71 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_002.csv">jm0c02111_si_002.csv (2.62 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_003.pdb">jm0c02111_si_003.pdb (784.85 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_004.pdb">jm0c02111_si_004.pdb (469.24 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_005.pdb">jm0c02111_si_005.pdb (469.24 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_006.pdb">jm0c02111_si_006.pdb (549.42 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_007.pdb">jm0c02111_si_007.pdb (549.62 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_008.pdb">jm0c02111_si_008.pdb (549.62 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c02111" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70113" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70113" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Min Huang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#ea87829f8b848daa99838787c48b89c48984"><span class="__cf_email__" data-cfemail="6c0104190d020b2c1f050101420d0f420f02">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong Liu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3685-6268" title="Orcid link">http://orcid.org/0000-0003-3685-6268</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#89e1e5e0fcc9e4e8e0e5a7fae1eae7eaa7e8eaa7eae7"><span class="__cf_email__" data-cfemail="f89094918db895999194d68b909b969bd6999bd69b96">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xuewu Liang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuai Tang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xuyi Liu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yingluo Liu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qifu Xu</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Shandong University, Ji’nan, Shandong 250012, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaomin Wang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Abdusaid Saidahmatov</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chunpu Li</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiang Wang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yu Zhou</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7684-2939" title="Orcid link">http://orcid.org/0000-0002-7684-2939</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yingjie Zhang</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Shandong University, Ji’nan, Shandong 250012, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6118-6695" title="Orcid link">http://orcid.org/0000-0001-6118-6695</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Meiyu Geng</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>X.W. Liang and S. Tang, contributed equally to this work. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e8610-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i126">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02832" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02832" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This study was supported by National Natural Science Foundation of China (21907102, 21632008, 91229204, 81473245, and 81772695).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myelocytic leukemia</p></td></tr><tr><td class="NLM_term">CTCL</td><td class="NLM_def"><p class="first last">cutaneous T cell lymphoma</p></td></tr><tr><td class="NLM_term">EL</td><td class="NLM_def"><p class="first last">erythroleukemia cell lines</p></td></tr><tr><td class="NLM_term">HDACs</td><td class="NLM_def"><p class="first last">histone deacetylases</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term">LIFR</td><td class="NLM_def"><p class="first last">leukemia inhibitory factor receptor</p></td></tr><tr><td class="NLM_term">MM</td><td class="NLM_def"><p class="first last">multiple myeloma</p></td></tr><tr><td class="NLM_term">INCB</td><td class="NLM_def"><p class="first last">ruxolitinib</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SRC</td><td class="NLM_def"><p class="first last">surface recognition cap</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducers and activators of transcription</p></td></tr><tr><td class="NLM_term">ZBG</td><td class="NLM_def"><p class="first last">zinc-binding group</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i128">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71074" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71074" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 33 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span> <span> </span><span class="NLM_article-title">Past, present, and future of targeting Ras for cancer therapies</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.2174/1389557515666151001154111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.2174%2F1389557515666151001154111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=26423695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC28XisVGmurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=345-357&author=Z.+Tanauthor=S.+Zhang&title=Past%2C+present%2C+and+future+of+targeting+Ras+for+cancer+therapies&doi=10.2174%2F1389557515666151001154111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Past, Present, and Future of Targeting Ras for Cancer Therapies</span></div><div class="casAuthors">Tan, Zhi; Zhang, Shuxing</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">345-357</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">For decades, mutant Ras (mut-Ras) proteins have been identified as drivers of multiple cancers including pancreatic, lung, and colon cancers.  However, targeting this oncogene has been challenging and no Ras inhibitors are on the market to date.  Lately several candidates targeting the downstream pathways of Ras signaling, including PI3K and Raf, were approved for cancer treatment.  However, they do not present promising therapeutic effects on patients harboring Ras mutations.  Recently, a variety of compds. have been reported to impair the activity of Ras, and these exciting discoveries reignite the hope for development of novel drugs targeting mut-Ras.  In this article, we will review the progress made in this field and the current state-of-the-art technologies to develop Ras inhibitors.  Also we will discuss the future direction of targeting Ras.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW9CfYW_naDbVg90H21EOLACvtfcHk0lgJWCgdoLLquw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVGmurg%253D&md5=2d7864a13e4e46aa0dcdf03cc2f4f22e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2174%2F1389557515666151001154111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557515666151001154111%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DS.%26atitle%3DPast%252C%2520present%252C%2520and%2520future%2520of%2520targeting%2520Ras%2520for%2520cancer%2520therapies%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2016%26volume%3D16%26spage%3D345%26epage%3D357%26doi%3D10.2174%2F1389557515666151001154111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology in drug development: A minireview of current technologies</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1211</span>– <span class="NLM_lpage">1218</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.1002%2Fcmdc.201600067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=27154144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlWjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1211-1218&author=Z.+Tanauthor=R.+Chaudhaiauthor=S.+Zhang&title=Polypharmacology+in+drug+development%3A+A+minireview+of+current+technologies&doi=10.1002%2Fcmdc.201600067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology in Drug Development: A Minireview of Current Technologies</span></div><div class="casAuthors">Tan, Zhi; Chaudhai, Rajan; Zhang, Shuxing</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1211-1218</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Polypharmacol., the process in which a single drug is able to bind to multiple targets specifically and simultaneously, is an emerging paradigm in drug development.  The potency of a given drug can be increased through the engagement of multiple targets involved in a certain disease.  Polypharmacol. may also help identify novel applications of existing drugs through drug repositioning.  However, many problems and challenges remain in this field.  Rather than covering all aspects of polypharmacol., this Minireview is focused primarily on recently reported techniques, from bioinformatics technologies to cheminformatics approaches as well as text-mining-based methods, all of which have made significant contributions to the research of polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIgmsYIGVssLVg90H21EOLACvtfcHk0liRgP4RrMvUDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlWjsrs%253D&md5=e836929674d5cde6b8431bc1eec36d36</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600067%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DChaudhai%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DS.%26atitle%3DPolypharmacology%2520in%2520drug%2520development%253A%2520A%2520minireview%2520of%2520current%2520technologies%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D1211%26epage%3D1218%26doi%3D10.1002%2Fcmdc.201600067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, C. T.</span></span> <span> </span><span class="NLM_article-title">Multi-target therapeutics: when the whole is greater than the sum of the parts</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2006.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.1016%2Fj.drudis.2006.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=17198971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1ygtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=34-42&author=G.+R.+Zimmermannauthor=J.+Leharauthor=C.+T.+Keith&title=Multi-target+therapeutics%3A+when+the+whole+is+greater+than+the+sum+of+the+parts&doi=10.1016%2Fj.drudis.2006.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target therapeutics: when the whole is greater than the sum of the parts</span></div><div class="casAuthors">Zimmermann Grant R; Lehar Joseph; Keith Curtis T</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">34-42</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">Drugs designed to act against individual molecular targets cannot usually combat multigenic diseases such as cancer, or diseases that affect multiple tissues or cell types such as diabetes and immunoinflammatory disorders.  Combination drugs that impact multiple targets simultaneously are better at controlling complex disease systems, are less prone to drug resistance and are the standard of care in many important therapeutic areas.  The combination drugs currently employed are primarily of rational design, but the increased efficacy they provide justifies in vitro discovery efforts for identifying novel multi-target mechanisms.  In this review, we discuss the biological rationale for combination therapeutics, review some existing combination drugs and present a systematic approach to identify interactions between molecular pathways that could be leveraged for therapeutic benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTI14vYK2Q1LENHe_gFldTbfW6udTcc2ebn0ZaSxPAIvbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1ygtQ%253D%253D&md5=66715499ce21c2855dc6c477aa87f161</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2006.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2006.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DG.%2BR.%26aulast%3DLehar%26aufirst%3DJ.%26aulast%3DKeith%26aufirst%3DC.%2BT.%26atitle%3DMulti-target%2520therapeutics%253A%2520when%2520the%2520whole%2520is%2520greater%2520than%2520the%2520sum%2520of%2520the%2520parts%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26spage%3D34%26epage%3D42%26doi%3D10.1016%2Fj.drudis.2006.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designed multiple ligands. An emerging drug discovery paradigm</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6523</span>– <span class="NLM_lpage">6543</span>, <span class="refDoi"> DOI: 10.1021/jm058225d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+multiple+ligands.+An+emerging+drug+discovery+paradigm&doi=10.1021%2Fjm058225d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0liRgP4RrMvUDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520multiple%2520ligands.%2520An%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543%26doi%3D10.1021%2Fjm058225d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Csermely, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agoston, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pongor, S.</span></span> <span> </span><span class="NLM_article-title">The efficiency of multi-target drugs: the network approach might help drug design</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">182</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2005.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.1016%2Fj.tips.2005.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=15808341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivV2ht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2005&pages=178-182&author=P.+Csermelyauthor=V.+Agostonauthor=S.+Pongor&title=The+efficiency+of+multi-target+drugs%3A+the+network+approach+might+help+drug+design&doi=10.1016%2Fj.tips.2005.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The efficiency of multi-target drugs: the network approach might help drug design</span></div><div class="casAuthors">Csermely, Peter; Agoston, Vilmos; Pongor, Sandor</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">178-182</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Despite considerable progress in genome- and proteome-based high-throughput screening methods and rational drug design, the no. of successful single-target drugs did not increase appreciably during the past decade.  Network models suggest that partial inhibition of a surprisingly small no. of targets can be more efficient than the complete inhibition of a single target.  This and the success stories of multi-target drugs and combinatorial therapies led us to suggest that systematic drug-design strategies should be directed against multiple targets.  The authors propose that the final effect of partial, but multiple, drug actions might often surpass that of complete drug action at a single target.  The future success of this novel drug-design paradigm will depend not only on a new generation of computer models to identify the correct multiple targets and their multi-fitting, low-affinity drug candidates but also on more-efficient in vivo testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQRoFMVKb5m7Vg90H21EOLACvtfcHk0liVFN_HhJ2hBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivV2ht70%253D&md5=4f1383f4699221ef99041dffafe03e8c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2005.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2005.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DCsermely%26aufirst%3DP.%26aulast%3DAgoston%26aufirst%3DV.%26aulast%3DPongor%26aufirst%3DS.%26atitle%3DThe%2520efficiency%2520of%2520multi-target%2520drugs%253A%2520the%2520network%2520approach%2520might%2520help%2520drug%2520design%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2005%26volume%3D26%26spage%3D178%26epage%3D182%26doi%3D10.1016%2Fj.tips.2005.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, J. L. t.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garvik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartwell, L.</span></span> <span> </span><span class="NLM_article-title">Principles for the buffering of genetic variation</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>291</i></span>,  <span class="NLM_fpage">1001</span>– <span class="NLM_lpage">1004</span>, <span class="refDoi"> DOI: 10.1126/science.291.5506.1001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.1126%2Fscience.291.5506.1001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=11232561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtFGlur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2001&pages=1001-1004&author=J.+L.+t.+Hartmanauthor=B.+Garvikauthor=L.+Hartwell&title=Principles+for+the+buffering+of+genetic+variation&doi=10.1126%2Fscience.291.5506.1001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Cell biology: Principles for the buffering of genetic variation</span></div><div class="casAuthors">Hartman, John L., IV; Garvik, Barbara; Hartwell, Lee</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">5506</span>),
    <span class="NLM_cas:pages">1001-1004</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review, with 51 refs.  Most genetic research has used inbred organisms and has not explored the complexity of natural genetic variation present in outbred populations.  The translation of genotype to phenotype is complicated by gene interactions obsd. as epistasis, canalization, robustness, or buffering.  Anal. of double mutations in inbred exptl. organisms suggests some principles for gene interaction that may apply to natural variation as well.  The buffering of variation in one gene is most often due to a small no. of other genes that function in the same biochem. process.  However, buffering can also result from genes functioning in process extrinsic to that of the primary gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIRpsoLwtorrVg90H21EOLACvtfcHk0liVFN_HhJ2hBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtFGlur4%253D&md5=16d535a0c5abc4ce6d08dedffdc33255</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1126%2Fscience.291.5506.1001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.291.5506.1001%26sid%3Dliteratum%253Aachs%26aulast%3DHartman%26aufirst%3DJ.%2BL.%2Bt.%26aulast%3DGarvik%26aufirst%3DB.%26aulast%3DHartwell%26aufirst%3DL.%26atitle%3DPrinciples%2520for%2520the%2520buffering%2520of%2520genetic%2520variation%26jtitle%3DScience%26date%3D2001%26volume%3D291%26spage%3D1001%26epage%3D1004%26doi%3D10.1126%2Fscience.291.5506.1001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hesham, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasheen, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abouzid, K. A. M.</span></span> <span> </span><span class="NLM_article-title">Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">2058</span>– <span class="NLM_lpage">2109</span>, <span class="refDoi"> DOI: 10.1002/med.21505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.1002%2Fmed.21505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=29733427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A280%3ADC%252BC1MfgsV2htQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=2058-2109&author=H.+M.+Heshamauthor=D.+S.+Lasheenauthor=K.+A.+M.+Abouzid&title=Chimeric+HDAC+inhibitors%3A+Comprehensive+review+on+the+HDAC-based+strategies+developed+to+combat+cancer&doi=10.1002%2Fmed.21505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer</span></div><div class="casAuthors">Hesham Heba M; Lasheen Deena S; Abouzid Khaled A M</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal research reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2058-2109</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Recently, molecular hybridization paradigm became an interesting and smart way to defeat the multifaceted cancer disease by a single molecular entity that acts via several mechanisms just like a magic bullet.  Also, HDAC is an important epigenetic target in drug discovery, and the HDAC inhibitors showed successful pattern as cytotoxic agents.  Because of their flexible structure activity relationship, it was easy to link them to other anticancer scaffolds.  So, many dual action HDAC inhibitors have been developed and most of these hybrids have higher potency than the constituting parents in fighting of the cancer cells.  This review describes potential applications of chimeric HDAC inhibitors, which simultaneously modulate not only HDAC but also multiple targets, in treatment of relapsing and drug-resistant cancers.  We have nearly collected most of the reported dual action HDAC inhibitors yet to provide a comprehensive guide for the drug discovery process for developing more efficient anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7h5aD28C1RtbHMBt0mMIXfW6udTcc2ebVUmaBo6vwR7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MfgsV2htQ%253D%253D&md5=c935014e94bf04c21eafbcb2f8ef8218</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fmed.21505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21505%26sid%3Dliteratum%253Aachs%26aulast%3DHesham%26aufirst%3DH.%2BM.%26aulast%3DLasheen%26aufirst%3DD.%2BS.%26aulast%3DAbouzid%26aufirst%3DK.%2BA.%2BM.%26atitle%3DChimeric%2520HDAC%2520inhibitors%253A%2520Comprehensive%2520review%2520on%2520the%2520HDAC-based%2520strategies%2520developed%2520to%2520combat%2520cancer%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2018%26volume%3D38%26spage%3D2058%26epage%3D2109%26doi%3D10.1002%2Fmed.21505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmigiani, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, P. A.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors: molecular mechanisms of action</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5541</span>– <span class="NLM_lpage">5552</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1210620</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.1038%2Fsj.onc.1210620" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=17694093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFersrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=5541-5552&author=W.+S.+Xuauthor=R.+B.+Parmigianiauthor=P.+A.+Marks&title=Histone+deacetylase+inhibitors%3A+molecular+mechanisms+of+action&doi=10.1038%2Fsj.onc.1210620"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors: molecular mechanisms of action</span></div><div class="casAuthors">Xu, W. S.; Parmigiani, R. B.; Marks, P. A.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">5541-5552</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  This review focuses on the mechanisms of action of histone deacetylase (HDAC) inhibitors (HDACi), a group of recently discovered targeted' anticancer agents.  There are 18 HDACs, which are generally divided into four classes, based on sequence homol. to yeast counterparts.  Classical HDACi such as the hydroxamic acid-based vorinostat (also known as SAHA and Zolinza) inhibits classes I, II and IV, but not the NAD+-dependent class III enzymes.  In clin. trials, vorinostat has activity against hematol. and solid cancers at doses well tolerated by patients.  In addn. to histones, HDACs have many other protein substrates involved in regulation of gene expression, cell proliferation and cell death.  Inhibition of HDACs causes accumulation of acetylated forms of these proteins, altering their function.  Thus, HDACs are more properly called 'lysine deacetylases.'.  HDACi induces different phenotypes in various transformed cells, including growth arrest, activation of the extrinsic and/or intrinsic apoptotic pathways, autophagic cell death, reactive oxygen species (ROS)-induced cell death, mitotic cell death and senescence.  In comparison, normal cells are relatively more resistant to HDACi-induced cell death.  The plurality of mechanisms of HDACi-induced cell death reflects both the multiple substrates of HDACs and the heterogeneous patterns of mol. alterations present in different cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5ircqtUCkCLVg90H21EOLACvtfcHk0lggWBdIaHo-Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFersrY%253D&md5=227a7c5d26028e99d412441596ba02ae</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210620&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210620%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DW.%2BS.%26aulast%3DParmigiani%26aufirst%3DR.%2BB.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26atitle%3DHistone%2520deacetylase%2520inhibitors%253A%2520molecular%2520mechanisms%2520of%2520action%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D5541%26epage%3D5552%26doi%3D10.1038%2Fsj.onc.1210620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Potent dual BET/HDAC inhibitors for efficient treatment of pancreatic cancer</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3028</span>– <span class="NLM_lpage">3032</span>, <span class="refDoi"> DOI: 10.1002/anie.201915896</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.1002%2Fanie.201915896" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFegtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2020&pages=3028-3032&author=S.+Heauthor=G.+Dongauthor=Y.+Liauthor=S.+Wuauthor=W.+Wangauthor=C.+Sheng&title=Potent+dual+BET%2FHDAC+inhibitors+for+efficient+treatment+of+pancreatic+cancer&doi=10.1002%2Fanie.201915896"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer</span></div><div class="casAuthors">He, Shipeng; Dong, Guoqiang; Li, Yu; Wu, Shanchao; Wang, Wei; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3028-3032</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">As one of the most aggressive and lethal human malignancies with extremely poor prognosis, there is an urgent demand of more effective therapy for the treatment of pancreatic cancer.  Reported here is a new, effective therapeutic strategy and the design of small-mol. inhibitors that simultaneously target bromodomain and extra-terminal (BET) and histone deacetylase (HDAC), potentially serving as promising therapeutic agents for pancreatic cancer.  A highly potent dual inhibitor (13 a) is identified to possess excellent and balanced activities against BRD4 BD1 (IC50=11 nM) and HDAC1 (IC50=21 nM).  Notably, this compd. shows higher in vitro and in vivo antitumor potency than the BET inhibitor (+)-JQ1 and the HDAC inhibitor vorinostat, either alone or and in combination, highlighting the advantages of BET/HDAC dual inhibitors for more effective treatment of pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9BFNcLfkA4bVg90H21EOLACvtfcHk0lggWBdIaHo-Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFegtLw%253D&md5=78db62cb533611939d9abd0e654ff5f3</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1002%2Fanie.201915896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201915896%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DPotent%2520dual%2520BET%252FHDAC%2520inhibitors%2520for%2520efficient%2520treatment%2520of%2520pancreatic%2520cancer%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2020%26volume%3D59%26spage%3D3028%26epage%3D3032%26doi%3D10.1002%2Fanie.201915896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Novel-targeted therapy for hematological malignancies with JAK and HDAC dual inhibitors</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1849</span>– <span class="NLM_lpage">1852</span>, <span class="refDoi"> DOI: 10.4155/fmc-2019-0168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.4155%2Ffmc-2019-0168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=31517536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslGksbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=1849-1852&author=X.+Liangauthor=H.+Liuauthor=Y.+Zhang&title=Novel-targeted+therapy+for+hematological+malignancies+with+JAK+and+HDAC+dual+inhibitors&doi=10.4155%2Ffmc-2019-0168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Novel-targeted therapy for hematological malignancies with JAK and HDAC dual inhibitors</span></div><div class="casAuthors">Liang, Xuewu; Liu, Hong; Zhang, Yingjie</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1849-1852</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLsT-Fq4Y_LLVg90H21EOLACvtfcHk0lggWBdIaHo-Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslGksbrF&md5=c762aee6742cfadba21d2d1c8f40299c</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2019-0168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2019-0168%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DNovel-targeted%2520therapy%2520for%2520hematological%2520malignancies%2520with%2520JAK%2520and%2520HDAC%2520dual%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2019%26volume%3D11%26spage%3D1849%26epage%3D1852%26doi%3D10.4155%2Ffmc-2019-0168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slingerland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guchelaar, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelderblom, H.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.1097/CAD.0000000000000040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.1097%2FCAD.0000000000000040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=24185382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOms7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=140-149&author=M.+Slingerlandauthor=H.+J.+Guchelaarauthor=H.+Gelderblom&title=Histone+deacetylase+inhibitors%3A+an+overview+of+the+clinical+studies+in+solid+tumors&doi=10.1097%2FCAD.0000000000000040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors</span></div><div class="casAuthors">Slingerland, Marije; Guchelaar, Henk-Jan; Gelderblom, Hans</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">140-149</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  The histone deacetylase inhibitors (HDACi) are a group of small mols. that target histone deacetylases (HDACs) by inhibiting their activity.  HDACi have a long history of use in neurol. and psychiatry as antiepileptics and mood stabilizers.  More recently, they have been investigated as possible treatments for cancer.  HDACi have undergone rapid clin. development in recent years, on the basis of their preclin. in-vitro and in-vivo antitumor activity in hematol. malignancies and solid tumors.  Many HDACi have entered phase I-III clin. trials.  Among the HDACi, vorinostat and romidepsin are currently the most extensively studied.  In 2006 and 2009, resp., they received approval by the United States Food and Drug Administration for treatment of cutaneous T-cell lymphoma and romidepsin for the treatment of peripheral T-cell lymphoma.  Other HDACi, such as panobinostat and valproic acid, also demonstrated activity as therapeutic anticancer agents.  In this article we give an overview of the clin. studies of HDACi in solid tumors.  We start with a short description of the working mechanism of HDACi in general.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1KRdJ1NsR87Vg90H21EOLACvtfcHk0li2wvSDIbT9Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOms7vJ&md5=a14500b8a14b556a955a9db34cff08b0</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1097%2FCAD.0000000000000040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0000000000000040%26sid%3Dliteratum%253Aachs%26aulast%3DSlingerland%26aufirst%3DM.%26aulast%3DGuchelaar%26aufirst%3DH.%2BJ.%26aulast%3DGelderblom%26aufirst%3DH.%26atitle%3DHistone%2520deacetylase%2520inhibitors%253A%2520an%2520overview%2520of%2520the%2520clinical%2520studies%2520in%2520solid%2520tumors%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2014%26volume%3D25%26spage%3D140%26epage%3D149%26doi%3D10.1097%2FCAD.0000000000000040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stadler, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferber, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCulloch, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, J. A.</span></span> <span> </span><span class="NLM_article-title">A phase II study of depsipeptide in refractory metastatic renal cell cancer</span>. <i>Clin. Genitourin. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.3816/CGC.2006.n.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.3816%2FCGC.2006.n.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=16859580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BD28XotVCmsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=57-60&author=W.+M.+Stadlerauthor=K.+Margolinauthor=S.+Ferberauthor=W.+McCullochauthor=J.+A.+Thompson&title=A+phase+II+study+of+depsipeptide+in+refractory+metastatic+renal+cell+cancer&doi=10.3816%2FCGC.2006.n.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II study of depsipeptide in refractory metastatic renal cell cancer</span></div><div class="casAuthors">Stadler, Walter M.; Margolin, Kim; Ferber, Sandy; McCulloch, William; Thompson, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Genitourinary Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-60</span>CODEN:
                <span class="NLM_cas:coden">CGCLA7</span>;
        ISSN:<span class="NLM_cas:issn">1558-7673</span>.
    
            (<span class="NLM_cas:orgname">Cancer Information Group</span>)
        </div><div class="casAbstract">Therapeutic options for renal cell cancer are inadequate.  Depsipeptide is a histone deacetylase inhibitor with promising preclin. and early clin. activity.  Patients with refractory renal cell cancer with normal organ function and no history of significant cardiovascular disease were enrolled on a multi-institutional, single-arm, phase II study.  Patients received depsipeptide 13 mg/m2 i.v. over 4 h on days 1, 8, and 15 of a 28-day cycle with disease reevaluation performed every 8 wk.  One response in the initial 16 enrolled patients was required for full accrual to 25 patients, from which 5 responses needed to be obsd. in order to consider the agent appropriate for further study.  Toxicity was assessed using National Cancer Institute Common Toxicity Criteria, version 2.0.  The 29 evaluable patients, who were accrued so that 25 patients who received ≥3 doses of depsipeptide could be obsd., were heavily pretreated with a median of 2 previous systemic therapies and a 2-yr median duration of metastatic disease.  Twenty-four had clear-cell histol.  The most common serious toxicities were fatigue, nausea, vomiting, and anemia.  Two patients developed a prolonged QTc interval, one patient each developed grade 3 atrial fibrillation and tachycardia, and there was 1 sudden death.  Two patients experienced an objective response (1 complete response) for an overall response rate of 7% (95% CI, 0.8%-23%).  Depsipeptide at this dose and schedule does not have sufficient activity for further investigation in this patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2x500kPN76bVg90H21EOLACvtfcHk0li2wvSDIbT9Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotVCmsr8%253D&md5=410a6ab15f374e6243042dddc3760e68</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.3816%2FCGC.2006.n.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3816%252FCGC.2006.n.018%26sid%3Dliteratum%253Aachs%26aulast%3DStadler%26aufirst%3DW.%2BM.%26aulast%3DMargolin%26aufirst%3DK.%26aulast%3DFerber%26aufirst%3DS.%26aulast%3DMcCulloch%26aufirst%3DW.%26aulast%3DThompson%26aufirst%3DJ.%2BA.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520depsipeptide%2520in%2520refractory%2520metastatic%2520renal%2520cell%2520cancer%26jtitle%3DClin.%2520Genitourin.%2520Cancer%26date%3D2006%26volume%3D5%26spage%3D57%26epage%3D60%26doi%3D10.3816%2FCGC.2006.n.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Molife, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karavasilis, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riggs, C. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadler, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCulloch, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dearnaley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bono, J. S.</span></span> <span> </span><span class="NLM_article-title">Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)</span>. <i>Ann. Oncol</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">113</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdp270</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.1093%2Fannonc%2Fmdp270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=19608618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A280%3ADC%252BD1Mfisl2htg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=109-113&author=L.+R.+Molifeauthor=G.+Attardauthor=P.+C.+Fongauthor=V.+Karavasilisauthor=A.+H.+Reidauthor=S.+Pattersonauthor=C.+E.+Riggsauthor=C.+Higanoauthor=W.+M.+Stadlerauthor=W.+McCullochauthor=D.+Dearnaleyauthor=C.+Parkerauthor=J.+S.+de+Bono&title=Phase+II%2C+two-stage%2C+single-arm+trial+of+the+histone+deacetylase+inhibitor+%28HDACi%29+romidepsin+in+metastatic+castration-resistant+prostate+cancer+%28CRPC%29&doi=10.1093%2Fannonc%2Fmdp270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)</span></div><div class="casAuthors">Molife L R; Attard G; Fong P C; Karavasilis V; Reid A H M; Patterson S; Riggs C E Jr; Higano C; Stadler W M; McCulloch W; Dearnaley D; Parker C; de Bono J S</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">109-13</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Histone deacetylase blockade can promote heat shock protein 90 (HSP90) acetylation, abrogating androgen receptor signaling.  A phase II trial of the histone deacetylase inhibitor (HDACi) romidepsin was conducted in patients with progressing, metastatic, castration-resistant prostate cancer (CRPC).  PATIENTS AND METHODS:  A dose of 13 mg/m(2) was administered i.v. over 4 h on days 1, 8 and 15 every 28 days.  The primary end point was rate of disease control defined as no evidence of radiological progression at 6 months.  A sample size of 16 assessable patients in stage 1 and nine assessable patients in stage 2 was selected; progression to stage 2 required one or more patients with disease control in stage 1 (H(o) = 0.10, H(a) = 0.30; alpha and beta = 0.10).  RESULTS:  Thirty-five patients were enrolled.  Two patients achieved a confirmed radiological partial response (RECIST) lasting > or = 6 months, along with a confirmed prostate-specific antigen decline of > or = 50%.  Eleven patients experienced toxicity necessitating early discontinuation.  The commonest adverse events were nausea (30 patients; 85.7%), fatigue (28 patients; 80.0%), vomiting (23 patients; 65.7%) and anorexia (20 patients; 57.1%).  There was no significant cardiac toxicity.  CONCLUSIONS:  At the dose and schedule selected, romidepsin demonstrated minimal antitumor activity in chemonaive patients with CRPC.  Further studies of improved HDACi, alone and in combination with other therapies, should nevertheless be investigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTcTdc2c-lnpTQLBVDQn4bCfW6udTcc2ebuJrOD0v2D77ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mfisl2htg%253D%253D&md5=6a04735a4117394e94bda2a43f05c417</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdp270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdp270%26sid%3Dliteratum%253Aachs%26aulast%3DMolife%26aufirst%3DL.%2BR.%26aulast%3DAttard%26aufirst%3DG.%26aulast%3DFong%26aufirst%3DP.%2BC.%26aulast%3DKaravasilis%26aufirst%3DV.%26aulast%3DReid%26aufirst%3DA.%2BH.%26aulast%3DPatterson%26aufirst%3DS.%26aulast%3DRiggs%26aufirst%3DC.%2BE.%26aulast%3DHigano%26aufirst%3DC.%26aulast%3DStadler%26aufirst%3DW.%2BM.%26aulast%3DMcCulloch%26aufirst%3DW.%26aulast%3DDearnaley%26aufirst%3DD.%26aulast%3DParker%26aufirst%3DC.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26atitle%3DPhase%2520II%252C%2520two-stage%252C%2520single-arm%2520trial%2520of%2520the%2520histone%2520deacetylase%2520inhibitor%2520%2528HDACi%2529%2520romidepsin%2520in%2520metastatic%2520castration-resistant%2520prostate%2520cancer%2520%2528CRPC%2529%26jtitle%3DAnn.%2520Oncol%26date%3D2010%26volume%3D21%26spage%3D109%26epage%3D113%26doi%3D10.1093%2Fannonc%2Fmdp270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haigentz, M.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keresztes, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culliney, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaba, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirieac, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariadason, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belbin, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greally, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddad, R. I.</span></span> <span> </span><span class="NLM_article-title">Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer</span>. <i>Oral Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">1281</span>– <span class="NLM_lpage">1288</span>, <span class="refDoi"> DOI: 10.1016/j.oraloncology.2012.05.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.1016%2Fj.oraloncology.2012.05.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=22748449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFGntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2012&pages=1281-1288&author=M.+Haigentzauthor=M.+Kimauthor=C.+Sartaauthor=J.+Linauthor=R.+S.+Keresztesauthor=B.+Cullineyauthor=A.+G.+Gabaauthor=R.+V.+Smithauthor=G.+I.+Shapiroauthor=L.+R.+Chirieacauthor=J.+M.+Mariadasonauthor=T.+J.+Belbinauthor=J.+M.+Greallyauthor=J.+J.+Wrightauthor=R.+I.+Haddad&title=Phase+II+trial+of+the+histone+deacetylase+inhibitor+romidepsin+in+patients+with+recurrent%2Fmetastatic+head+and+neck+cancer&doi=10.1016%2Fj.oraloncology.2012.05.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer</span></div><div class="casAuthors">Haigentz, Missak; Kim, Mimi; Sarta, Catherine; Lin, Juan; Keresztes, Roger S.; Culliney, Bruce; Gaba, Anu G.; Smith, Richard V.; Shapiro, Geoffrey I.; Chirieac, Lucian R.; Mariadason, John M.; Belbin, Thomas J.; Greally, John M.; Wright, John J.; Haddad, Robert I.</div><div class="citationInfo"><span class="NLM_cas:title">Oral Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">v1281-1288</span>CODEN:
                <span class="NLM_cas:coden">EJCCER</span>;
        ISSN:<span class="NLM_cas:issn">1368-8375</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Objectives: Patients with advanced squamous cell carcinoma of the head and neck (SCCHN) have limited treatment options.  Inhibition of histone deacetylases (HDACs) represents a novel therapeutic approach warranting addnl. investigation in solid tumors.  Methods: A phase II trial of single agent romidepsin, an HDAC inhibitor, was performed in 14 patients with SCCHN who provided consent for pre- and post-therapy samples of accessible tumor, blood and uninvolved oral mucosa.  Romidepsin was administered at 13 mg/m2 as a 4-h i.v. infusion on days 1, 8 and 15 of 28 day cycles, with response assessment by RECIST every 8 wk.  Results: Objective responses were not obsd., although 2 heavily pretreated patients had brief clin. disease stabilization.  Obsd. toxicities were expected, including frequent severe fatigue.  Immunohistochem. anal. of 7 pre- and post-treatment tumor pairs demonstrated induction of p21Waf1/Cip1 characteristic of HDAC inhibition, as well as decreased Ki67 staining.  Exploratory microarray analyses of mucosal and tumor samples detected changes in gene expression following romidepsin treatment that were most commonly assocd. with regulation of transcription, cell cycle control, signal transduction, and electron transport.  Treatment with romidepsin did not alter the extent of DNA methylation of candidate gene loci (including CDH1 and hMLH1) in SCCHN tumors.  Conclusions: Single agent romidepsin has limited activity for the treatment of SCCHN but can effectively achieve tumor-assocd. HDAC inhibition.  Although tolerability of romidepsin in this setting may be limiting, further evaluation of other HDAC inhibitors in combination with active therapies may be justified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN0KyybKp80bVg90H21EOLACvtfcHk0lisIKmRyFw-zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFGntbo%253D&md5=1766ff37fd8bb92b0101f9d1da093e73</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.oraloncology.2012.05.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.oraloncology.2012.05.024%26sid%3Dliteratum%253Aachs%26aulast%3DHaigentz%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DSarta%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DKeresztes%26aufirst%3DR.%2BS.%26aulast%3DCulliney%26aufirst%3DB.%26aulast%3DGaba%26aufirst%3DA.%2BG.%26aulast%3DSmith%26aufirst%3DR.%2BV.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DMariadason%26aufirst%3DJ.%2BM.%26aulast%3DBelbin%26aufirst%3DT.%2BJ.%26aulast%3DGreally%26aufirst%3DJ.%2BM.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%26aulast%3DHaddad%26aufirst%3DR.%2BI.%26atitle%3DPhase%2520II%2520trial%2520of%2520the%2520histone%2520deacetylase%2520inhibitor%2520romidepsin%2520in%2520patients%2520with%2520recurrent%252Fmetastatic%2520head%2520and%2520neck%2520cancer%26jtitle%3DOral%2520Oncol.%26date%3D2012%26volume%3D48%26spage%3D1281%26epage%3D1288%26doi%3D10.1016%2Fj.oraloncology.2012.05.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, G.</span></span> <span> </span><span class="NLM_article-title">Dual-target inhibitors based on HDACs: novel antitumor agents for cancer therapy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">8977</span>– <span class="NLM_lpage">9002</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00491</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00491" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnslShtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=8977-9002&author=T.+Liuauthor=Y.+Wanauthor=Y.+Xiaoauthor=C.+Xiaauthor=G.+Duan&title=Dual-target+inhibitors+based+on+HDACs%3A+novel+antitumor+agents+for+cancer+therapy&doi=10.1021%2Facs.jmedchem.0c00491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy</span></div><div class="casAuthors">Liu, Tingting; Wan, Yichao; Xiao, Yuliang; Xia, Chengcai; Duan, Guiyun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">8977-9002</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) play an important role in regulating target gene expression.  They have been highlighted as a novel category of anticancer targets, and their inhibition can induce apoptosis, differentiation, and growth arrest in cancer cells.  In view of the fact that HDAC inhibitors and other antitumor agents, such as BET inhibitors, topoisomerase inhibitors, and RTK pathway inhibitors, exert a synergistic effect on cellular processes in cancer cells, the combined inhibition of two targets is regarded as a rational strategy to improve the effectiveness of these single-target drugs for cancer treatment.  In this review, we discuss the theor. basis for designing HDAC-involved dual-target drugs and provide insight into the structure-activity relationships of these dual-target agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohbD4ktOU4jbVg90H21EOLACvtfcHk0lisIKmRyFw-zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnslShtL8%253D&md5=fa6764d35879c6a8973d57231854f821</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00491%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DXia%26aufirst%3DC.%26aulast%3DDuan%26aufirst%3DG.%26atitle%3DDual-target%2520inhibitors%2520based%2520on%2520HDACs%253A%2520novel%2520antitumor%2520agents%2520for%2520cancer%2520therapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D8977%26epage%3D9002%26doi%3D10.1021%2Facs.jmedchem.0c00491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahboobi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichhorn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pongratz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciossek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckers, T.</span></span> <span> </span><span class="NLM_article-title">Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">8546</span>– <span class="NLM_lpage">8555</span>, <span class="refDoi"> DOI: 10.1021/jm100665z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100665z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeksL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8546-8555&author=S.+Mahboobiauthor=A.+Sellmerauthor=M.+Winklerauthor=E.+Eichhornauthor=H.+Pongratzauthor=T.+Ciossekauthor=T.+Baerauthor=T.+Maierauthor=T.+Beckers&title=Novel+chimeric+histone+deacetylase+inhibitors%3A+a+series+of+lapatinib+hybrides+as+potent+inhibitors+of+epidermal+growth+factor+receptor+%28EGFR%29%2C+human+epidermal+growth+factor+receptor+2+%28HER2%29%2C+and+histone+deacetylase+activity&doi=10.1021%2Fjm100665z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Chimeric Histone Deacetylase Inhibitors: A Series of Lapatinib Hybrids as Potent Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and Histone Deacetylase Activity</span></div><div class="casAuthors">Mahboobi, Siavosh; Sellmer, Andreas; Winkler, Matthias; Eichhorn, Emerich; Pongratz, Herwig; Ciossek, Thomas; Baer, Thomas; Maier, Thomas; Beckers, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8546-8555</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Reversible lysine-specific acetylation has been described as an important posttranslational modification, regulating chromatin structure and transcriptional activity in the case of core histone proteins.  Histone deacetylases (HDAC) are considered as a promising target for anticancer drug development, with I as pan-HDAC inhibitor approved for cutaneous T-cell lymphoma therapy and several other HDAC inhibitors currently in preclin. and clin. development.  Protein kinases are a well-established target for cancer therapy with the EGFR/HER2 inhibitor II approved for treatment of advanced, HER2 pos. breast cancer as a prominent example.  The present report presents a novel strategy for cancer drug development by combination of EGFR/HER2 kinase and HDAC inhibitory activity in one mol.  By combining the structural features of II with an (E)-3-(aryl)-N-hydroxyacrylamide motif known from HDAC inhibitors like III or IV, selective inhibitors were obtained for both targets with potent cellular activity (target inhibition and cytotoxicity) of selected compds. V (X = m-phenylene, 2,5-furandiyl).  By combining two distinct pharmacol. properties in one mol., a broader activity spectrum is postulated and less likelihood of drug resistance in cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEElZRNfAQZ7Vg90H21EOLACvtfcHk0lisIKmRyFw-zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeksL3I&md5=81bba7c00bb26b42c54075acce5ba525</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm100665z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100665z%26sid%3Dliteratum%253Aachs%26aulast%3DMahboobi%26aufirst%3DS.%26aulast%3DSellmer%26aufirst%3DA.%26aulast%3DWinkler%26aufirst%3DM.%26aulast%3DEichhorn%26aufirst%3DE.%26aulast%3DPongratz%26aufirst%3DH.%26aulast%3DCiossek%26aufirst%3DT.%26aulast%3DBaer%26aufirst%3DT.%26aulast%3DMaier%26aufirst%3DT.%26aulast%3DBeckers%26aufirst%3DT.%26atitle%3DNovel%2520chimeric%2520histone%2520deacetylase%2520inhibitors%253A%2520a%2520series%2520of%2520lapatinib%2520hybrides%2520as%2520potent%2520inhibitors%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%252C%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202%2520%2528HER2%2529%252C%2520and%2520histone%2520deacetylase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8546%26epage%3D8555%26doi%3D10.1021%2Fjm100665z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.12.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.1016%2Fj.ejmech.2015.12.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=26741358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVOj" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2016&pages=1-12&author=F.+W.+Pengauthor=J.+Xuanauthor=T.+T.+Wuauthor=J.+Y.+Xueauthor=Z.+W.+Renauthor=D.+K.+Liuauthor=X.+Q.+Wangauthor=X.+H.+Chenauthor=J.+W.+Zhangauthor=Y.+G.+Xuauthor=L.+Shi&title=Design%2C+synthesis+and+biological+evaluation+of+N-phenylquinazolin-4-amine+hybrids+as+dual+inhibitors+of+VEGFR-2+and+HDAC&doi=10.1016%2Fj.ejmech.2015.12.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC</span></div><div class="casAuthors">Peng, Fan-Wei; Xuan, Ji; Wu, Ting-Ting; Xue, Jia-Yu; Ren, Zi-Wei; Liu, Da-Ke; Wang, Xiu-Qi; Chen, Xin-Hang; Zhang, Jia-Wei; Xu, Yun-Gen; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In this work, a series of hybrids bearing N-phenylquinazolin-4-amine and hydroxamic acid moieties I (R1, R2 = H, F, Cl, Br, n = 2, 3, 4, 5) were designed and identified as dual VEGFR-2/HDAC inhibitors.  Compd. I (R1 = H, R2 = Br, n = 5) exhibited the most potent inhibitory activity against HDAC with IC50 of 2.2 nM and strong inhibitory effect against VEGFR-2 with IC50 of 74 nM.  It also showed the most potent inhibitory activity against a human breast cancer cell line MCF-7 with IC50 of 0.85 μM.  Docking simulation supported the initial pharmacophoric hypothesis and suggested a common mode of interaction at the active binding sites of VEGFR-2 and HDLP (Histone Deacetylase-Like Protein), which demonstrates that compd. I (R1 = H, R2 = Br, n = 5) is a potential agent for cancer therapy deserving further researching.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT_jbaom_UR7Vg90H21EOLACvtfcHk0lgSOclI4CcaFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVOj&md5=1a0c299ec484daa522da5969e8a35cec</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.12.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.12.033%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DF.%2BW.%26aulast%3DXuan%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DT.%2BT.%26aulast%3DXue%26aufirst%3DJ.%2BY.%26aulast%3DRen%26aufirst%3DZ.%2BW.%26aulast%3DLiu%26aufirst%3DD.%2BK.%26aulast%3DWang%26aufirst%3DX.%2BQ.%26aulast%3DChen%26aufirst%3DX.%2BH.%26aulast%3DZhang%26aufirst%3DJ.%2BW.%26aulast%3DXu%26aufirst%3DY.%2BG.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520N-phenylquinazolin-4-amine%2520hybrids%2520as%2520dual%2520inhibitors%2520of%2520VEGFR-2%2520and%2520HDAC%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D109%26spage%3D1%26epage%3D12%26doi%3D10.1016%2Fj.ejmech.2015.12.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel Pazopanib-based HDAC and VEGFR dual inhibitors targeting cancer epigenetics and angiogenesis simultaneously</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5304</span>– <span class="NLM_lpage">5322</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00384</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00384" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpvVGrsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5304-5322&author=J.+Zangauthor=X.+Liangauthor=Y.+Huangauthor=Y.+Jiaauthor=X.+Liauthor=W.+Xuauthor=C.+J.+Chouauthor=Y.+Zhang&title=Discovery+of+novel+Pazopanib-based+HDAC+and+VEGFR+dual+inhibitors+targeting+cancer+epigenetics+and+angiogenesis+simultaneously&doi=10.1021%2Facs.jmedchem.8b00384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously</span></div><div class="casAuthors">Zang, Jie; Liang, Xuewu; Huang, Yongxue; Jia, Yuping; Li, Xiaoyang; Xu, Wenfang; Chou, C. James; Zhang, Yingjie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5304-5322</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein a novel series of pazopanib hybrids as polypharmacol. antitumor agents were developed based on the crosstalk between histone deacetylases (HDACs) and vascular endothelial growth factor (VEGF) pathway.  Among them, one ortho-aminoanilide 6d and one hydroxamic acid 13f exhibited considerable total HDACs and VEGFR-2 inhibitory activities.  The HDAC inhibitory activities endowed 6d and 13f with potent antiproliferative activities, which was not obsd. in the approved VEGFR inhibitor pazopanib.  Compds. 6d and 13f possessed comparable HDAC isoform selectivity profiles to the clin. class I HDAC inhibitor MS-275 and the approved pan-HDAC inhibitor SAHA, resp. 6d and 13f also exhibited uncompromised multiple tyrosine kinases inhibitory activities relative to pazopanib.  The intracellular dual inhibition to HDAC and VEGFR of 6d and 13f was validated by Western blot anal.  In both HUVECs tube formation assay and rat thoracic aorta rings assay, 6d and 13f showed comparable antiangiogenic potencies to pazopanib.  What's more, 6d possessed desirable pharmacokinetic profiles with the oral bioavailability of 72% in SD rats and considerable in vivo antitumor efficacy in a human colorectal adenocarcinoma (HT-29) xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpmz6rwKiKSbVg90H21EOLACvtfcHk0lgSOclI4CcaFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpvVGrsL8%253D&md5=437da0a6cca1ec211219aef87a6ddbc5</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00384%26sid%3Dliteratum%253Aachs%26aulast%3DZang%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DChou%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520novel%2520Pazopanib-based%2520HDAC%2520and%2520VEGFR%2520dual%2520inhibitors%2520targeting%2520cancer%2520epigenetics%2520and%2520angiogenesis%2520simultaneously%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5304%26epage%3D5322%26doi%3D10.1021%2Facs.jmedchem.8b00384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ko, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffey, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandvold, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soellner, M. B.</span></span> <span> </span><span class="NLM_article-title">Development of a chimeric c-Src kinase and HDAC inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">783</span>, <span class="refDoi"> DOI: 10.1021/ml400175d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400175d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVKit7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=779-783&author=K.+S.+Koauthor=M.+E.+Steffeyauthor=K.+R.+Brandvoldauthor=M.+B.+Soellner&title=Development+of+a+chimeric+c-Src+kinase+and+HDAC+inhibitor&doi=10.1021%2Fml400175d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Chimeric c-Src Kinase and HDAC Inhibitor</span></div><div class="casAuthors">Ko, Kristin S.; Steffey, Michael E.; Brandvold, Kristoffer R.; Soellner, Matthew B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">779-783</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">On the basis of synergism obsd. between a selective c-Src kinase inhibitor with an HDAC inhibitor, the development of the first chimeric c-Src kinase and HDAC inhibitor is described.  The optimized chimeric inhibitor is shown to be a potent c-Src and HDAC inhibitor.  Chimeric inhibitor (I) is further shown to be highly efficacious in cancer cell lines and significantly more efficacious than a dual-targeting strategy using discrete c-Src and HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzi2suGn-7ErVg90H21EOLACvtfcHk0ljoU7iFL-i9NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVKit7rL&md5=5f34ce3b1f65a8ac1a4341f563a5e1d9</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fml400175d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400175d%26sid%3Dliteratum%253Aachs%26aulast%3DKo%26aufirst%3DK.%2BS.%26aulast%3DSteffey%26aufirst%3DM.%2BE.%26aulast%3DBrandvold%26aufirst%3DK.%2BR.%26aulast%3DSoellner%26aufirst%3DM.%2BB.%26atitle%3DDevelopment%2520of%2520a%2520chimeric%2520c-Src%2520kinase%2520and%2520HDAC%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D779%26epage%3D783%26doi%3D10.1021%2Fml400175d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Makarevic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juengel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maxeiner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsaur, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roos, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaheta, R. A.</span></span> <span> </span><span class="NLM_article-title">HDAC inhibition counteracts metastatic re-activation of prostate cancer cells induced by chronic mTOR suppression</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.3390/cells7090129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.3390%2Fcells7090129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVOju7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=129-146&author=J.+Makarevicauthor=J.+Rutzauthor=E.+Juengelauthor=S.+Maxeinerauthor=J.+Maniauthor=S.+Valloauthor=I.+Tsaurauthor=F.+Roosauthor=F.+K.+Chunauthor=R.+A.+Blaheta&title=HDAC+inhibition+counteracts+metastatic+re-activation+of+prostate+cancer+cells+induced+by+chronic+mTOR+suppression&doi=10.3390%2Fcells7090129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibition counteracts metastatic re-activation of prostate cancer cells induced by chronic mTOR suppression</span></div><div class="casAuthors">Makarevic, Jasmina; Rutz, Jochen; Juengel, Eva; Maxeiner, Sebastian; Mani, Jens; Vallo, Stefan; Tsaur, Igor; Roos, Frederik; Chun, Felix K.-H.; Blaheta, Roman A.</div><div class="citationInfo"><span class="NLM_cas:title">Cells</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">129</span>CODEN:
                <span class="NLM_cas:coden">CELLC6</span>;
        ISSN:<span class="NLM_cas:issn">2073-4409</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">This study was designed to investigate whether epigenetic modulation by histone deacetylase (HDAC) inhibition might circumvent resistance towards the mechanistic target of rapamycin (mTOR) inhibitor temsirolimus in a prostate cancer cell model.  Parental (par) and temsirolimus-resistant (res) PC3 prostate cancer cells were exposed to the HDAC inhibitor valproic acid (VPA), and tumor cell adhesion, chemotaxis, migration, and invasion were evaluated.  Temsirolimus resistance was characterized by reduced binding of PC3res cells to endothelium, immobilized collagen, and fibronectin, but increased adhesion to laminin, as compared to the parental cells.  Chemotaxis, migration, and invasion of PC3res cells were enhanced following temsirolimus re-treatment.  Integrin α and β receptors were significantly altered in PC3res compared to PC3par cells.  VPA significantly counteracted temsirolimus resistance by down-regulating tumor cell-matrix interaction, chemotaxis, and migration.  Evaluation of integrin expression in the presence of VPA revealed a significant down-regulation of integrin α5 in PC3res cells.  Blocking studies demonstrated a close assocn. between α5 expression on PC3res and chemotaxis.  In this in vitro model, temsirolimus resistance drove prostate cancer cells to become highly motile, while HDAC inhibition reversed the metastatic activity.  The VPA-induced inhibition of metastatic activity was accompanied by a lowered integrin α5 surface level on the tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS9P6pTqxjq7Vg90H21EOLACvtfcHk0ljoU7iFL-i9NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVOju7rO&md5=a8db40231a1f0b786549f9b3768b3c4c</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.3390%2Fcells7090129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells7090129%26sid%3Dliteratum%253Aachs%26aulast%3DMakarevic%26aufirst%3DJ.%26aulast%3DRutz%26aufirst%3DJ.%26aulast%3DJuengel%26aufirst%3DE.%26aulast%3DMaxeiner%26aufirst%3DS.%26aulast%3DMani%26aufirst%3DJ.%26aulast%3DVallo%26aufirst%3DS.%26aulast%3DTsaur%26aufirst%3DI.%26aulast%3DRoos%26aufirst%3DF.%26aulast%3DChun%26aufirst%3DF.%2BK.%26aulast%3DBlaheta%26aufirst%3DR.%2BA.%26atitle%3DHDAC%2520inhibition%2520counteracts%2520metastatic%2520re-activation%2520of%2520prostate%2520cancer%2520cells%2520induced%2520by%2520chronic%2520mTOR%2520suppression%26jtitle%3DCells%26date%3D2018%26volume%3D7%26spage%3D129%26epage%3D146%26doi%3D10.3390%2Fcells7090129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Terranova-Barberio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlowska, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krings, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenblum, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budillon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P. N.</span></span> <span> </span><span class="NLM_article-title">HDAC inhibition potentiates immunotherapy in triple negative breast cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">114156</span>– <span class="NLM_lpage">114172</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.23169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.18632%2Foncotarget.23169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=29371976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A280%3ADC%252BC1MvksFSrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=114156-114172&author=M.+Terranova-Barberioauthor=S.+Thomasauthor=N.+Aliauthor=N.+Pawlowskaauthor=J.+Parkauthor=G.+Kringsauthor=M.+D.+Rosenblumauthor=A.+Budillonauthor=P.+N.+Munster&title=HDAC+inhibition+potentiates+immunotherapy+in+triple+negative+breast+cancer&doi=10.18632%2Foncotarget.23169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibition potentiates immunotherapy in triple negative breast cancer</span></div><div class="casAuthors">Terranova-Barberio Manuela; Thomas Scott; Pawlowska Nela; Park Jeenah; Munster Pamela N; Ali Niwa; Rosenblum Michael D; Krings Gregor; Budillon Alfredo</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">69</span>),
    <span class="NLM_cas:pages">114156-114172</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Triple-negative breast cancer (TNBC) represents a more aggressive and difficult subtype of breast cancer where responses to chemotherapy occur, but toxicity is significant and resistance often follows.  Immunotherapy has shown promising results in various types of cancer, including breast cancer.  Here, we investigated a new combination strategy where histone deacetylase inhibitors (HDACi) are applied with immune checkpoint inhibitors to improve immunotherapy responses in TNBC.  Testing different epigenetic modifiers, we focused on the mechanisms underlying HDACi as priming modulators of immunotherapy.  Tumor cells were co-cultured with human peripheral blood mononuclear cells (PBMCs) and flow cytometric immunophenotyping was performed to define the role of epigenetic priming in promoting tumor antigen presentation and immune cell activation.  We found that HDACi up-regulate PD-L1 mRNA and protein expression in a time-dependent manner in TNBC cells, but not in hormone responsive cells.  Focusing on TNBC, HDACi up-regulated PD-L1 and HLA-DR on tumor cells when co-cultured with PBMCs and down-regulated CD4(+) Foxp3(+) Treg in vitro.  HDACi significantly enhanced the in vivo response to PD-1/CTLA-4 blockade in the triple-negative 4T1 breast cancer mouse model, the only currently available experimental system with functional resemblance to human TNBC.  This resulted in a significant decrease in tumor growth and increased survival, associated with increased T cell tumor infiltration and a reduction in CD4(+) Foxp3(+) T cells in the tumor microenvironment.  Overall, our results suggest a novel role for HDAC inhibition in combination with immune checkpoint inhibitors and identify a promising therapeutic strategy, supporting its further clinical evaluation for TNBC treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSUq_R8b5qOmiSm0e6ZOaemfW6udTcc2eZ2Im0b0XOWqLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvksFSrsw%253D%253D&md5=c9511d4998918fe6313ea5cdea6dd924</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.23169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.23169%26sid%3Dliteratum%253Aachs%26aulast%3DTerranova-Barberio%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DAli%26aufirst%3DN.%26aulast%3DPawlowska%26aufirst%3DN.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DKrings%26aufirst%3DG.%26aulast%3DRosenblum%26aufirst%3DM.%2BD.%26aulast%3DBudillon%26aufirst%3DA.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26atitle%3DHDAC%2520inhibition%2520potentiates%2520immunotherapy%2520in%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D114156%26epage%3D114172%26doi%3D10.18632%2Foncotarget.23169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span> <span> </span><span class="NLM_article-title">Feedback activation of leukemia inhibitory factor receptor limits response to histone deacetylase inhibitors in breast cancer</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">473</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2016.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.1016%2Fj.ccell.2016.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=27622335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWitrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=459-473&author=H.+Zengauthor=J.+Quauthor=N.+Jinauthor=J.+Xuauthor=C.+Linauthor=Y.+Chenauthor=X.+Yangauthor=X.+Heauthor=S.+Tangauthor=X.+Lanauthor=X.+Yangauthor=Z.+Chenauthor=M.+Huangauthor=J.+Dingauthor=M.+Geng&title=Feedback+activation+of+leukemia+inhibitory+factor+receptor+limits+response+to+histone+deacetylase+inhibitors+in+breast+cancer&doi=10.1016%2Fj.ccell.2016.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer</span></div><div class="casAuthors">Zeng, Hanlin; Qu, Jia; Jin, Nan; Xu, Jun; Lin, Chenchu; Chen, Yi; Yang, Xinying; He, Xiang; Tang, Shuai; Lan, Xiaojing; Yang, Xiaotong; Chen, Ziqi; Huang, Min; Ding, Jian; Geng, Meiyu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">459-473</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors have demonstrated clin. benefits in subtypes of hematol. malignancies.  However, the efficacy of HDAC inhibitors in solid tumors remains uncertain.  This study takes breast cancer as a model to understand mechanisms accounting for limited response of HDAC inhibitors in solid tumors and to seek combination solns.  We discover that feedback activation of leukemia inhibitory factor receptor (LIFR) signaling in breast cancer limits the response to HDAC inhibition.  Mechanistically, HDAC inhibition increases histone acetylation at the LIFR gene promoter, which recruits bromodomain protein BRD4, upregulates LIFR expression, and activates JAK1-STAT3 signaling.  Importantly, JAK1 or BRD4 inhibition sensitizes breast cancer to HDAC inhibitors, implicating combination inhibition of HDAC with JAK1 or BRD4 as potential therapies for breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL24sYbhFYeLVg90H21EOLACvtfcHk0ljprdDjWwABWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWitrnI&md5=9ce620c7a19519a95edd714f8012518c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2016.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2016.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DH.%26aulast%3DQu%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DN.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DLan%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DGeng%26aufirst%3DM.%26atitle%3DFeedback%2520activation%2520of%2520leukemia%2520inhibitory%2520factor%2520receptor%2520limits%2520response%2520to%2520histone%2520deacetylase%2520inhibitors%2520in%2520breast%2520cancer%26jtitle%3DCancer%2520Cell%26date%3D2016%26volume%3D30%26spage%3D459%26epage%3D473%26doi%3D10.1016%2Fj.ccell.2016.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J. B.</span></span> <span> </span><span class="NLM_article-title">Discovery and development of janus kinase (JAK) inhibitors for inflammatory diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5023</span>– <span class="NLM_lpage">5038</span>, <span class="refDoi"> DOI: 10.1021/jm401490p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401490p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5023-5038&author=J.+D.+Clarkauthor=M.+E.+Flanaganauthor=J.+B.+Telliez&title=Discovery+and+development+of+janus+kinase+%28JAK%29+inhibitors+for+inflammatory+diseases&doi=10.1021%2Fjm401490p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span></div><div class="casAuthors">Clark, James D.; Flanagan, Mark E.; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5023-5038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases.  As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnol. industries as therapeutic targets.  Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications.  Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3f7W5g8N6brVg90H21EOLACvtfcHk0ljprdDjWwABWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D&md5=6763ae2d46f52ddcda23e235a60634ae</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401490p%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DTelliez%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520and%2520development%2520of%2520janus%2520kinase%2520%2528JAK%2529%2520inhibitors%2520for%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5023%26epage%3D5038%26doi%3D10.1021%2Fjm401490p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pellegrini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dusanter-Fourt, I.</span></span> <span> </span><span class="NLM_article-title">The structure, regulation and function of the janus kinases (JAKs) and the signal transducers and activators of transcription (STATs)</span>. <i>Eur. J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>248</i></span>,  <span class="NLM_fpage">615</span>– <span class="NLM_lpage">633</span>, <span class="refDoi"> DOI: 10.1111/j.1432-1033.1997.00615.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.1111%2Fj.1432-1033.1997.00615.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=9342212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADyaK2sXmvFKhtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=248&publication_year=1997&pages=615-633&author=S.+Pellegriniauthor=I.+Dusanter-Fourt&title=The+structure%2C+regulation+and+function+of+the+janus+kinases+%28JAKs%29+and+the+signal+transducers+and+activators+of+transcription+%28STATs%29&doi=10.1111%2Fj.1432-1033.1997.00615.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The structure, regulation and function of the Janus kinases (JAKs) and the signal transducers and activators of transcription (STATs)</span></div><div class="casAuthors">Pellegrini, Sandra; Dusanter-Fourt, Isabelle</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">248</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">615-633</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review with 228 refs.  Since the discovery of their physiol. roles in cytokine signaling, the Janus kinases (JAKs) and the signal transducers and activators of transcription (STATs) have attracted considerable attention, to the point that the concept of a intracellular signaling pathway, named JAK/STAT, has emerged.  As originally defined, this pathway involves ligand-dependent activation of a particular class of receptor-assocd. tyrosine kinases, the JAK proteins, which phosphorylate themselves and receptor components, creating recruitment sites for STAT transcription factors.  The STATs are phosphorylated, they dissoc. from the receptor · JAK complex and translocate to the nucleus where they participate in transcriptional gene activation.  Although this pathway was found initially to be activated by interferons, it is now known that a large no. of cytokines, growth factors and hormonal factors activate JAK and/or STAT proteins.  Recent findings have suggested that the interdependence of JAKs and STATs might not be abs. as originally thought.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphjB67aUuu0LVg90H21EOLACvtfcHk0ljprdDjWwABWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmvFKhtr8%253D&md5=fcca548af2fb3f5d692d19b2b0cc2a90</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1111%2Fj.1432-1033.1997.00615.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1432-1033.1997.00615.x%26sid%3Dliteratum%253Aachs%26aulast%3DPellegrini%26aufirst%3DS.%26aulast%3DDusanter-Fourt%26aufirst%3DI.%26atitle%3DThe%2520structure%252C%2520regulation%2520and%2520function%2520of%2520the%2520janus%2520kinases%2520%2528JAKs%2529%2520and%2520the%2520signal%2520transducers%2520and%2520activators%2520of%2520transcription%2520%2528STATs%2529%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D1997%26volume%3D248%26spage%3D615%26epage%3D633%26doi%3D10.1111%2Fj.1432-1033.1997.00615.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nosaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamura, T.</span></span> <span> </span><span class="NLM_article-title">Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) in hematopoietic cells</span>. <i>Int. J. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">319</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10905049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlsV2ktrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2000&pages=309-319&author=T.+Nosakaauthor=T.+Kitamura&title=Janus+kinases+%28JAKs%29+and+signal+transducers+and+activators+of+transcription+%28STATs%29+in+hematopoietic+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) in hematopoietic cells</span></div><div class="casAuthors">Nosaka, Tetsuya; Kitamura, Toshio</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Hematology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-319</span>CODEN:
                <span class="NLM_cas:coden">IJHEEY</span>;
        ISSN:<span class="NLM_cas:issn">0925-5710</span>.
    
            (<span class="NLM_cas:orgname">Carden Jennings Publishing</span>)
        </div><div class="casAbstract">A review is given with 124 refs.  Hematopoietic cell growth and differentiation are controlled by a no. of cytokines.  Ligand stimulation induces rapid phosphorylation of the Tyr residues of the cytokine receptor and a variety of cellular mols.  Among them, Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) have recently been found to play a unique role in cytokine receptor-mediated intracellular signaling and hematopoietic cell development.  Abnormal signaling of the JAK-STAT pathway results in hematopoietic disorders, including severe combined immunodeficiency and leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoE78wv5FjPi7Vg90H21EOLACvtfcHk0ljprdDjWwABWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlsV2ktrk%253D&md5=b04cf4a4dd8e8f1fc0bbea8d980bf866</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNosaka%26aufirst%3DT.%26aulast%3DKitamura%26aufirst%3DT.%26atitle%3DJanus%2520kinases%2520%2528JAKs%2529%2520and%2520signal%2520transducers%2520and%2520activators%2520of%2520transcription%2520%2528STATs%2529%2520in%2520hematopoietic%2520cells%26jtitle%3DInt.%2520J.%2520Hematol.%26date%3D2000%26volume%3D71%26spage%3D309%26epage%3D319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamaoka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saharinen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">The janus kinases (Jaks)</span>. <i>Genome Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">253</span>, <span class="refDoi"> DOI: 10.1186/gb-2004-5-12-253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.1186%2Fgb-2004-5-12-253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=15575979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A280%3ADC%252BD2cngtlKktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=253&author=K.+Yamaokaauthor=P.+Saharinenauthor=M.+Pesuauthor=V.+E.+Holtauthor=O.+Silvennoinenauthor=J.+J.+O%E2%80%99Shea&title=The+janus+kinases+%28Jaks%29&doi=10.1186%2Fgb-2004-5-12-253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The Janus kinases (Jaks)</span></div><div class="casAuthors">Yamaoka Kunihiro; Saharinen Pipsa; Pesu Marko; Holt Vance E T 3rd; Silvennoinen Olli; O'Shea John J</div><div class="citationInfo"><span class="NLM_cas:title">Genome biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">253</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Janus kinase (Jak) family is one of ten recognized families of non-receptor tyrosine kinases.  Mammals have four members of this family, Jak1, Jak2, Jak3 and Tyrosine kinase 2 (Tyk2).  Birds, fish and insects also have Jaks.  Each protein has a kinase domain and a catalytically inactive pseudo-kinase domain, and they each bind cytokine receptors through amino-terminal FERM (Band-4.1, ezrin, radixin, moesin) domains.  Upon binding of cytokines to their receptors, Jaks are activated and phosphorylate the receptors, creating docking sites for signaling molecules, especially members of the signal transducer and activator of transcription (Stat) family.  Mutations of the Drosophila Jak (Hopscotch) have revealed developmental defects, and constitutive activation of Jaks in flies and humans is associated with leukemia-like syndromes.  Through the generation of Jak-deficient cell lines and gene-targeted mice, the essential, nonredundant functions of Jaks in cytokine signaling have been established.  Importantly, deficiency of Jak3 is the basis of human autosomal recessive severe combined immunodeficiency (SCID); accordingly, a selective Jak3 inhibitor has been developed, forming a new class of immunosuppressive drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0BwDh7EYTsV1C8OJBvdfbfW6udTcc2ebOzOu5QHCjlrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2cngtlKktg%253D%253D&md5=4f8335c37dc8c20245e771224c1d5b12</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1186%2Fgb-2004-5-12-253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fgb-2004-5-12-253%26sid%3Dliteratum%253Aachs%26aulast%3DYamaoka%26aufirst%3DK.%26aulast%3DSaharinen%26aufirst%3DP.%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DHolt%26aufirst%3DV.%2BE.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520janus%2520kinases%2520%2528Jaks%2529%26jtitle%3DGenome%2520Biol.%26date%3D2004%26volume%3D5%26spage%3D253%26doi%3D10.1186%2Fgb-2004-5-12-253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of Janus kinase 2 (JAK2) and histone deacetlyase (HDAC) bispecific inhibitors based on Pacritinib and evidence of dual pathway inhibition in hematological cell lines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8233</span>– <span class="NLM_lpage">8262</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00157</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00157" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8233-8262&author=E.+G.+Yangauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Yenauthor=B.+W.+Dymock&title=Design+and+synthesis+of+Janus+kinase+2+%28JAK2%29+and+histone+deacetlyase+%28HDAC%29+bispecific+inhibitors+based+on+Pacritinib+and+evidence+of+dual+pathway+inhibition+in+hematological+cell+lines&doi=10.1021%2Facs.jmedchem.6b00157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines</span></div><div class="casAuthors">Yang, Eugene Guorong; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8233-8262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Blockage of more than one oncoprotein or pathway is now a std. approach in modern cancer therapy.  Multiple inhibition is typically achieved with two or more drugs.  Herein the authors describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorinostat, to create bispecific single mols. with both JAK and HDAC targeted inhibition.  A preferred ether hydroxamate, compd. 51 (11-(4-(N-hydroxyheptanamide)oxy)-[4,1,9]dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12-(27),16,21,23-decaene) inhibits JAK2 and HDAC6 with low nanomolar potency, is <100 nM potent against HDACs 2 and 10, sub-micromolar potent against HDACs 1, 8 and 11, and >50-fold selective for JAK2 in a panel of 97 kinases.  Broad cellular antiproliferative potency is supported by demonstration of JAK-STAT and HDAC pathway blockade in several hematol. cell lines, inhibition of colony formation in HEL cells, and anal. of apoptosis.  This study provides new tool compds. for further exploration of dual JAK-HDAC pathway inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeUHzB39AGWrVg90H21EOLACvtfcHk0ljMtZyZ_4Rlmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL&md5=aa9ae07a1ac1aa21d70ee0f24621fe82</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00157%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DE.%2BG.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520Janus%2520kinase%25202%2520%2528JAK2%2529%2520and%2520histone%2520deacetlyase%2520%2528HDAC%2529%2520bispecific%2520inhibitors%2520based%2520on%2520Pacritinib%2520and%2520evidence%2520of%2520dual%2520pathway%2520inhibition%2520in%2520hematological%2520cell%2520lines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8233%26epage%3D8262%26doi%3D10.1021%2Facs.jmedchem.6b00157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong-Thi, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohlson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of ligand efficient dual inhibitors of Janus kinase (JAK) and histone deacetylase (HDAC) based on ruxolitinib and vorinostat</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8336</span>– <span class="NLM_lpage">8357</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00678</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00678" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8336-8357&author=L.+Yaoauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+Singhauthor=M.+D.+Duong-Thiauthor=J.+X.+T.+Leeauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Y.+Yenauthor=S.+Ohlsonauthor=B.+W.+Dymock&title=Design+and+synthesis+of+ligand+efficient+dual+inhibitors+of+Janus+kinase+%28JAK%29+and+histone+deacetylase+%28HDAC%29+based+on+ruxolitinib+and+vorinostat&doi=10.1021%2Facs.jmedchem.7b00678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat</span></div><div class="casAuthors">Yao, Lianbin; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Singh, Prachi; Duong-Thi, Minh-Dao; Lee, Jeannie X. T.; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Ohlson, Sten; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8336-8357</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Concomitant inhibition of multiple oncogenic pathways is a desirable goal in cancer therapy.  To achieve such an outcome with a single mol. would simplify treatment regimes.  Herein the core features of ruxolitinib, a marketed JAK1/2 inhibitor, have been merged with the HDAC inhibitor vorinostat, leading to new mols. that are bispecific targeted JAK/HDAC inhibitors.  A preferred pyrazole substituted pyrrolopyrimidine, I (R = H), inhibits JAK1 and HDACs 1, 2, 3, 6, and 10 with IC50 values of less than 20 nM, is <100 nM potent against JAK2 and HDAC11, and is selective for the JAK family against a panel of 97 kinases.  Broad cellular antiproliferative potency of I (R = H) is supported by demonstration of JAK-STAT and HDAC pathway blockade in hematol. cell lines.  Me analog I (R = Me) has an even more selective profile.  This study provides new leads for assessment of JAK and HDAC pathway dual inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocWx3JXIW8YbVg90H21EOLACvtfcHk0ljMtZyZ_4Rlmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ&md5=5ac471ee0cc413b08b926803790de7f9</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00678%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DL.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DDuong-Thi%26aufirst%3DM.%2BD.%26aulast%3DLee%26aufirst%3DJ.%2BX.%2BT.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%2BY.%26aulast%3DOhlson%26aufirst%3DS.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520ligand%2520efficient%2520dual%2520inhibitors%2520of%2520Janus%2520kinase%2520%2528JAK%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520based%2520on%2520ruxolitinib%2520and%2520vorinostat%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8336%26epage%3D8357%26doi%3D10.1021%2Facs.jmedchem.7b00678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu-Farseeva, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">619</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.09.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.1016%2Fj.ejmech.2018.09.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=30243158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOltL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2018&pages=593-619&author=Y.+Y.+Chu-Farseevaauthor=N.+Mustafaauthor=A.+Poulsenauthor=E.+C.+Tanauthor=J.+J.+Y.+Yenauthor=W.+J.+Chngauthor=B.+W.+Dymock&title=Design+and+synthesis+of+potent+dual+inhibitors+of+JAK2+and+HDAC+based+on+fusing+the+pharmacophores+of+XL019+and+vorinostat&doi=10.1016%2Fj.ejmech.2018.09.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat</span></div><div class="casAuthors">Chu-Farseeva, Yu-yi; Mustafa, Nurulhuda; Poulsen, Anders; Tan, Eng Chong; Yen, Jeffrey J. Y.; Chng, Wee Joo; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">593-619</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Specifically blocking more than one oncogenic pathway simultaneously in a cancer cell with a combination of different drugs is the mainstay of the majority of cancer treatments.  Being able to do this via two targeted pathways without inducing side effects through a general mechanism, such as chemotherapy, could bring benefit to patients.  In this work we describe a new dual inhibitor of the JAK-STAT and HDAC pathways through designing and developing two types of mol. based on the JAK2 selective inhibitor XL019 and the pan-HDAC inhibitor, vorinostat.  Both series of compds. had examples with low nanomolar JAK2 and HDAC1/6 inhibition.  In some cases good HDAC1 selectivity was achieved while retaining HDAC6 activity.  The obsd. potency is explained through mol. docking studies of all three enzymes.  One example, 69c had 16-25 fold selectivity against the three other JAK-family proteins JAK1, JAK3 and TYK2.  A no. of compds. had sub-micromolar potencies against a panel of 4 solid tumor cell lines and 4 hematol. cell lines with the most potent compd., 45h, having a cellular IC50 of 70 nM against the multiple myeloma cell line KMS-12-BM.  Evidence of both JAK and HDAC pathway inhibition is presented in Hela cells showing that both pathways are modulated.  Evidence of apoptosis with two compds. in 4 sold tumor cell lines is also presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppP3twGjwSkLVg90H21EOLACvtfcHk0lhLLLbT3fMM4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOltL%252FK&md5=a6a1456126270e44dfa2f28916f7b7c0</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.09.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.09.024%26sid%3Dliteratum%253Aachs%26aulast%3DChu-Farseeva%26aufirst%3DY.%2BY.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%2BY.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520potent%2520dual%2520inhibitors%2520of%2520JAK2%2520and%2520HDAC%2520based%2520on%2520fusing%2520the%2520pharmacophores%2520of%2520XL019%2520and%2520vorinostat%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D158%26spage%3D593%26epage%3D619%26doi%3D10.1016%2Fj.ejmech.2018.09.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of janus kinase 2 (JAK2) and histone deacetylase (HDAC) dual inhibitors as a novel strategy for the combinational treatment of leukemia and invasive fungal infections</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6056</span>– <span class="NLM_lpage">6074</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00393</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00393" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Snu7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6056-6074&author=Y.+Huangauthor=G.+Dongauthor=H.+Liauthor=N.+Liuauthor=W.+Zhangauthor=C.+Sheng&title=Discovery+of+janus+kinase+2+%28JAK2%29+and+histone+deacetylase+%28HDAC%29+dual+inhibitors+as+a+novel+strategy+for+the+combinational+treatment+of+leukemia+and+invasive+fungal+infections&doi=10.1021%2Facs.jmedchem.8b00393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections</span></div><div class="casAuthors">Huang, Yahui; Dong, Guoqiang; Li, Huanqiu; Liu, Na; Zhang, Wannian; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6056-6074</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Clin., leukemia patients often suffer from the limited efficacy of chemotherapy and high risks of infection by invasive fungal pathogens.  Herein, a novel therapeutic strategy was developed in which a small mol. can simultaneously treat leukemia and invasive fungal infections (IFIs).  Novel Janus kinase 2 (JAK2) and histone deacetylase (HDAC) dual inhibitors were identified to possess potent anti-proliferative activity toward hematol. cell lines and excellent synergistic effects with fluconazole to treat resistant Candida albicans infections.  In particular, compd. I, a highly active and selective JAK2/HDAC6 dual inhibitor, showed excellent in vivo antitumor efficacy in several acute myeloid leukemia (AML) models and synergized with fluconazole for the treatment of resistant C. albicans infections.  This study highlights the therapeutic potential of JAK2/HDAC dual inhibitors in treating AML and IFIs and provides an efficient strategy for multitargeting drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3_ii7EQG1qLVg90H21EOLACvtfcHk0lhLLLbT3fMM4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Snu7rN&md5=ba7cf74761120f0526ab520196e3dded</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00393%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520janus%2520kinase%25202%2520%2528JAK2%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520dual%2520inhibitors%2520as%2520a%2520novel%2520strategy%2520for%2520the%2520combinational%2520treatment%2520of%2520leukemia%2520and%2520invasive%2520fungal%2520infections%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6056%26epage%3D6074%26doi%3D10.1021%2Facs.jmedchem.8b00393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel janus kinase (JAK) and histone deacetylase (HDAC) dual inhibitors for the treatment of hematological malignancies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3898</span>– <span class="NLM_lpage">3923</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01597</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01597" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvVSls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3898-3923&author=X.+Liangauthor=J.+Zangauthor=X.+Liauthor=S.+Tangauthor=M.+Huangauthor=M.+Gengauthor=C.+J.+Chouauthor=C.+Liauthor=Y.+Caoauthor=W.+Xuauthor=H.+Liuauthor=Y.+Zhang&title=Discovery+of+novel+janus+kinase+%28JAK%29+and+histone+deacetylase+%28HDAC%29+dual+inhibitors+for+the+treatment+of+hematological+malignancies&doi=10.1021%2Facs.jmedchem.8b01597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies</span></div><div class="casAuthors">Liang, Xuewu; Zang, Jie; Li, Xiaoyang; Tang, Shuai; Huang, Min; Geng, Meiyu; Chou, C. James; Li, Chunpu; Cao, Yichun; Xu, Wenfang; Liu, Hong; Zhang, Yingjie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3898-3923</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Concurrent inhibition of Janus kinase (JAK) and histone deacetylase (HDAC) could potentially improve the efficacy of the HDAC inhibitors in the treatment of cancers and resolve the problem of HDAC inhibitor resistance in some tumors.  Here, a novel series of pyrimidin-2-amino-pyrazol hydroxamate derivs. as JAK and HDAC dual inhibitors was designed, synthesized, and evaluated, among which I possessed potent and balanced activities against both JAK2 and HDAC6 with half-maximal inhibitory concn. at the nanomolar level. I exhibited improved antiproliferative and proapoptotic activities over SAHA and ruxolitinib in several hematol. cell lines.  Remarkably, I exhibited more potent antiproliferation effect than the combination of SAHA and ruxolitinib in HEL cells bearing JAK2V617F mutation.  Pharmacokinetic studies in mice showed that I possessed good bioavailability after i.p. administration.  Finally, I showed antitumor efficacy with no significant toxicity in a HEL xenograft model.  Collectively, the results confirm the therapeutic potential of JAK and HDAC dual inhibitors in hematol. malignancies and provide valuable leads for further structural optimization and antitumor mechanism study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOXlwxqcv7m7Vg90H21EOLACvtfcHk0lhLLLbT3fMM4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvVSls7o%253D&md5=356363f40f24ac2ef32194e23a29328e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01597%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DZang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DChou%26aufirst%3DC.%2BJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520novel%2520janus%2520kinase%2520%2528JAK%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520dual%2520inhibitors%2520for%2520the%2520treatment%2520of%2520hematological%2520malignancies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3898%26epage%3D3923%26doi%3D10.1021%2Facs.jmedchem.8b01597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kulagowski, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bull, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyke, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liimatta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bir Kohli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maxey, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendonca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narukulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ubhayakar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Abbema, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waszkowycz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zak, M.</span></span> <span> </span><span class="NLM_article-title">Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">5901</span>– <span class="NLM_lpage">5921</span>, <span class="refDoi"> DOI: 10.1021/jm300438j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300438j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC38XntVOktL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5901-5921&author=J.+J.+Kulagowskiauthor=W.+Blairauthor=R.+J.+Bullauthor=C.+Changauthor=G.+Deshmukhauthor=H.+J.+Dykeauthor=C.+Eigenbrotauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=T.+K.+Harrisonauthor=P.+R.+Hewittauthor=M.+Liimattaauthor=C.+A.+Hurleyauthor=A.+Johnsonauthor=T.+Johnsonauthor=J.+R.+Kennyauthor=P.+Bir+Kohliauthor=R.+J.+Maxeyauthor=R.+Mendoncaauthor=K.+Mortaraauthor=J.+Murrayauthor=R.+Narukullaauthor=S.+Shiaauthor=M.+Steffekauthor=S.+Ubhayakarauthor=M.+Ultschauthor=A.+van+Abbemaauthor=S.+I.+Wardauthor=B.+Waszkowyczauthor=M.+Zak&title=Identification+of+imidazo-pyrrolopyridines+as+novel+and+potent+JAK1+inhibitors&doi=10.1021%2Fjm300438j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Imidazo-Pyrrolopyridines as Novel and Potent JAK1 Inhibitors</span></div><div class="casAuthors">Kulagowski, Janusz J.; Blair, Wade; Bull, Richard J.; Chang, Christine; Deshmukh, Gauri; Dyke, Hazel J.; Eigenbrot, Charles; Ghilardi, Nico; Gibbons, Paul; Harrison, Trevor K.; Hewitt, Peter R.; Liimatta, Marya; Hurley, Christopher A.; Johnson, Adam; Johnson, Tony; Kenny, Jane R.; Bir Kohli, Pawan; Maxey, Robert J.; Mendonca, Rohan; Mortara, Kyle; Murray, Jeremy; Narukulla, Raman; Shia, Steven; Steffek, Micah; Ubhayakar, Savita; Ultsch, Mark; van Abbema, Anne; Ward, Stuart I.; Waszkowycz, Bohdan; Zak, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5901-5921</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A therapeutic rationale is proposed for the treatment of inflammatory diseases, such as rheumatoid arthritis (RA), by specific targeting of the JAK1 pathway.  Examn. of the preferred binding conformation of clin. effective, pan-JAK inhibitor 1 led to identification of a novel, tricyclic hinge binding scaffold 3.  Exploration of SAR through a series of cycloamino and cycloalkylamino analogs demonstrated this template to be highly tolerant of substitution, with a predisposition to moderate selectivity for the JAK1 isoform over JAK2.  This study culminated in the identification of subnanomolar JAK1 inhibitors such as 22 and 49, having excellent cell potency, good rat pharmacokinetic characteristics, and excellent kinase selectivity.  Detn. of the binding modes of the series in JAK1 and JAK2 by X-ray crystallog. supported the design of analogs to enhance affinity and selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpamrk0bG1MK7Vg90H21EOLACvtfcHk0lhbLI5qk_jpAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntVOktL0%253D&md5=d91bc0e24abf14adcf44caf61e3e879f</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm300438j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300438j%26sid%3Dliteratum%253Aachs%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26aulast%3DBlair%26aufirst%3DW.%26aulast%3DBull%26aufirst%3DR.%2BJ.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DDyke%26aufirst%3DH.%2BJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DHarrison%26aufirst%3DT.%2BK.%26aulast%3DHewitt%26aufirst%3DP.%2BR.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DBir%2BKohli%26aufirst%3DP.%26aulast%3DMaxey%26aufirst%3DR.%2BJ.%26aulast%3DMendonca%26aufirst%3DR.%26aulast%3DMortara%26aufirst%3DK.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DNarukulla%26aufirst%3DR.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DSteffek%26aufirst%3DM.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DS.%2BI.%26aulast%3DWaszkowycz%26aufirst%3DB.%26aulast%3DZak%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520imidazo-pyrrolopyridines%2520as%2520novel%2520and%2520potent%2520JAK1%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5901%26epage%3D5921%26doi%3D10.1021%2Fjm300438j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioannidis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuaqui, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimzhanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebernitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivard
Costa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">144</span>– <span class="NLM_lpage">158</span>, <span class="refDoi"> DOI: 10.1021/jm401546n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401546n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWltLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=144-158&author=Q.+Suauthor=S.+Ioannidisauthor=C.+Chuaquiauthor=L.+Almeidaauthor=M.+Alimzhanovauthor=G.+Bebernitzauthor=K.+Bellauthor=M.+Blockauthor=T.+Howardauthor=S.+Huangauthor=D.+Huszarauthor=J.+A.+Readauthor=C.+Rivard%0ACostaauthor=J.+Shiauthor=M.+Suauthor=M.+Yeauthor=M.+Zinda&title=Discovery+of+1-methyl-1H-imidazole+derivatives+as+potent+Jak2+inhibitors&doi=10.1021%2Fjm401546n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-Methyl-1H-imidazole Derivatives as Potent Jak2 Inhibitors</span></div><div class="casAuthors">Su, Qibin; Ioannidis, Stephanos; Chuaqui, Claudio; Almeida, Lynsie; Alimzhanov, Marat; Bebernitz, Geraldine; Bell, Kirsten; Block, Michael; Howard, Tina; Huang, Shan; Huszar, Dennis; Read, Jon A.; Rivard Costa, Caroline; Shi, Jie; Su, Mei; Ye, Minwei; Zinda, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">144-158</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure based design, synthesis, and biol. evaluation of a novel series of 1-methyl-1H-imidazole, as potent Jak2 inhibitors to modulate the Jak/STAT pathway, are described.  Using the C-ring fragment from our first clin. candidate AZD1480 (I), optimization of the series led to the discovery of compd. II, a potent, orally bioavailable Jak2 inhibitor.  Compd. II displayed a high level of cellular activity in hematopoietic cell lines harboring the V617F mutation and in murine BaF3 TEL-Jak2 cells.  Compd. II demonstrated significant tumor growth inhibition in a UKE-1 xenograft model within a well-tolerated dose range.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqczgU5RpFv1bVg90H21EOLACvtfcHk0lhbLI5qk_jpAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWltLnL&md5=88c57119ec77d084a91a1123fd9dea86</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm401546n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401546n%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DChuaqui%26aufirst%3DC.%26aulast%3DAlmeida%26aufirst%3DL.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DBlock%26aufirst%3DM.%26aulast%3DHoward%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DHuszar%26aufirst%3DD.%26aulast%3DRead%26aufirst%3DJ.%2BA.%26aulast%3DRivard%2BCosta%26aufirst%3DC.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DZinda%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25201-methyl-1H-imidazole%2520derivatives%2520as%2520potent%2520Jak2%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D144%26epage%3D158%26doi%3D10.1021%2Fjm401546n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02111&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0001.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of representative JAK/HDAC dual inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02111&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Rational design of novel JAK and HDAC dual inhibitors. (A) Predicted binding mode of compound <b>5b</b> in the ATP pocket of JAK2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>). The unoccupied pocket is indicated by arrow. (B) Design strategy of JAK and HDAC dual inhibitors based on compound <b>5b</b>. The three parts of HDAC inhibitor pharmacophore are indicated in three colors (ZBG, zinc-binding group). In addition, the structure of compound <b>6a</b> is shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02111&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) The predicted binding mode of compound <b>6a</b> in the ATP pocket of JAK2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>). (B) The predicted binding mode of compound <b>6a</b> in the active site of HDAC6 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI">5EEI</a>). (C) Surface representation of compound <b>6a</b> in the ATP pocket of JAK2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>). (D) Surface representation of compound <b>6a</b> in the active site of HDAC6 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI">5EEI</a>). Yellow dashed lines represent the hydrogen bonds. In the ligand, oxygen, nitrogen, carbon, and polar hydrogen atoms are shown in red, blue, green, and white, respectively. The figures were generated using PyMol (<a href="http://www.pymol.org/" class="extLink">http://www.pymol.org/</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02111&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0012.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Intermediate Compounds <b>11a</b>,<b>b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02111&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Conditions and reagents: (a) Pd/C, H<sub>2</sub>, EtOH, rt, 2 days, 90%; (b) (Boc)<sub>2</sub>O, NaHCO<sub>3</sub>/H<sub>2</sub>O, THF, rt, 2 days, 75%; (c) Cs<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, 40–50 °C, 10 h, 76–78%; (d) HCl/EtOAc, rt, 10 h, 63–75%.</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0013.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Intermediate Compounds <b>13a</b>–<b>s</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02111&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Conditions and reagents: (e) for <b>13a</b>–<b>e</b>. CuI, <i>trans</i>-1,2-cyclohexanediamine, K<sub>3</sub>PO<sub>4</sub>, dioxane, 130 °C, microwave 1 h, 20–50%; For <b>13f</b>–<b>s</b>, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, 40–50 °C, 5 h, 67–96%.</p></p></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0014.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Target Compounds <b>6a</b>–<b>g</b>, <b>15a</b>–<b>l</b>, <b>16a</b>–<b>j</b>, and <b>17a</b>–<b>c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02111&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Conditions and reagents: (f) EtOH, 130 °C, microwave 2 h, 18–41%; (g) NH<sub>2</sub>OK, CH<sub>3</sub>OH, rt, 0.5–1 h, 70–95%.</p></p></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Predicted binding mode of compound <b>15d</b> in the ATP pocket of JAK2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>). (B) Predicted binding mode of compound <b>16b</b> in the ATP pocket of JAK2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>). (C) Predicted binding mode of compound <b>15d</b> in the active site of HDAC6 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI">5EEI</a>). (D) Predicted binding mode of compound <b>16b</b> in the active site of HDAC6 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI">5EEI</a>). Yellow dashed lines represent the hydrogen bonds. In the ligand, oxygen, nitrogen, carbon, fluoro, and in polar hydrogen atoms are shown in red, blue, green, pale cyan, and white, respectively. The repulsion force between the ligand molecule with the Lys857 residue of JAK2 protein was shown in a red dashed line. The figures were generated using PyMol (<a href="http://www.pymol.org/" class="extLink">http://www.pymol.org/</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02111&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) MDA-MB-231 cells were treated with DMSO or compounds at 10 μM for 12 h. (B) MDA-MB-231 cells were treated with DMSO or compounds at 3 μM for 12 h. The levels of phosphorylated STAT3 (<i>p</i>-STAT3-Tyr705), STAT3, acetyl-α-tubulin (Ac-tubulin), acetyl-H3K9/14 (Ac-H3K9/14) were determined by immunoblotting. β-Actin was used as a loading control. Ruxolitinib was indicated by INCB in the combined treatment group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02111&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0006.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. BT-549 cells were treated with DMSO or compounds at 3 μM for 12 h. The levels of phosphorylated STAT3 (<i>p</i>-STAT3-Tyr705), acetyl-α-tubulin (Ac-tubulin), and acetyl-H3K9/14 (Ac-H3K9/14) were determined by immunoblotting. GAPDH was used as a loading control. Ruxolitinib was indicated by INCB in the combined treatment group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02111&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0007.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Induction of apoptosis in MDA-MB-231 cells after 48 h of treatment. (B) Efficacy of compound <b>15d</b> at different concentrations to induce apoptosis in MDA-MB-231 cells after 48 h of treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02111&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0008.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Induction of apoptosis in 4T1 cells after 48 h of treatment. (B) Efficacy of compound <b>15d</b> at different concentrations to induce apoptosis in 4T1 cells after 48 h of treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02111&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0009.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) Compounds <b>15d</b> and <b>15h</b> inhibited LIFR-JAK-STAT signaling in MDA-MB-231 stimulated by the  conditioned medium (CM) of Wl-38 cells. The concentrations of compounds <b>15d</b>, <b>15h</b>, and SAHA were all 3 μM in this Western blot. (B) Compounds <b>15d</b> and <b>15h</b> could diminish the activation of LIFR-JAK-STAT signaling triggered by tumor-associated fibroblasts, which suggests that JAK/HDAC dual inhibitors could potentially overcome the drug resistance caused by the tumor microenvironment and improve the in vivo anticancer activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02111&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0010.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Growth curve of the implanted MDA-MB-231 xenograft in mice (RTV ± SEM). Ruxolitinib was indicated by INCB.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02111&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/medium/jm0c02111_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0011.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Kinome selectivity profiles for compound <b>15d</b>. Percent inhibition of phosphorylation of substrates at the indicated test compound concentration using a LANCE or HTRF detection method supplied by Eurofins Cerep Corporation. In these heat maps, inhibition <50% is assigned as green, inhibition >90% inhibition is assigned as red, and 50% < inhibition < 90% is assigned as yellow. In the kinome selectivity profiles, ATP concentration is close to the <i>K</i><sub>m</sub> of each tested kinase.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c02111/20210215/images/large/jm0c02111_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02111&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i128">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26401" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26401" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 33 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span> <span> </span><span class="NLM_article-title">Past, present, and future of targeting Ras for cancer therapies</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.2174/1389557515666151001154111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.2174%2F1389557515666151001154111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=26423695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC28XisVGmurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=345-357&author=Z.+Tanauthor=S.+Zhang&title=Past%2C+present%2C+and+future+of+targeting+Ras+for+cancer+therapies&doi=10.2174%2F1389557515666151001154111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Past, Present, and Future of Targeting Ras for Cancer Therapies</span></div><div class="casAuthors">Tan, Zhi; Zhang, Shuxing</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">345-357</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">For decades, mutant Ras (mut-Ras) proteins have been identified as drivers of multiple cancers including pancreatic, lung, and colon cancers.  However, targeting this oncogene has been challenging and no Ras inhibitors are on the market to date.  Lately several candidates targeting the downstream pathways of Ras signaling, including PI3K and Raf, were approved for cancer treatment.  However, they do not present promising therapeutic effects on patients harboring Ras mutations.  Recently, a variety of compds. have been reported to impair the activity of Ras, and these exciting discoveries reignite the hope for development of novel drugs targeting mut-Ras.  In this article, we will review the progress made in this field and the current state-of-the-art technologies to develop Ras inhibitors.  Also we will discuss the future direction of targeting Ras.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW9CfYW_naDbVg90H21EOLACvtfcHk0ljgLmcgliJ7vA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVGmurg%253D&md5=2d7864a13e4e46aa0dcdf03cc2f4f22e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2174%2F1389557515666151001154111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557515666151001154111%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DS.%26atitle%3DPast%252C%2520present%252C%2520and%2520future%2520of%2520targeting%2520Ras%2520for%2520cancer%2520therapies%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2016%26volume%3D16%26spage%3D345%26epage%3D357%26doi%3D10.2174%2F1389557515666151001154111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology in drug development: A minireview of current technologies</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1211</span>– <span class="NLM_lpage">1218</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.1002%2Fcmdc.201600067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=27154144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlWjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1211-1218&author=Z.+Tanauthor=R.+Chaudhaiauthor=S.+Zhang&title=Polypharmacology+in+drug+development%3A+A+minireview+of+current+technologies&doi=10.1002%2Fcmdc.201600067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology in Drug Development: A Minireview of Current Technologies</span></div><div class="casAuthors">Tan, Zhi; Chaudhai, Rajan; Zhang, Shuxing</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1211-1218</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Polypharmacol., the process in which a single drug is able to bind to multiple targets specifically and simultaneously, is an emerging paradigm in drug development.  The potency of a given drug can be increased through the engagement of multiple targets involved in a certain disease.  Polypharmacol. may also help identify novel applications of existing drugs through drug repositioning.  However, many problems and challenges remain in this field.  Rather than covering all aspects of polypharmacol., this Minireview is focused primarily on recently reported techniques, from bioinformatics technologies to cheminformatics approaches as well as text-mining-based methods, all of which have made significant contributions to the research of polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIgmsYIGVssLVg90H21EOLACvtfcHk0ljgLmcgliJ7vA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlWjsrs%253D&md5=e836929674d5cde6b8431bc1eec36d36</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600067%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DChaudhai%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DS.%26atitle%3DPolypharmacology%2520in%2520drug%2520development%253A%2520A%2520minireview%2520of%2520current%2520technologies%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D1211%26epage%3D1218%26doi%3D10.1002%2Fcmdc.201600067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, C. T.</span></span> <span> </span><span class="NLM_article-title">Multi-target therapeutics: when the whole is greater than the sum of the parts</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2006.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.1016%2Fj.drudis.2006.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=17198971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1ygtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=34-42&author=G.+R.+Zimmermannauthor=J.+Leharauthor=C.+T.+Keith&title=Multi-target+therapeutics%3A+when+the+whole+is+greater+than+the+sum+of+the+parts&doi=10.1016%2Fj.drudis.2006.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target therapeutics: when the whole is greater than the sum of the parts</span></div><div class="casAuthors">Zimmermann Grant R; Lehar Joseph; Keith Curtis T</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">34-42</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">Drugs designed to act against individual molecular targets cannot usually combat multigenic diseases such as cancer, or diseases that affect multiple tissues or cell types such as diabetes and immunoinflammatory disorders.  Combination drugs that impact multiple targets simultaneously are better at controlling complex disease systems, are less prone to drug resistance and are the standard of care in many important therapeutic areas.  The combination drugs currently employed are primarily of rational design, but the increased efficacy they provide justifies in vitro discovery efforts for identifying novel multi-target mechanisms.  In this review, we discuss the biological rationale for combination therapeutics, review some existing combination drugs and present a systematic approach to identify interactions between molecular pathways that could be leveraged for therapeutic benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTI14vYK2Q1LENHe_gFldTbfW6udTcc2eanydVwDmsTPLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1ygtQ%253D%253D&md5=66715499ce21c2855dc6c477aa87f161</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2006.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2006.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DG.%2BR.%26aulast%3DLehar%26aufirst%3DJ.%26aulast%3DKeith%26aufirst%3DC.%2BT.%26atitle%3DMulti-target%2520therapeutics%253A%2520when%2520the%2520whole%2520is%2520greater%2520than%2520the%2520sum%2520of%2520the%2520parts%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26spage%3D34%26epage%3D42%26doi%3D10.1016%2Fj.drudis.2006.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designed multiple ligands. An emerging drug discovery paradigm</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6523</span>– <span class="NLM_lpage">6543</span>, <span class="refDoi"> DOI: 10.1021/jm058225d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+multiple+ligands.+An+emerging+drug+discovery+paradigm&doi=10.1021%2Fjm058225d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0lhU8ZYksFB02A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520multiple%2520ligands.%2520An%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543%26doi%3D10.1021%2Fjm058225d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Csermely, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agoston, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pongor, S.</span></span> <span> </span><span class="NLM_article-title">The efficiency of multi-target drugs: the network approach might help drug design</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">182</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2005.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.1016%2Fj.tips.2005.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=15808341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivV2ht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2005&pages=178-182&author=P.+Csermelyauthor=V.+Agostonauthor=S.+Pongor&title=The+efficiency+of+multi-target+drugs%3A+the+network+approach+might+help+drug+design&doi=10.1016%2Fj.tips.2005.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The efficiency of multi-target drugs: the network approach might help drug design</span></div><div class="casAuthors">Csermely, Peter; Agoston, Vilmos; Pongor, Sandor</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">178-182</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Despite considerable progress in genome- and proteome-based high-throughput screening methods and rational drug design, the no. of successful single-target drugs did not increase appreciably during the past decade.  Network models suggest that partial inhibition of a surprisingly small no. of targets can be more efficient than the complete inhibition of a single target.  This and the success stories of multi-target drugs and combinatorial therapies led us to suggest that systematic drug-design strategies should be directed against multiple targets.  The authors propose that the final effect of partial, but multiple, drug actions might often surpass that of complete drug action at a single target.  The future success of this novel drug-design paradigm will depend not only on a new generation of computer models to identify the correct multiple targets and their multi-fitting, low-affinity drug candidates but also on more-efficient in vivo testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQRoFMVKb5m7Vg90H21EOLACvtfcHk0lhU8ZYksFB02A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivV2ht70%253D&md5=4f1383f4699221ef99041dffafe03e8c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2005.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2005.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DCsermely%26aufirst%3DP.%26aulast%3DAgoston%26aufirst%3DV.%26aulast%3DPongor%26aufirst%3DS.%26atitle%3DThe%2520efficiency%2520of%2520multi-target%2520drugs%253A%2520the%2520network%2520approach%2520might%2520help%2520drug%2520design%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2005%26volume%3D26%26spage%3D178%26epage%3D182%26doi%3D10.1016%2Fj.tips.2005.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, J. L. t.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garvik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartwell, L.</span></span> <span> </span><span class="NLM_article-title">Principles for the buffering of genetic variation</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>291</i></span>,  <span class="NLM_fpage">1001</span>– <span class="NLM_lpage">1004</span>, <span class="refDoi"> DOI: 10.1126/science.291.5506.1001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.1126%2Fscience.291.5506.1001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=11232561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtFGlur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2001&pages=1001-1004&author=J.+L.+t.+Hartmanauthor=B.+Garvikauthor=L.+Hartwell&title=Principles+for+the+buffering+of+genetic+variation&doi=10.1126%2Fscience.291.5506.1001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Cell biology: Principles for the buffering of genetic variation</span></div><div class="casAuthors">Hartman, John L., IV; Garvik, Barbara; Hartwell, Lee</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">5506</span>),
    <span class="NLM_cas:pages">1001-1004</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review, with 51 refs.  Most genetic research has used inbred organisms and has not explored the complexity of natural genetic variation present in outbred populations.  The translation of genotype to phenotype is complicated by gene interactions obsd. as epistasis, canalization, robustness, or buffering.  Anal. of double mutations in inbred exptl. organisms suggests some principles for gene interaction that may apply to natural variation as well.  The buffering of variation in one gene is most often due to a small no. of other genes that function in the same biochem. process.  However, buffering can also result from genes functioning in process extrinsic to that of the primary gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIRpsoLwtorrVg90H21EOLACvtfcHk0lhU8ZYksFB02A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtFGlur4%253D&md5=16d535a0c5abc4ce6d08dedffdc33255</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1126%2Fscience.291.5506.1001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.291.5506.1001%26sid%3Dliteratum%253Aachs%26aulast%3DHartman%26aufirst%3DJ.%2BL.%2Bt.%26aulast%3DGarvik%26aufirst%3DB.%26aulast%3DHartwell%26aufirst%3DL.%26atitle%3DPrinciples%2520for%2520the%2520buffering%2520of%2520genetic%2520variation%26jtitle%3DScience%26date%3D2001%26volume%3D291%26spage%3D1001%26epage%3D1004%26doi%3D10.1126%2Fscience.291.5506.1001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hesham, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasheen, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abouzid, K. A. M.</span></span> <span> </span><span class="NLM_article-title">Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">2058</span>– <span class="NLM_lpage">2109</span>, <span class="refDoi"> DOI: 10.1002/med.21505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.1002%2Fmed.21505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=29733427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A280%3ADC%252BC1MfgsV2htQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=2058-2109&author=H.+M.+Heshamauthor=D.+S.+Lasheenauthor=K.+A.+M.+Abouzid&title=Chimeric+HDAC+inhibitors%3A+Comprehensive+review+on+the+HDAC-based+strategies+developed+to+combat+cancer&doi=10.1002%2Fmed.21505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer</span></div><div class="casAuthors">Hesham Heba M; Lasheen Deena S; Abouzid Khaled A M</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal research reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2058-2109</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Recently, molecular hybridization paradigm became an interesting and smart way to defeat the multifaceted cancer disease by a single molecular entity that acts via several mechanisms just like a magic bullet.  Also, HDAC is an important epigenetic target in drug discovery, and the HDAC inhibitors showed successful pattern as cytotoxic agents.  Because of their flexible structure activity relationship, it was easy to link them to other anticancer scaffolds.  So, many dual action HDAC inhibitors have been developed and most of these hybrids have higher potency than the constituting parents in fighting of the cancer cells.  This review describes potential applications of chimeric HDAC inhibitors, which simultaneously modulate not only HDAC but also multiple targets, in treatment of relapsing and drug-resistant cancers.  We have nearly collected most of the reported dual action HDAC inhibitors yet to provide a comprehensive guide for the drug discovery process for developing more efficient anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7h5aD28C1RtbHMBt0mMIXfW6udTcc2earyrI2KBz7Gbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MfgsV2htQ%253D%253D&md5=c935014e94bf04c21eafbcb2f8ef8218</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fmed.21505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21505%26sid%3Dliteratum%253Aachs%26aulast%3DHesham%26aufirst%3DH.%2BM.%26aulast%3DLasheen%26aufirst%3DD.%2BS.%26aulast%3DAbouzid%26aufirst%3DK.%2BA.%2BM.%26atitle%3DChimeric%2520HDAC%2520inhibitors%253A%2520Comprehensive%2520review%2520on%2520the%2520HDAC-based%2520strategies%2520developed%2520to%2520combat%2520cancer%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2018%26volume%3D38%26spage%3D2058%26epage%3D2109%26doi%3D10.1002%2Fmed.21505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmigiani, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, P. A.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors: molecular mechanisms of action</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5541</span>– <span class="NLM_lpage">5552</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1210620</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.1038%2Fsj.onc.1210620" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=17694093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFersrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=5541-5552&author=W.+S.+Xuauthor=R.+B.+Parmigianiauthor=P.+A.+Marks&title=Histone+deacetylase+inhibitors%3A+molecular+mechanisms+of+action&doi=10.1038%2Fsj.onc.1210620"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors: molecular mechanisms of action</span></div><div class="casAuthors">Xu, W. S.; Parmigiani, R. B.; Marks, P. A.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">5541-5552</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  This review focuses on the mechanisms of action of histone deacetylase (HDAC) inhibitors (HDACi), a group of recently discovered targeted' anticancer agents.  There are 18 HDACs, which are generally divided into four classes, based on sequence homol. to yeast counterparts.  Classical HDACi such as the hydroxamic acid-based vorinostat (also known as SAHA and Zolinza) inhibits classes I, II and IV, but not the NAD+-dependent class III enzymes.  In clin. trials, vorinostat has activity against hematol. and solid cancers at doses well tolerated by patients.  In addn. to histones, HDACs have many other protein substrates involved in regulation of gene expression, cell proliferation and cell death.  Inhibition of HDACs causes accumulation of acetylated forms of these proteins, altering their function.  Thus, HDACs are more properly called 'lysine deacetylases.'.  HDACi induces different phenotypes in various transformed cells, including growth arrest, activation of the extrinsic and/or intrinsic apoptotic pathways, autophagic cell death, reactive oxygen species (ROS)-induced cell death, mitotic cell death and senescence.  In comparison, normal cells are relatively more resistant to HDACi-induced cell death.  The plurality of mechanisms of HDACi-induced cell death reflects both the multiple substrates of HDACs and the heterogeneous patterns of mol. alterations present in different cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5ircqtUCkCLVg90H21EOLACvtfcHk0liUqUI2hX-wxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFersrY%253D&md5=227a7c5d26028e99d412441596ba02ae</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210620&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210620%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DW.%2BS.%26aulast%3DParmigiani%26aufirst%3DR.%2BB.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26atitle%3DHistone%2520deacetylase%2520inhibitors%253A%2520molecular%2520mechanisms%2520of%2520action%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D5541%26epage%3D5552%26doi%3D10.1038%2Fsj.onc.1210620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Potent dual BET/HDAC inhibitors for efficient treatment of pancreatic cancer</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3028</span>– <span class="NLM_lpage">3032</span>, <span class="refDoi"> DOI: 10.1002/anie.201915896</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.1002%2Fanie.201915896" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFegtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2020&pages=3028-3032&author=S.+Heauthor=G.+Dongauthor=Y.+Liauthor=S.+Wuauthor=W.+Wangauthor=C.+Sheng&title=Potent+dual+BET%2FHDAC+inhibitors+for+efficient+treatment+of+pancreatic+cancer&doi=10.1002%2Fanie.201915896"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer</span></div><div class="casAuthors">He, Shipeng; Dong, Guoqiang; Li, Yu; Wu, Shanchao; Wang, Wei; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3028-3032</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">As one of the most aggressive and lethal human malignancies with extremely poor prognosis, there is an urgent demand of more effective therapy for the treatment of pancreatic cancer.  Reported here is a new, effective therapeutic strategy and the design of small-mol. inhibitors that simultaneously target bromodomain and extra-terminal (BET) and histone deacetylase (HDAC), potentially serving as promising therapeutic agents for pancreatic cancer.  A highly potent dual inhibitor (13 a) is identified to possess excellent and balanced activities against BRD4 BD1 (IC50=11 nM) and HDAC1 (IC50=21 nM).  Notably, this compd. shows higher in vitro and in vivo antitumor potency than the BET inhibitor (+)-JQ1 and the HDAC inhibitor vorinostat, either alone or and in combination, highlighting the advantages of BET/HDAC dual inhibitors for more effective treatment of pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9BFNcLfkA4bVg90H21EOLACvtfcHk0liUqUI2hX-wxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFegtLw%253D&md5=78db62cb533611939d9abd0e654ff5f3</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1002%2Fanie.201915896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201915896%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DPotent%2520dual%2520BET%252FHDAC%2520inhibitors%2520for%2520efficient%2520treatment%2520of%2520pancreatic%2520cancer%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2020%26volume%3D59%26spage%3D3028%26epage%3D3032%26doi%3D10.1002%2Fanie.201915896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Novel-targeted therapy for hematological malignancies with JAK and HDAC dual inhibitors</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1849</span>– <span class="NLM_lpage">1852</span>, <span class="refDoi"> DOI: 10.4155/fmc-2019-0168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.4155%2Ffmc-2019-0168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=31517536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslGksbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=1849-1852&author=X.+Liangauthor=H.+Liuauthor=Y.+Zhang&title=Novel-targeted+therapy+for+hematological+malignancies+with+JAK+and+HDAC+dual+inhibitors&doi=10.4155%2Ffmc-2019-0168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Novel-targeted therapy for hematological malignancies with JAK and HDAC dual inhibitors</span></div><div class="casAuthors">Liang, Xuewu; Liu, Hong; Zhang, Yingjie</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1849-1852</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLsT-Fq4Y_LLVg90H21EOLACvtfcHk0liUqUI2hX-wxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslGksbrF&md5=c762aee6742cfadba21d2d1c8f40299c</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2019-0168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2019-0168%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DNovel-targeted%2520therapy%2520for%2520hematological%2520malignancies%2520with%2520JAK%2520and%2520HDAC%2520dual%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2019%26volume%3D11%26spage%3D1849%26epage%3D1852%26doi%3D10.4155%2Ffmc-2019-0168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slingerland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guchelaar, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelderblom, H.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.1097/CAD.0000000000000040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.1097%2FCAD.0000000000000040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=24185382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOms7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=140-149&author=M.+Slingerlandauthor=H.+J.+Guchelaarauthor=H.+Gelderblom&title=Histone+deacetylase+inhibitors%3A+an+overview+of+the+clinical+studies+in+solid+tumors&doi=10.1097%2FCAD.0000000000000040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors</span></div><div class="casAuthors">Slingerland, Marije; Guchelaar, Henk-Jan; Gelderblom, Hans</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">140-149</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  The histone deacetylase inhibitors (HDACi) are a group of small mols. that target histone deacetylases (HDACs) by inhibiting their activity.  HDACi have a long history of use in neurol. and psychiatry as antiepileptics and mood stabilizers.  More recently, they have been investigated as possible treatments for cancer.  HDACi have undergone rapid clin. development in recent years, on the basis of their preclin. in-vitro and in-vivo antitumor activity in hematol. malignancies and solid tumors.  Many HDACi have entered phase I-III clin. trials.  Among the HDACi, vorinostat and romidepsin are currently the most extensively studied.  In 2006 and 2009, resp., they received approval by the United States Food and Drug Administration for treatment of cutaneous T-cell lymphoma and romidepsin for the treatment of peripheral T-cell lymphoma.  Other HDACi, such as panobinostat and valproic acid, also demonstrated activity as therapeutic anticancer agents.  In this article we give an overview of the clin. studies of HDACi in solid tumors.  We start with a short description of the working mechanism of HDACi in general.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1KRdJ1NsR87Vg90H21EOLACvtfcHk0ljAW-ky-M8uiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOms7vJ&md5=a14500b8a14b556a955a9db34cff08b0</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1097%2FCAD.0000000000000040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0000000000000040%26sid%3Dliteratum%253Aachs%26aulast%3DSlingerland%26aufirst%3DM.%26aulast%3DGuchelaar%26aufirst%3DH.%2BJ.%26aulast%3DGelderblom%26aufirst%3DH.%26atitle%3DHistone%2520deacetylase%2520inhibitors%253A%2520an%2520overview%2520of%2520the%2520clinical%2520studies%2520in%2520solid%2520tumors%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2014%26volume%3D25%26spage%3D140%26epage%3D149%26doi%3D10.1097%2FCAD.0000000000000040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stadler, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferber, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCulloch, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, J. A.</span></span> <span> </span><span class="NLM_article-title">A phase II study of depsipeptide in refractory metastatic renal cell cancer</span>. <i>Clin. Genitourin. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.3816/CGC.2006.n.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.3816%2FCGC.2006.n.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=16859580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BD28XotVCmsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=57-60&author=W.+M.+Stadlerauthor=K.+Margolinauthor=S.+Ferberauthor=W.+McCullochauthor=J.+A.+Thompson&title=A+phase+II+study+of+depsipeptide+in+refractory+metastatic+renal+cell+cancer&doi=10.3816%2FCGC.2006.n.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II study of depsipeptide in refractory metastatic renal cell cancer</span></div><div class="casAuthors">Stadler, Walter M.; Margolin, Kim; Ferber, Sandy; McCulloch, William; Thompson, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Genitourinary Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-60</span>CODEN:
                <span class="NLM_cas:coden">CGCLA7</span>;
        ISSN:<span class="NLM_cas:issn">1558-7673</span>.
    
            (<span class="NLM_cas:orgname">Cancer Information Group</span>)
        </div><div class="casAbstract">Therapeutic options for renal cell cancer are inadequate.  Depsipeptide is a histone deacetylase inhibitor with promising preclin. and early clin. activity.  Patients with refractory renal cell cancer with normal organ function and no history of significant cardiovascular disease were enrolled on a multi-institutional, single-arm, phase II study.  Patients received depsipeptide 13 mg/m2 i.v. over 4 h on days 1, 8, and 15 of a 28-day cycle with disease reevaluation performed every 8 wk.  One response in the initial 16 enrolled patients was required for full accrual to 25 patients, from which 5 responses needed to be obsd. in order to consider the agent appropriate for further study.  Toxicity was assessed using National Cancer Institute Common Toxicity Criteria, version 2.0.  The 29 evaluable patients, who were accrued so that 25 patients who received ≥3 doses of depsipeptide could be obsd., were heavily pretreated with a median of 2 previous systemic therapies and a 2-yr median duration of metastatic disease.  Twenty-four had clear-cell histol.  The most common serious toxicities were fatigue, nausea, vomiting, and anemia.  Two patients developed a prolonged QTc interval, one patient each developed grade 3 atrial fibrillation and tachycardia, and there was 1 sudden death.  Two patients experienced an objective response (1 complete response) for an overall response rate of 7% (95% CI, 0.8%-23%).  Depsipeptide at this dose and schedule does not have sufficient activity for further investigation in this patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2x500kPN76bVg90H21EOLACvtfcHk0ljAW-ky-M8uiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotVCmsr8%253D&md5=410a6ab15f374e6243042dddc3760e68</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.3816%2FCGC.2006.n.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3816%252FCGC.2006.n.018%26sid%3Dliteratum%253Aachs%26aulast%3DStadler%26aufirst%3DW.%2BM.%26aulast%3DMargolin%26aufirst%3DK.%26aulast%3DFerber%26aufirst%3DS.%26aulast%3DMcCulloch%26aufirst%3DW.%26aulast%3DThompson%26aufirst%3DJ.%2BA.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520depsipeptide%2520in%2520refractory%2520metastatic%2520renal%2520cell%2520cancer%26jtitle%3DClin.%2520Genitourin.%2520Cancer%26date%3D2006%26volume%3D5%26spage%3D57%26epage%3D60%26doi%3D10.3816%2FCGC.2006.n.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Molife, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karavasilis, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riggs, C. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadler, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCulloch, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dearnaley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bono, J. S.</span></span> <span> </span><span class="NLM_article-title">Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)</span>. <i>Ann. Oncol</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">113</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdp270</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.1093%2Fannonc%2Fmdp270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=19608618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A280%3ADC%252BD1Mfisl2htg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=109-113&author=L.+R.+Molifeauthor=G.+Attardauthor=P.+C.+Fongauthor=V.+Karavasilisauthor=A.+H.+Reidauthor=S.+Pattersonauthor=C.+E.+Riggsauthor=C.+Higanoauthor=W.+M.+Stadlerauthor=W.+McCullochauthor=D.+Dearnaleyauthor=C.+Parkerauthor=J.+S.+de+Bono&title=Phase+II%2C+two-stage%2C+single-arm+trial+of+the+histone+deacetylase+inhibitor+%28HDACi%29+romidepsin+in+metastatic+castration-resistant+prostate+cancer+%28CRPC%29&doi=10.1093%2Fannonc%2Fmdp270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)</span></div><div class="casAuthors">Molife L R; Attard G; Fong P C; Karavasilis V; Reid A H M; Patterson S; Riggs C E Jr; Higano C; Stadler W M; McCulloch W; Dearnaley D; Parker C; de Bono J S</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">109-13</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Histone deacetylase blockade can promote heat shock protein 90 (HSP90) acetylation, abrogating androgen receptor signaling.  A phase II trial of the histone deacetylase inhibitor (HDACi) romidepsin was conducted in patients with progressing, metastatic, castration-resistant prostate cancer (CRPC).  PATIENTS AND METHODS:  A dose of 13 mg/m(2) was administered i.v. over 4 h on days 1, 8 and 15 every 28 days.  The primary end point was rate of disease control defined as no evidence of radiological progression at 6 months.  A sample size of 16 assessable patients in stage 1 and nine assessable patients in stage 2 was selected; progression to stage 2 required one or more patients with disease control in stage 1 (H(o) = 0.10, H(a) = 0.30; alpha and beta = 0.10).  RESULTS:  Thirty-five patients were enrolled.  Two patients achieved a confirmed radiological partial response (RECIST) lasting > or = 6 months, along with a confirmed prostate-specific antigen decline of > or = 50%.  Eleven patients experienced toxicity necessitating early discontinuation.  The commonest adverse events were nausea (30 patients; 85.7%), fatigue (28 patients; 80.0%), vomiting (23 patients; 65.7%) and anorexia (20 patients; 57.1%).  There was no significant cardiac toxicity.  CONCLUSIONS:  At the dose and schedule selected, romidepsin demonstrated minimal antitumor activity in chemonaive patients with CRPC.  Further studies of improved HDACi, alone and in combination with other therapies, should nevertheless be investigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTcTdc2c-lnpTQLBVDQn4bCfW6udTcc2eYtnSsWw66VJ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mfisl2htg%253D%253D&md5=6a04735a4117394e94bda2a43f05c417</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdp270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdp270%26sid%3Dliteratum%253Aachs%26aulast%3DMolife%26aufirst%3DL.%2BR.%26aulast%3DAttard%26aufirst%3DG.%26aulast%3DFong%26aufirst%3DP.%2BC.%26aulast%3DKaravasilis%26aufirst%3DV.%26aulast%3DReid%26aufirst%3DA.%2BH.%26aulast%3DPatterson%26aufirst%3DS.%26aulast%3DRiggs%26aufirst%3DC.%2BE.%26aulast%3DHigano%26aufirst%3DC.%26aulast%3DStadler%26aufirst%3DW.%2BM.%26aulast%3DMcCulloch%26aufirst%3DW.%26aulast%3DDearnaley%26aufirst%3DD.%26aulast%3DParker%26aufirst%3DC.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26atitle%3DPhase%2520II%252C%2520two-stage%252C%2520single-arm%2520trial%2520of%2520the%2520histone%2520deacetylase%2520inhibitor%2520%2528HDACi%2529%2520romidepsin%2520in%2520metastatic%2520castration-resistant%2520prostate%2520cancer%2520%2528CRPC%2529%26jtitle%3DAnn.%2520Oncol%26date%3D2010%26volume%3D21%26spage%3D109%26epage%3D113%26doi%3D10.1093%2Fannonc%2Fmdp270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haigentz, M.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keresztes, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culliney, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaba, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirieac, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariadason, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belbin, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greally, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddad, R. I.</span></span> <span> </span><span class="NLM_article-title">Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer</span>. <i>Oral Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">1281</span>– <span class="NLM_lpage">1288</span>, <span class="refDoi"> DOI: 10.1016/j.oraloncology.2012.05.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.1016%2Fj.oraloncology.2012.05.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=22748449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFGntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2012&pages=1281-1288&author=M.+Haigentzauthor=M.+Kimauthor=C.+Sartaauthor=J.+Linauthor=R.+S.+Keresztesauthor=B.+Cullineyauthor=A.+G.+Gabaauthor=R.+V.+Smithauthor=G.+I.+Shapiroauthor=L.+R.+Chirieacauthor=J.+M.+Mariadasonauthor=T.+J.+Belbinauthor=J.+M.+Greallyauthor=J.+J.+Wrightauthor=R.+I.+Haddad&title=Phase+II+trial+of+the+histone+deacetylase+inhibitor+romidepsin+in+patients+with+recurrent%2Fmetastatic+head+and+neck+cancer&doi=10.1016%2Fj.oraloncology.2012.05.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer</span></div><div class="casAuthors">Haigentz, Missak; Kim, Mimi; Sarta, Catherine; Lin, Juan; Keresztes, Roger S.; Culliney, Bruce; Gaba, Anu G.; Smith, Richard V.; Shapiro, Geoffrey I.; Chirieac, Lucian R.; Mariadason, John M.; Belbin, Thomas J.; Greally, John M.; Wright, John J.; Haddad, Robert I.</div><div class="citationInfo"><span class="NLM_cas:title">Oral Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">v1281-1288</span>CODEN:
                <span class="NLM_cas:coden">EJCCER</span>;
        ISSN:<span class="NLM_cas:issn">1368-8375</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Objectives: Patients with advanced squamous cell carcinoma of the head and neck (SCCHN) have limited treatment options.  Inhibition of histone deacetylases (HDACs) represents a novel therapeutic approach warranting addnl. investigation in solid tumors.  Methods: A phase II trial of single agent romidepsin, an HDAC inhibitor, was performed in 14 patients with SCCHN who provided consent for pre- and post-therapy samples of accessible tumor, blood and uninvolved oral mucosa.  Romidepsin was administered at 13 mg/m2 as a 4-h i.v. infusion on days 1, 8 and 15 of 28 day cycles, with response assessment by RECIST every 8 wk.  Results: Objective responses were not obsd., although 2 heavily pretreated patients had brief clin. disease stabilization.  Obsd. toxicities were expected, including frequent severe fatigue.  Immunohistochem. anal. of 7 pre- and post-treatment tumor pairs demonstrated induction of p21Waf1/Cip1 characteristic of HDAC inhibition, as well as decreased Ki67 staining.  Exploratory microarray analyses of mucosal and tumor samples detected changes in gene expression following romidepsin treatment that were most commonly assocd. with regulation of transcription, cell cycle control, signal transduction, and electron transport.  Treatment with romidepsin did not alter the extent of DNA methylation of candidate gene loci (including CDH1 and hMLH1) in SCCHN tumors.  Conclusions: Single agent romidepsin has limited activity for the treatment of SCCHN but can effectively achieve tumor-assocd. HDAC inhibition.  Although tolerability of romidepsin in this setting may be limiting, further evaluation of other HDAC inhibitors in combination with active therapies may be justified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN0KyybKp80bVg90H21EOLACvtfcHk0lhPNjJiGvkZbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFGntbo%253D&md5=1766ff37fd8bb92b0101f9d1da093e73</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.oraloncology.2012.05.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.oraloncology.2012.05.024%26sid%3Dliteratum%253Aachs%26aulast%3DHaigentz%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DSarta%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DKeresztes%26aufirst%3DR.%2BS.%26aulast%3DCulliney%26aufirst%3DB.%26aulast%3DGaba%26aufirst%3DA.%2BG.%26aulast%3DSmith%26aufirst%3DR.%2BV.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DMariadason%26aufirst%3DJ.%2BM.%26aulast%3DBelbin%26aufirst%3DT.%2BJ.%26aulast%3DGreally%26aufirst%3DJ.%2BM.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%26aulast%3DHaddad%26aufirst%3DR.%2BI.%26atitle%3DPhase%2520II%2520trial%2520of%2520the%2520histone%2520deacetylase%2520inhibitor%2520romidepsin%2520in%2520patients%2520with%2520recurrent%252Fmetastatic%2520head%2520and%2520neck%2520cancer%26jtitle%3DOral%2520Oncol.%26date%3D2012%26volume%3D48%26spage%3D1281%26epage%3D1288%26doi%3D10.1016%2Fj.oraloncology.2012.05.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, G.</span></span> <span> </span><span class="NLM_article-title">Dual-target inhibitors based on HDACs: novel antitumor agents for cancer therapy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">8977</span>– <span class="NLM_lpage">9002</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00491</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00491" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnslShtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=8977-9002&author=T.+Liuauthor=Y.+Wanauthor=Y.+Xiaoauthor=C.+Xiaauthor=G.+Duan&title=Dual-target+inhibitors+based+on+HDACs%3A+novel+antitumor+agents+for+cancer+therapy&doi=10.1021%2Facs.jmedchem.0c00491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy</span></div><div class="casAuthors">Liu, Tingting; Wan, Yichao; Xiao, Yuliang; Xia, Chengcai; Duan, Guiyun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">8977-9002</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) play an important role in regulating target gene expression.  They have been highlighted as a novel category of anticancer targets, and their inhibition can induce apoptosis, differentiation, and growth arrest in cancer cells.  In view of the fact that HDAC inhibitors and other antitumor agents, such as BET inhibitors, topoisomerase inhibitors, and RTK pathway inhibitors, exert a synergistic effect on cellular processes in cancer cells, the combined inhibition of two targets is regarded as a rational strategy to improve the effectiveness of these single-target drugs for cancer treatment.  In this review, we discuss the theor. basis for designing HDAC-involved dual-target drugs and provide insight into the structure-activity relationships of these dual-target agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohbD4ktOU4jbVg90H21EOLACvtfcHk0lhPNjJiGvkZbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnslShtL8%253D&md5=fa6764d35879c6a8973d57231854f821</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00491%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DXia%26aufirst%3DC.%26aulast%3DDuan%26aufirst%3DG.%26atitle%3DDual-target%2520inhibitors%2520based%2520on%2520HDACs%253A%2520novel%2520antitumor%2520agents%2520for%2520cancer%2520therapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D8977%26epage%3D9002%26doi%3D10.1021%2Facs.jmedchem.0c00491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahboobi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichhorn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pongratz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciossek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckers, T.</span></span> <span> </span><span class="NLM_article-title">Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">8546</span>– <span class="NLM_lpage">8555</span>, <span class="refDoi"> DOI: 10.1021/jm100665z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100665z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeksL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8546-8555&author=S.+Mahboobiauthor=A.+Sellmerauthor=M.+Winklerauthor=E.+Eichhornauthor=H.+Pongratzauthor=T.+Ciossekauthor=T.+Baerauthor=T.+Maierauthor=T.+Beckers&title=Novel+chimeric+histone+deacetylase+inhibitors%3A+a+series+of+lapatinib+hybrides+as+potent+inhibitors+of+epidermal+growth+factor+receptor+%28EGFR%29%2C+human+epidermal+growth+factor+receptor+2+%28HER2%29%2C+and+histone+deacetylase+activity&doi=10.1021%2Fjm100665z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Chimeric Histone Deacetylase Inhibitors: A Series of Lapatinib Hybrids as Potent Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and Histone Deacetylase Activity</span></div><div class="casAuthors">Mahboobi, Siavosh; Sellmer, Andreas; Winkler, Matthias; Eichhorn, Emerich; Pongratz, Herwig; Ciossek, Thomas; Baer, Thomas; Maier, Thomas; Beckers, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8546-8555</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Reversible lysine-specific acetylation has been described as an important posttranslational modification, regulating chromatin structure and transcriptional activity in the case of core histone proteins.  Histone deacetylases (HDAC) are considered as a promising target for anticancer drug development, with I as pan-HDAC inhibitor approved for cutaneous T-cell lymphoma therapy and several other HDAC inhibitors currently in preclin. and clin. development.  Protein kinases are a well-established target for cancer therapy with the EGFR/HER2 inhibitor II approved for treatment of advanced, HER2 pos. breast cancer as a prominent example.  The present report presents a novel strategy for cancer drug development by combination of EGFR/HER2 kinase and HDAC inhibitory activity in one mol.  By combining the structural features of II with an (E)-3-(aryl)-N-hydroxyacrylamide motif known from HDAC inhibitors like III or IV, selective inhibitors were obtained for both targets with potent cellular activity (target inhibition and cytotoxicity) of selected compds. V (X = m-phenylene, 2,5-furandiyl).  By combining two distinct pharmacol. properties in one mol., a broader activity spectrum is postulated and less likelihood of drug resistance in cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEElZRNfAQZ7Vg90H21EOLACvtfcHk0lhzmBnAZ-tB7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeksL3I&md5=81bba7c00bb26b42c54075acce5ba525</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm100665z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100665z%26sid%3Dliteratum%253Aachs%26aulast%3DMahboobi%26aufirst%3DS.%26aulast%3DSellmer%26aufirst%3DA.%26aulast%3DWinkler%26aufirst%3DM.%26aulast%3DEichhorn%26aufirst%3DE.%26aulast%3DPongratz%26aufirst%3DH.%26aulast%3DCiossek%26aufirst%3DT.%26aulast%3DBaer%26aufirst%3DT.%26aulast%3DMaier%26aufirst%3DT.%26aulast%3DBeckers%26aufirst%3DT.%26atitle%3DNovel%2520chimeric%2520histone%2520deacetylase%2520inhibitors%253A%2520a%2520series%2520of%2520lapatinib%2520hybrides%2520as%2520potent%2520inhibitors%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%252C%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202%2520%2528HER2%2529%252C%2520and%2520histone%2520deacetylase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8546%26epage%3D8555%26doi%3D10.1021%2Fjm100665z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.12.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.1016%2Fj.ejmech.2015.12.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=26741358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVOj" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2016&pages=1-12&author=F.+W.+Pengauthor=J.+Xuanauthor=T.+T.+Wuauthor=J.+Y.+Xueauthor=Z.+W.+Renauthor=D.+K.+Liuauthor=X.+Q.+Wangauthor=X.+H.+Chenauthor=J.+W.+Zhangauthor=Y.+G.+Xuauthor=L.+Shi&title=Design%2C+synthesis+and+biological+evaluation+of+N-phenylquinazolin-4-amine+hybrids+as+dual+inhibitors+of+VEGFR-2+and+HDAC&doi=10.1016%2Fj.ejmech.2015.12.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC</span></div><div class="casAuthors">Peng, Fan-Wei; Xuan, Ji; Wu, Ting-Ting; Xue, Jia-Yu; Ren, Zi-Wei; Liu, Da-Ke; Wang, Xiu-Qi; Chen, Xin-Hang; Zhang, Jia-Wei; Xu, Yun-Gen; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In this work, a series of hybrids bearing N-phenylquinazolin-4-amine and hydroxamic acid moieties I (R1, R2 = H, F, Cl, Br, n = 2, 3, 4, 5) were designed and identified as dual VEGFR-2/HDAC inhibitors.  Compd. I (R1 = H, R2 = Br, n = 5) exhibited the most potent inhibitory activity against HDAC with IC50 of 2.2 nM and strong inhibitory effect against VEGFR-2 with IC50 of 74 nM.  It also showed the most potent inhibitory activity against a human breast cancer cell line MCF-7 with IC50 of 0.85 μM.  Docking simulation supported the initial pharmacophoric hypothesis and suggested a common mode of interaction at the active binding sites of VEGFR-2 and HDLP (Histone Deacetylase-Like Protein), which demonstrates that compd. I (R1 = H, R2 = Br, n = 5) is a potential agent for cancer therapy deserving further researching.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT_jbaom_UR7Vg90H21EOLACvtfcHk0lhzmBnAZ-tB7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVOj&md5=1a0c299ec484daa522da5969e8a35cec</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.12.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.12.033%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DF.%2BW.%26aulast%3DXuan%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DT.%2BT.%26aulast%3DXue%26aufirst%3DJ.%2BY.%26aulast%3DRen%26aufirst%3DZ.%2BW.%26aulast%3DLiu%26aufirst%3DD.%2BK.%26aulast%3DWang%26aufirst%3DX.%2BQ.%26aulast%3DChen%26aufirst%3DX.%2BH.%26aulast%3DZhang%26aufirst%3DJ.%2BW.%26aulast%3DXu%26aufirst%3DY.%2BG.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520N-phenylquinazolin-4-amine%2520hybrids%2520as%2520dual%2520inhibitors%2520of%2520VEGFR-2%2520and%2520HDAC%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D109%26spage%3D1%26epage%3D12%26doi%3D10.1016%2Fj.ejmech.2015.12.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel Pazopanib-based HDAC and VEGFR dual inhibitors targeting cancer epigenetics and angiogenesis simultaneously</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5304</span>– <span class="NLM_lpage">5322</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00384</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00384" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpvVGrsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5304-5322&author=J.+Zangauthor=X.+Liangauthor=Y.+Huangauthor=Y.+Jiaauthor=X.+Liauthor=W.+Xuauthor=C.+J.+Chouauthor=Y.+Zhang&title=Discovery+of+novel+Pazopanib-based+HDAC+and+VEGFR+dual+inhibitors+targeting+cancer+epigenetics+and+angiogenesis+simultaneously&doi=10.1021%2Facs.jmedchem.8b00384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously</span></div><div class="casAuthors">Zang, Jie; Liang, Xuewu; Huang, Yongxue; Jia, Yuping; Li, Xiaoyang; Xu, Wenfang; Chou, C. James; Zhang, Yingjie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5304-5322</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein a novel series of pazopanib hybrids as polypharmacol. antitumor agents were developed based on the crosstalk between histone deacetylases (HDACs) and vascular endothelial growth factor (VEGF) pathway.  Among them, one ortho-aminoanilide 6d and one hydroxamic acid 13f exhibited considerable total HDACs and VEGFR-2 inhibitory activities.  The HDAC inhibitory activities endowed 6d and 13f with potent antiproliferative activities, which was not obsd. in the approved VEGFR inhibitor pazopanib.  Compds. 6d and 13f possessed comparable HDAC isoform selectivity profiles to the clin. class I HDAC inhibitor MS-275 and the approved pan-HDAC inhibitor SAHA, resp. 6d and 13f also exhibited uncompromised multiple tyrosine kinases inhibitory activities relative to pazopanib.  The intracellular dual inhibition to HDAC and VEGFR of 6d and 13f was validated by Western blot anal.  In both HUVECs tube formation assay and rat thoracic aorta rings assay, 6d and 13f showed comparable antiangiogenic potencies to pazopanib.  What's more, 6d possessed desirable pharmacokinetic profiles with the oral bioavailability of 72% in SD rats and considerable in vivo antitumor efficacy in a human colorectal adenocarcinoma (HT-29) xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpmz6rwKiKSbVg90H21EOLACvtfcHk0lhzmBnAZ-tB7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpvVGrsL8%253D&md5=437da0a6cca1ec211219aef87a6ddbc5</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00384%26sid%3Dliteratum%253Aachs%26aulast%3DZang%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DChou%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520novel%2520Pazopanib-based%2520HDAC%2520and%2520VEGFR%2520dual%2520inhibitors%2520targeting%2520cancer%2520epigenetics%2520and%2520angiogenesis%2520simultaneously%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5304%26epage%3D5322%26doi%3D10.1021%2Facs.jmedchem.8b00384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ko, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffey, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandvold, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soellner, M. B.</span></span> <span> </span><span class="NLM_article-title">Development of a chimeric c-Src kinase and HDAC inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">783</span>, <span class="refDoi"> DOI: 10.1021/ml400175d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400175d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVKit7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=779-783&author=K.+S.+Koauthor=M.+E.+Steffeyauthor=K.+R.+Brandvoldauthor=M.+B.+Soellner&title=Development+of+a+chimeric+c-Src+kinase+and+HDAC+inhibitor&doi=10.1021%2Fml400175d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Chimeric c-Src Kinase and HDAC Inhibitor</span></div><div class="casAuthors">Ko, Kristin S.; Steffey, Michael E.; Brandvold, Kristoffer R.; Soellner, Matthew B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">779-783</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">On the basis of synergism obsd. between a selective c-Src kinase inhibitor with an HDAC inhibitor, the development of the first chimeric c-Src kinase and HDAC inhibitor is described.  The optimized chimeric inhibitor is shown to be a potent c-Src and HDAC inhibitor.  Chimeric inhibitor (I) is further shown to be highly efficacious in cancer cell lines and significantly more efficacious than a dual-targeting strategy using discrete c-Src and HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzi2suGn-7ErVg90H21EOLACvtfcHk0lj9QU9TX811tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVKit7rL&md5=5f34ce3b1f65a8ac1a4341f563a5e1d9</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fml400175d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400175d%26sid%3Dliteratum%253Aachs%26aulast%3DKo%26aufirst%3DK.%2BS.%26aulast%3DSteffey%26aufirst%3DM.%2BE.%26aulast%3DBrandvold%26aufirst%3DK.%2BR.%26aulast%3DSoellner%26aufirst%3DM.%2BB.%26atitle%3DDevelopment%2520of%2520a%2520chimeric%2520c-Src%2520kinase%2520and%2520HDAC%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D779%26epage%3D783%26doi%3D10.1021%2Fml400175d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Makarevic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juengel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maxeiner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsaur, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roos, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaheta, R. A.</span></span> <span> </span><span class="NLM_article-title">HDAC inhibition counteracts metastatic re-activation of prostate cancer cells induced by chronic mTOR suppression</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.3390/cells7090129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.3390%2Fcells7090129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVOju7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=129-146&author=J.+Makarevicauthor=J.+Rutzauthor=E.+Juengelauthor=S.+Maxeinerauthor=J.+Maniauthor=S.+Valloauthor=I.+Tsaurauthor=F.+Roosauthor=F.+K.+Chunauthor=R.+A.+Blaheta&title=HDAC+inhibition+counteracts+metastatic+re-activation+of+prostate+cancer+cells+induced+by+chronic+mTOR+suppression&doi=10.3390%2Fcells7090129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibition counteracts metastatic re-activation of prostate cancer cells induced by chronic mTOR suppression</span></div><div class="casAuthors">Makarevic, Jasmina; Rutz, Jochen; Juengel, Eva; Maxeiner, Sebastian; Mani, Jens; Vallo, Stefan; Tsaur, Igor; Roos, Frederik; Chun, Felix K.-H.; Blaheta, Roman A.</div><div class="citationInfo"><span class="NLM_cas:title">Cells</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">129</span>CODEN:
                <span class="NLM_cas:coden">CELLC6</span>;
        ISSN:<span class="NLM_cas:issn">2073-4409</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">This study was designed to investigate whether epigenetic modulation by histone deacetylase (HDAC) inhibition might circumvent resistance towards the mechanistic target of rapamycin (mTOR) inhibitor temsirolimus in a prostate cancer cell model.  Parental (par) and temsirolimus-resistant (res) PC3 prostate cancer cells were exposed to the HDAC inhibitor valproic acid (VPA), and tumor cell adhesion, chemotaxis, migration, and invasion were evaluated.  Temsirolimus resistance was characterized by reduced binding of PC3res cells to endothelium, immobilized collagen, and fibronectin, but increased adhesion to laminin, as compared to the parental cells.  Chemotaxis, migration, and invasion of PC3res cells were enhanced following temsirolimus re-treatment.  Integrin α and β receptors were significantly altered in PC3res compared to PC3par cells.  VPA significantly counteracted temsirolimus resistance by down-regulating tumor cell-matrix interaction, chemotaxis, and migration.  Evaluation of integrin expression in the presence of VPA revealed a significant down-regulation of integrin α5 in PC3res cells.  Blocking studies demonstrated a close assocn. between α5 expression on PC3res and chemotaxis.  In this in vitro model, temsirolimus resistance drove prostate cancer cells to become highly motile, while HDAC inhibition reversed the metastatic activity.  The VPA-induced inhibition of metastatic activity was accompanied by a lowered integrin α5 surface level on the tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS9P6pTqxjq7Vg90H21EOLACvtfcHk0lj9QU9TX811tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVOju7rO&md5=a8db40231a1f0b786549f9b3768b3c4c</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.3390%2Fcells7090129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells7090129%26sid%3Dliteratum%253Aachs%26aulast%3DMakarevic%26aufirst%3DJ.%26aulast%3DRutz%26aufirst%3DJ.%26aulast%3DJuengel%26aufirst%3DE.%26aulast%3DMaxeiner%26aufirst%3DS.%26aulast%3DMani%26aufirst%3DJ.%26aulast%3DVallo%26aufirst%3DS.%26aulast%3DTsaur%26aufirst%3DI.%26aulast%3DRoos%26aufirst%3DF.%26aulast%3DChun%26aufirst%3DF.%2BK.%26aulast%3DBlaheta%26aufirst%3DR.%2BA.%26atitle%3DHDAC%2520inhibition%2520counteracts%2520metastatic%2520re-activation%2520of%2520prostate%2520cancer%2520cells%2520induced%2520by%2520chronic%2520mTOR%2520suppression%26jtitle%3DCells%26date%3D2018%26volume%3D7%26spage%3D129%26epage%3D146%26doi%3D10.3390%2Fcells7090129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Terranova-Barberio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlowska, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krings, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenblum, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budillon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P. N.</span></span> <span> </span><span class="NLM_article-title">HDAC inhibition potentiates immunotherapy in triple negative breast cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">114156</span>– <span class="NLM_lpage">114172</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.23169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.18632%2Foncotarget.23169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=29371976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A280%3ADC%252BC1MvksFSrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=114156-114172&author=M.+Terranova-Barberioauthor=S.+Thomasauthor=N.+Aliauthor=N.+Pawlowskaauthor=J.+Parkauthor=G.+Kringsauthor=M.+D.+Rosenblumauthor=A.+Budillonauthor=P.+N.+Munster&title=HDAC+inhibition+potentiates+immunotherapy+in+triple+negative+breast+cancer&doi=10.18632%2Foncotarget.23169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibition potentiates immunotherapy in triple negative breast cancer</span></div><div class="casAuthors">Terranova-Barberio Manuela; Thomas Scott; Pawlowska Nela; Park Jeenah; Munster Pamela N; Ali Niwa; Rosenblum Michael D; Krings Gregor; Budillon Alfredo</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">69</span>),
    <span class="NLM_cas:pages">114156-114172</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Triple-negative breast cancer (TNBC) represents a more aggressive and difficult subtype of breast cancer where responses to chemotherapy occur, but toxicity is significant and resistance often follows.  Immunotherapy has shown promising results in various types of cancer, including breast cancer.  Here, we investigated a new combination strategy where histone deacetylase inhibitors (HDACi) are applied with immune checkpoint inhibitors to improve immunotherapy responses in TNBC.  Testing different epigenetic modifiers, we focused on the mechanisms underlying HDACi as priming modulators of immunotherapy.  Tumor cells were co-cultured with human peripheral blood mononuclear cells (PBMCs) and flow cytometric immunophenotyping was performed to define the role of epigenetic priming in promoting tumor antigen presentation and immune cell activation.  We found that HDACi up-regulate PD-L1 mRNA and protein expression in a time-dependent manner in TNBC cells, but not in hormone responsive cells.  Focusing on TNBC, HDACi up-regulated PD-L1 and HLA-DR on tumor cells when co-cultured with PBMCs and down-regulated CD4(+) Foxp3(+) Treg in vitro.  HDACi significantly enhanced the in vivo response to PD-1/CTLA-4 blockade in the triple-negative 4T1 breast cancer mouse model, the only currently available experimental system with functional resemblance to human TNBC.  This resulted in a significant decrease in tumor growth and increased survival, associated with increased T cell tumor infiltration and a reduction in CD4(+) Foxp3(+) T cells in the tumor microenvironment.  Overall, our results suggest a novel role for HDAC inhibition in combination with immune checkpoint inhibitors and identify a promising therapeutic strategy, supporting its further clinical evaluation for TNBC treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSUq_R8b5qOmiSm0e6ZOaemfW6udTcc2eZeRuzMQ7ZH-rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvksFSrsw%253D%253D&md5=c9511d4998918fe6313ea5cdea6dd924</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.23169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.23169%26sid%3Dliteratum%253Aachs%26aulast%3DTerranova-Barberio%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DAli%26aufirst%3DN.%26aulast%3DPawlowska%26aufirst%3DN.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DKrings%26aufirst%3DG.%26aulast%3DRosenblum%26aufirst%3DM.%2BD.%26aulast%3DBudillon%26aufirst%3DA.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26atitle%3DHDAC%2520inhibition%2520potentiates%2520immunotherapy%2520in%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D114156%26epage%3D114172%26doi%3D10.18632%2Foncotarget.23169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span> <span> </span><span class="NLM_article-title">Feedback activation of leukemia inhibitory factor receptor limits response to histone deacetylase inhibitors in breast cancer</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">473</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2016.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.1016%2Fj.ccell.2016.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=27622335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWitrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=459-473&author=H.+Zengauthor=J.+Quauthor=N.+Jinauthor=J.+Xuauthor=C.+Linauthor=Y.+Chenauthor=X.+Yangauthor=X.+Heauthor=S.+Tangauthor=X.+Lanauthor=X.+Yangauthor=Z.+Chenauthor=M.+Huangauthor=J.+Dingauthor=M.+Geng&title=Feedback+activation+of+leukemia+inhibitory+factor+receptor+limits+response+to+histone+deacetylase+inhibitors+in+breast+cancer&doi=10.1016%2Fj.ccell.2016.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer</span></div><div class="casAuthors">Zeng, Hanlin; Qu, Jia; Jin, Nan; Xu, Jun; Lin, Chenchu; Chen, Yi; Yang, Xinying; He, Xiang; Tang, Shuai; Lan, Xiaojing; Yang, Xiaotong; Chen, Ziqi; Huang, Min; Ding, Jian; Geng, Meiyu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">459-473</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors have demonstrated clin. benefits in subtypes of hematol. malignancies.  However, the efficacy of HDAC inhibitors in solid tumors remains uncertain.  This study takes breast cancer as a model to understand mechanisms accounting for limited response of HDAC inhibitors in solid tumors and to seek combination solns.  We discover that feedback activation of leukemia inhibitory factor receptor (LIFR) signaling in breast cancer limits the response to HDAC inhibition.  Mechanistically, HDAC inhibition increases histone acetylation at the LIFR gene promoter, which recruits bromodomain protein BRD4, upregulates LIFR expression, and activates JAK1-STAT3 signaling.  Importantly, JAK1 or BRD4 inhibition sensitizes breast cancer to HDAC inhibitors, implicating combination inhibition of HDAC with JAK1 or BRD4 as potential therapies for breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL24sYbhFYeLVg90H21EOLACvtfcHk0lg8FlmfUJ0SGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWitrnI&md5=9ce620c7a19519a95edd714f8012518c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2016.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2016.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DH.%26aulast%3DQu%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DN.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DLan%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DGeng%26aufirst%3DM.%26atitle%3DFeedback%2520activation%2520of%2520leukemia%2520inhibitory%2520factor%2520receptor%2520limits%2520response%2520to%2520histone%2520deacetylase%2520inhibitors%2520in%2520breast%2520cancer%26jtitle%3DCancer%2520Cell%26date%3D2016%26volume%3D30%26spage%3D459%26epage%3D473%26doi%3D10.1016%2Fj.ccell.2016.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J. B.</span></span> <span> </span><span class="NLM_article-title">Discovery and development of janus kinase (JAK) inhibitors for inflammatory diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5023</span>– <span class="NLM_lpage">5038</span>, <span class="refDoi"> DOI: 10.1021/jm401490p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401490p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5023-5038&author=J.+D.+Clarkauthor=M.+E.+Flanaganauthor=J.+B.+Telliez&title=Discovery+and+development+of+janus+kinase+%28JAK%29+inhibitors+for+inflammatory+diseases&doi=10.1021%2Fjm401490p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span></div><div class="casAuthors">Clark, James D.; Flanagan, Mark E.; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5023-5038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases.  As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnol. industries as therapeutic targets.  Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications.  Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3f7W5g8N6brVg90H21EOLACvtfcHk0lhm_y8-173s3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D&md5=6763ae2d46f52ddcda23e235a60634ae</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401490p%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DTelliez%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520and%2520development%2520of%2520janus%2520kinase%2520%2528JAK%2529%2520inhibitors%2520for%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5023%26epage%3D5038%26doi%3D10.1021%2Fjm401490p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pellegrini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dusanter-Fourt, I.</span></span> <span> </span><span class="NLM_article-title">The structure, regulation and function of the janus kinases (JAKs) and the signal transducers and activators of transcription (STATs)</span>. <i>Eur. J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>248</i></span>,  <span class="NLM_fpage">615</span>– <span class="NLM_lpage">633</span>, <span class="refDoi"> DOI: 10.1111/j.1432-1033.1997.00615.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.1111%2Fj.1432-1033.1997.00615.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=9342212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADyaK2sXmvFKhtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=248&publication_year=1997&pages=615-633&author=S.+Pellegriniauthor=I.+Dusanter-Fourt&title=The+structure%2C+regulation+and+function+of+the+janus+kinases+%28JAKs%29+and+the+signal+transducers+and+activators+of+transcription+%28STATs%29&doi=10.1111%2Fj.1432-1033.1997.00615.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The structure, regulation and function of the Janus kinases (JAKs) and the signal transducers and activators of transcription (STATs)</span></div><div class="casAuthors">Pellegrini, Sandra; Dusanter-Fourt, Isabelle</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">248</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">615-633</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review with 228 refs.  Since the discovery of their physiol. roles in cytokine signaling, the Janus kinases (JAKs) and the signal transducers and activators of transcription (STATs) have attracted considerable attention, to the point that the concept of a intracellular signaling pathway, named JAK/STAT, has emerged.  As originally defined, this pathway involves ligand-dependent activation of a particular class of receptor-assocd. tyrosine kinases, the JAK proteins, which phosphorylate themselves and receptor components, creating recruitment sites for STAT transcription factors.  The STATs are phosphorylated, they dissoc. from the receptor · JAK complex and translocate to the nucleus where they participate in transcriptional gene activation.  Although this pathway was found initially to be activated by interferons, it is now known that a large no. of cytokines, growth factors and hormonal factors activate JAK and/or STAT proteins.  Recent findings have suggested that the interdependence of JAKs and STATs might not be abs. as originally thought.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphjB67aUuu0LVg90H21EOLACvtfcHk0lhm_y8-173s3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmvFKhtr8%253D&md5=fcca548af2fb3f5d692d19b2b0cc2a90</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1111%2Fj.1432-1033.1997.00615.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1432-1033.1997.00615.x%26sid%3Dliteratum%253Aachs%26aulast%3DPellegrini%26aufirst%3DS.%26aulast%3DDusanter-Fourt%26aufirst%3DI.%26atitle%3DThe%2520structure%252C%2520regulation%2520and%2520function%2520of%2520the%2520janus%2520kinases%2520%2528JAKs%2529%2520and%2520the%2520signal%2520transducers%2520and%2520activators%2520of%2520transcription%2520%2528STATs%2529%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D1997%26volume%3D248%26spage%3D615%26epage%3D633%26doi%3D10.1111%2Fj.1432-1033.1997.00615.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nosaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamura, T.</span></span> <span> </span><span class="NLM_article-title">Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) in hematopoietic cells</span>. <i>Int. J. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">319</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10905049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlsV2ktrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2000&pages=309-319&author=T.+Nosakaauthor=T.+Kitamura&title=Janus+kinases+%28JAKs%29+and+signal+transducers+and+activators+of+transcription+%28STATs%29+in+hematopoietic+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) in hematopoietic cells</span></div><div class="casAuthors">Nosaka, Tetsuya; Kitamura, Toshio</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Hematology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-319</span>CODEN:
                <span class="NLM_cas:coden">IJHEEY</span>;
        ISSN:<span class="NLM_cas:issn">0925-5710</span>.
    
            (<span class="NLM_cas:orgname">Carden Jennings Publishing</span>)
        </div><div class="casAbstract">A review is given with 124 refs.  Hematopoietic cell growth and differentiation are controlled by a no. of cytokines.  Ligand stimulation induces rapid phosphorylation of the Tyr residues of the cytokine receptor and a variety of cellular mols.  Among them, Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) have recently been found to play a unique role in cytokine receptor-mediated intracellular signaling and hematopoietic cell development.  Abnormal signaling of the JAK-STAT pathway results in hematopoietic disorders, including severe combined immunodeficiency and leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoE78wv5FjPi7Vg90H21EOLACvtfcHk0lhm_y8-173s3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlsV2ktrk%253D&md5=b04cf4a4dd8e8f1fc0bbea8d980bf866</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNosaka%26aufirst%3DT.%26aulast%3DKitamura%26aufirst%3DT.%26atitle%3DJanus%2520kinases%2520%2528JAKs%2529%2520and%2520signal%2520transducers%2520and%2520activators%2520of%2520transcription%2520%2528STATs%2529%2520in%2520hematopoietic%2520cells%26jtitle%3DInt.%2520J.%2520Hematol.%26date%3D2000%26volume%3D71%26spage%3D309%26epage%3D319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamaoka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saharinen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">The janus kinases (Jaks)</span>. <i>Genome Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">253</span>, <span class="refDoi"> DOI: 10.1186/gb-2004-5-12-253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.1186%2Fgb-2004-5-12-253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=15575979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A280%3ADC%252BD2cngtlKktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=253&author=K.+Yamaokaauthor=P.+Saharinenauthor=M.+Pesuauthor=V.+E.+Holtauthor=O.+Silvennoinenauthor=J.+J.+O%E2%80%99Shea&title=The+janus+kinases+%28Jaks%29&doi=10.1186%2Fgb-2004-5-12-253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The Janus kinases (Jaks)</span></div><div class="casAuthors">Yamaoka Kunihiro; Saharinen Pipsa; Pesu Marko; Holt Vance E T 3rd; Silvennoinen Olli; O'Shea John J</div><div class="citationInfo"><span class="NLM_cas:title">Genome biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">253</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Janus kinase (Jak) family is one of ten recognized families of non-receptor tyrosine kinases.  Mammals have four members of this family, Jak1, Jak2, Jak3 and Tyrosine kinase 2 (Tyk2).  Birds, fish and insects also have Jaks.  Each protein has a kinase domain and a catalytically inactive pseudo-kinase domain, and they each bind cytokine receptors through amino-terminal FERM (Band-4.1, ezrin, radixin, moesin) domains.  Upon binding of cytokines to their receptors, Jaks are activated and phosphorylate the receptors, creating docking sites for signaling molecules, especially members of the signal transducer and activator of transcription (Stat) family.  Mutations of the Drosophila Jak (Hopscotch) have revealed developmental defects, and constitutive activation of Jaks in flies and humans is associated with leukemia-like syndromes.  Through the generation of Jak-deficient cell lines and gene-targeted mice, the essential, nonredundant functions of Jaks in cytokine signaling have been established.  Importantly, deficiency of Jak3 is the basis of human autosomal recessive severe combined immunodeficiency (SCID); accordingly, a selective Jak3 inhibitor has been developed, forming a new class of immunosuppressive drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0BwDh7EYTsV1C8OJBvdfbfW6udTcc2eaKv-g3hTFRDbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2cngtlKktg%253D%253D&md5=4f8335c37dc8c20245e771224c1d5b12</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1186%2Fgb-2004-5-12-253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fgb-2004-5-12-253%26sid%3Dliteratum%253Aachs%26aulast%3DYamaoka%26aufirst%3DK.%26aulast%3DSaharinen%26aufirst%3DP.%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DHolt%26aufirst%3DV.%2BE.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520janus%2520kinases%2520%2528Jaks%2529%26jtitle%3DGenome%2520Biol.%26date%3D2004%26volume%3D5%26spage%3D253%26doi%3D10.1186%2Fgb-2004-5-12-253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of Janus kinase 2 (JAK2) and histone deacetlyase (HDAC) bispecific inhibitors based on Pacritinib and evidence of dual pathway inhibition in hematological cell lines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8233</span>– <span class="NLM_lpage">8262</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00157</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00157" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8233-8262&author=E.+G.+Yangauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Yenauthor=B.+W.+Dymock&title=Design+and+synthesis+of+Janus+kinase+2+%28JAK2%29+and+histone+deacetlyase+%28HDAC%29+bispecific+inhibitors+based+on+Pacritinib+and+evidence+of+dual+pathway+inhibition+in+hematological+cell+lines&doi=10.1021%2Facs.jmedchem.6b00157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines</span></div><div class="casAuthors">Yang, Eugene Guorong; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8233-8262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Blockage of more than one oncoprotein or pathway is now a std. approach in modern cancer therapy.  Multiple inhibition is typically achieved with two or more drugs.  Herein the authors describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorinostat, to create bispecific single mols. with both JAK and HDAC targeted inhibition.  A preferred ether hydroxamate, compd. 51 (11-(4-(N-hydroxyheptanamide)oxy)-[4,1,9]dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12-(27),16,21,23-decaene) inhibits JAK2 and HDAC6 with low nanomolar potency, is <100 nM potent against HDACs 2 and 10, sub-micromolar potent against HDACs 1, 8 and 11, and >50-fold selective for JAK2 in a panel of 97 kinases.  Broad cellular antiproliferative potency is supported by demonstration of JAK-STAT and HDAC pathway blockade in several hematol. cell lines, inhibition of colony formation in HEL cells, and anal. of apoptosis.  This study provides new tool compds. for further exploration of dual JAK-HDAC pathway inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeUHzB39AGWrVg90H21EOLACvtfcHk0lhzkaUIt9GR2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL&md5=aa9ae07a1ac1aa21d70ee0f24621fe82</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00157%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DE.%2BG.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520Janus%2520kinase%25202%2520%2528JAK2%2529%2520and%2520histone%2520deacetlyase%2520%2528HDAC%2529%2520bispecific%2520inhibitors%2520based%2520on%2520Pacritinib%2520and%2520evidence%2520of%2520dual%2520pathway%2520inhibition%2520in%2520hematological%2520cell%2520lines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8233%26epage%3D8262%26doi%3D10.1021%2Facs.jmedchem.6b00157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong-Thi, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohlson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of ligand efficient dual inhibitors of Janus kinase (JAK) and histone deacetylase (HDAC) based on ruxolitinib and vorinostat</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8336</span>– <span class="NLM_lpage">8357</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00678</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00678" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8336-8357&author=L.+Yaoauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+Singhauthor=M.+D.+Duong-Thiauthor=J.+X.+T.+Leeauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Y.+Yenauthor=S.+Ohlsonauthor=B.+W.+Dymock&title=Design+and+synthesis+of+ligand+efficient+dual+inhibitors+of+Janus+kinase+%28JAK%29+and+histone+deacetylase+%28HDAC%29+based+on+ruxolitinib+and+vorinostat&doi=10.1021%2Facs.jmedchem.7b00678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat</span></div><div class="casAuthors">Yao, Lianbin; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Singh, Prachi; Duong-Thi, Minh-Dao; Lee, Jeannie X. T.; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Ohlson, Sten; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8336-8357</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Concomitant inhibition of multiple oncogenic pathways is a desirable goal in cancer therapy.  To achieve such an outcome with a single mol. would simplify treatment regimes.  Herein the core features of ruxolitinib, a marketed JAK1/2 inhibitor, have been merged with the HDAC inhibitor vorinostat, leading to new mols. that are bispecific targeted JAK/HDAC inhibitors.  A preferred pyrazole substituted pyrrolopyrimidine, I (R = H), inhibits JAK1 and HDACs 1, 2, 3, 6, and 10 with IC50 values of less than 20 nM, is <100 nM potent against JAK2 and HDAC11, and is selective for the JAK family against a panel of 97 kinases.  Broad cellular antiproliferative potency of I (R = H) is supported by demonstration of JAK-STAT and HDAC pathway blockade in hematol. cell lines.  Me analog I (R = Me) has an even more selective profile.  This study provides new leads for assessment of JAK and HDAC pathway dual inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocWx3JXIW8YbVg90H21EOLACvtfcHk0lhzkaUIt9GR2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ&md5=5ac471ee0cc413b08b926803790de7f9</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00678%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DL.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DDuong-Thi%26aufirst%3DM.%2BD.%26aulast%3DLee%26aufirst%3DJ.%2BX.%2BT.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%2BY.%26aulast%3DOhlson%26aufirst%3DS.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520ligand%2520efficient%2520dual%2520inhibitors%2520of%2520Janus%2520kinase%2520%2528JAK%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520based%2520on%2520ruxolitinib%2520and%2520vorinostat%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8336%26epage%3D8357%26doi%3D10.1021%2Facs.jmedchem.7b00678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu-Farseeva, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">619</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.09.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=10.1016%2Fj.ejmech.2018.09.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=30243158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOltL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2018&pages=593-619&author=Y.+Y.+Chu-Farseevaauthor=N.+Mustafaauthor=A.+Poulsenauthor=E.+C.+Tanauthor=J.+J.+Y.+Yenauthor=W.+J.+Chngauthor=B.+W.+Dymock&title=Design+and+synthesis+of+potent+dual+inhibitors+of+JAK2+and+HDAC+based+on+fusing+the+pharmacophores+of+XL019+and+vorinostat&doi=10.1016%2Fj.ejmech.2018.09.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat</span></div><div class="casAuthors">Chu-Farseeva, Yu-yi; Mustafa, Nurulhuda; Poulsen, Anders; Tan, Eng Chong; Yen, Jeffrey J. Y.; Chng, Wee Joo; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">593-619</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Specifically blocking more than one oncogenic pathway simultaneously in a cancer cell with a combination of different drugs is the mainstay of the majority of cancer treatments.  Being able to do this via two targeted pathways without inducing side effects through a general mechanism, such as chemotherapy, could bring benefit to patients.  In this work we describe a new dual inhibitor of the JAK-STAT and HDAC pathways through designing and developing two types of mol. based on the JAK2 selective inhibitor XL019 and the pan-HDAC inhibitor, vorinostat.  Both series of compds. had examples with low nanomolar JAK2 and HDAC1/6 inhibition.  In some cases good HDAC1 selectivity was achieved while retaining HDAC6 activity.  The obsd. potency is explained through mol. docking studies of all three enzymes.  One example, 69c had 16-25 fold selectivity against the three other JAK-family proteins JAK1, JAK3 and TYK2.  A no. of compds. had sub-micromolar potencies against a panel of 4 solid tumor cell lines and 4 hematol. cell lines with the most potent compd., 45h, having a cellular IC50 of 70 nM against the multiple myeloma cell line KMS-12-BM.  Evidence of both JAK and HDAC pathway inhibition is presented in Hela cells showing that both pathways are modulated.  Evidence of apoptosis with two compds. in 4 sold tumor cell lines is also presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppP3twGjwSkLVg90H21EOLACvtfcHk0lhzkaUIt9GR2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOltL%252FK&md5=a6a1456126270e44dfa2f28916f7b7c0</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.09.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.09.024%26sid%3Dliteratum%253Aachs%26aulast%3DChu-Farseeva%26aufirst%3DY.%2BY.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%2BY.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520potent%2520dual%2520inhibitors%2520of%2520JAK2%2520and%2520HDAC%2520based%2520on%2520fusing%2520the%2520pharmacophores%2520of%2520XL019%2520and%2520vorinostat%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D158%26spage%3D593%26epage%3D619%26doi%3D10.1016%2Fj.ejmech.2018.09.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of janus kinase 2 (JAK2) and histone deacetylase (HDAC) dual inhibitors as a novel strategy for the combinational treatment of leukemia and invasive fungal infections</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6056</span>– <span class="NLM_lpage">6074</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00393</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00393" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Snu7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6056-6074&author=Y.+Huangauthor=G.+Dongauthor=H.+Liauthor=N.+Liuauthor=W.+Zhangauthor=C.+Sheng&title=Discovery+of+janus+kinase+2+%28JAK2%29+and+histone+deacetylase+%28HDAC%29+dual+inhibitors+as+a+novel+strategy+for+the+combinational+treatment+of+leukemia+and+invasive+fungal+infections&doi=10.1021%2Facs.jmedchem.8b00393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections</span></div><div class="casAuthors">Huang, Yahui; Dong, Guoqiang; Li, Huanqiu; Liu, Na; Zhang, Wannian; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6056-6074</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Clin., leukemia patients often suffer from the limited efficacy of chemotherapy and high risks of infection by invasive fungal pathogens.  Herein, a novel therapeutic strategy was developed in which a small mol. can simultaneously treat leukemia and invasive fungal infections (IFIs).  Novel Janus kinase 2 (JAK2) and histone deacetylase (HDAC) dual inhibitors were identified to possess potent anti-proliferative activity toward hematol. cell lines and excellent synergistic effects with fluconazole to treat resistant Candida albicans infections.  In particular, compd. I, a highly active and selective JAK2/HDAC6 dual inhibitor, showed excellent in vivo antitumor efficacy in several acute myeloid leukemia (AML) models and synergized with fluconazole for the treatment of resistant C. albicans infections.  This study highlights the therapeutic potential of JAK2/HDAC dual inhibitors in treating AML and IFIs and provides an efficient strategy for multitargeting drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3_ii7EQG1qLVg90H21EOLACvtfcHk0lhwNmllVo38Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Snu7rN&md5=ba7cf74761120f0526ab520196e3dded</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00393%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520janus%2520kinase%25202%2520%2528JAK2%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520dual%2520inhibitors%2520as%2520a%2520novel%2520strategy%2520for%2520the%2520combinational%2520treatment%2520of%2520leukemia%2520and%2520invasive%2520fungal%2520infections%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6056%26epage%3D6074%26doi%3D10.1021%2Facs.jmedchem.8b00393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel janus kinase (JAK) and histone deacetylase (HDAC) dual inhibitors for the treatment of hematological malignancies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3898</span>– <span class="NLM_lpage">3923</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01597</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01597" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvVSls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3898-3923&author=X.+Liangauthor=J.+Zangauthor=X.+Liauthor=S.+Tangauthor=M.+Huangauthor=M.+Gengauthor=C.+J.+Chouauthor=C.+Liauthor=Y.+Caoauthor=W.+Xuauthor=H.+Liuauthor=Y.+Zhang&title=Discovery+of+novel+janus+kinase+%28JAK%29+and+histone+deacetylase+%28HDAC%29+dual+inhibitors+for+the+treatment+of+hematological+malignancies&doi=10.1021%2Facs.jmedchem.8b01597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies</span></div><div class="casAuthors">Liang, Xuewu; Zang, Jie; Li, Xiaoyang; Tang, Shuai; Huang, Min; Geng, Meiyu; Chou, C. James; Li, Chunpu; Cao, Yichun; Xu, Wenfang; Liu, Hong; Zhang, Yingjie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3898-3923</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Concurrent inhibition of Janus kinase (JAK) and histone deacetylase (HDAC) could potentially improve the efficacy of the HDAC inhibitors in the treatment of cancers and resolve the problem of HDAC inhibitor resistance in some tumors.  Here, a novel series of pyrimidin-2-amino-pyrazol hydroxamate derivs. as JAK and HDAC dual inhibitors was designed, synthesized, and evaluated, among which I possessed potent and balanced activities against both JAK2 and HDAC6 with half-maximal inhibitory concn. at the nanomolar level. I exhibited improved antiproliferative and proapoptotic activities over SAHA and ruxolitinib in several hematol. cell lines.  Remarkably, I exhibited more potent antiproliferation effect than the combination of SAHA and ruxolitinib in HEL cells bearing JAK2V617F mutation.  Pharmacokinetic studies in mice showed that I possessed good bioavailability after i.p. administration.  Finally, I showed antitumor efficacy with no significant toxicity in a HEL xenograft model.  Collectively, the results confirm the therapeutic potential of JAK and HDAC dual inhibitors in hematol. malignancies and provide valuable leads for further structural optimization and antitumor mechanism study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOXlwxqcv7m7Vg90H21EOLACvtfcHk0lhwNmllVo38Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvVSls7o%253D&md5=356363f40f24ac2ef32194e23a29328e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01597%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DZang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DChou%26aufirst%3DC.%2BJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520novel%2520janus%2520kinase%2520%2528JAK%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520dual%2520inhibitors%2520for%2520the%2520treatment%2520of%2520hematological%2520malignancies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3898%26epage%3D3923%26doi%3D10.1021%2Facs.jmedchem.8b01597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kulagowski, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bull, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyke, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liimatta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bir Kohli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maxey, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendonca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narukulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ubhayakar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Abbema, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waszkowycz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zak, M.</span></span> <span> </span><span class="NLM_article-title">Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">5901</span>– <span class="NLM_lpage">5921</span>, <span class="refDoi"> DOI: 10.1021/jm300438j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300438j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC38XntVOktL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5901-5921&author=J.+J.+Kulagowskiauthor=W.+Blairauthor=R.+J.+Bullauthor=C.+Changauthor=G.+Deshmukhauthor=H.+J.+Dykeauthor=C.+Eigenbrotauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=T.+K.+Harrisonauthor=P.+R.+Hewittauthor=M.+Liimattaauthor=C.+A.+Hurleyauthor=A.+Johnsonauthor=T.+Johnsonauthor=J.+R.+Kennyauthor=P.+Bir+Kohliauthor=R.+J.+Maxeyauthor=R.+Mendoncaauthor=K.+Mortaraauthor=J.+Murrayauthor=R.+Narukullaauthor=S.+Shiaauthor=M.+Steffekauthor=S.+Ubhayakarauthor=M.+Ultschauthor=A.+van+Abbemaauthor=S.+I.+Wardauthor=B.+Waszkowyczauthor=M.+Zak&title=Identification+of+imidazo-pyrrolopyridines+as+novel+and+potent+JAK1+inhibitors&doi=10.1021%2Fjm300438j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Imidazo-Pyrrolopyridines as Novel and Potent JAK1 Inhibitors</span></div><div class="casAuthors">Kulagowski, Janusz J.; Blair, Wade; Bull, Richard J.; Chang, Christine; Deshmukh, Gauri; Dyke, Hazel J.; Eigenbrot, Charles; Ghilardi, Nico; Gibbons, Paul; Harrison, Trevor K.; Hewitt, Peter R.; Liimatta, Marya; Hurley, Christopher A.; Johnson, Adam; Johnson, Tony; Kenny, Jane R.; Bir Kohli, Pawan; Maxey, Robert J.; Mendonca, Rohan; Mortara, Kyle; Murray, Jeremy; Narukulla, Raman; Shia, Steven; Steffek, Micah; Ubhayakar, Savita; Ultsch, Mark; van Abbema, Anne; Ward, Stuart I.; Waszkowycz, Bohdan; Zak, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5901-5921</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A therapeutic rationale is proposed for the treatment of inflammatory diseases, such as rheumatoid arthritis (RA), by specific targeting of the JAK1 pathway.  Examn. of the preferred binding conformation of clin. effective, pan-JAK inhibitor 1 led to identification of a novel, tricyclic hinge binding scaffold 3.  Exploration of SAR through a series of cycloamino and cycloalkylamino analogs demonstrated this template to be highly tolerant of substitution, with a predisposition to moderate selectivity for the JAK1 isoform over JAK2.  This study culminated in the identification of subnanomolar JAK1 inhibitors such as 22 and 49, having excellent cell potency, good rat pharmacokinetic characteristics, and excellent kinase selectivity.  Detn. of the binding modes of the series in JAK1 and JAK2 by X-ray crystallog. supported the design of analogs to enhance affinity and selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpamrk0bG1MK7Vg90H21EOLACvtfcHk0ljBo7Dv8uvSyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntVOktL0%253D&md5=d91bc0e24abf14adcf44caf61e3e879f</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm300438j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300438j%26sid%3Dliteratum%253Aachs%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26aulast%3DBlair%26aufirst%3DW.%26aulast%3DBull%26aufirst%3DR.%2BJ.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DDyke%26aufirst%3DH.%2BJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DHarrison%26aufirst%3DT.%2BK.%26aulast%3DHewitt%26aufirst%3DP.%2BR.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DBir%2BKohli%26aufirst%3DP.%26aulast%3DMaxey%26aufirst%3DR.%2BJ.%26aulast%3DMendonca%26aufirst%3DR.%26aulast%3DMortara%26aufirst%3DK.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DNarukulla%26aufirst%3DR.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DSteffek%26aufirst%3DM.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DS.%2BI.%26aulast%3DWaszkowycz%26aufirst%3DB.%26aulast%3DZak%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520imidazo-pyrrolopyridines%2520as%2520novel%2520and%2520potent%2520JAK1%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5901%26epage%3D5921%26doi%3D10.1021%2Fjm300438j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioannidis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuaqui, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimzhanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebernitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivard
Costa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">144</span>– <span class="NLM_lpage">158</span>, <span class="refDoi"> DOI: 10.1021/jm401546n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401546n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWltLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=144-158&author=Q.+Suauthor=S.+Ioannidisauthor=C.+Chuaquiauthor=L.+Almeidaauthor=M.+Alimzhanovauthor=G.+Bebernitzauthor=K.+Bellauthor=M.+Blockauthor=T.+Howardauthor=S.+Huangauthor=D.+Huszarauthor=J.+A.+Readauthor=C.+Rivard%0ACostaauthor=J.+Shiauthor=M.+Suauthor=M.+Yeauthor=M.+Zinda&title=Discovery+of+1-methyl-1H-imidazole+derivatives+as+potent+Jak2+inhibitors&doi=10.1021%2Fjm401546n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-Methyl-1H-imidazole Derivatives as Potent Jak2 Inhibitors</span></div><div class="casAuthors">Su, Qibin; Ioannidis, Stephanos; Chuaqui, Claudio; Almeida, Lynsie; Alimzhanov, Marat; Bebernitz, Geraldine; Bell, Kirsten; Block, Michael; Howard, Tina; Huang, Shan; Huszar, Dennis; Read, Jon A.; Rivard Costa, Caroline; Shi, Jie; Su, Mei; Ye, Minwei; Zinda, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">144-158</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure based design, synthesis, and biol. evaluation of a novel series of 1-methyl-1H-imidazole, as potent Jak2 inhibitors to modulate the Jak/STAT pathway, are described.  Using the C-ring fragment from our first clin. candidate AZD1480 (I), optimization of the series led to the discovery of compd. II, a potent, orally bioavailable Jak2 inhibitor.  Compd. II displayed a high level of cellular activity in hematopoietic cell lines harboring the V617F mutation and in murine BaF3 TEL-Jak2 cells.  Compd. II demonstrated significant tumor growth inhibition in a UKE-1 xenograft model within a well-tolerated dose range.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqczgU5RpFv1bVg90H21EOLACvtfcHk0ljBo7Dv8uvSyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWltLnL&md5=88c57119ec77d084a91a1123fd9dea86</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm401546n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401546n%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DChuaqui%26aufirst%3DC.%26aulast%3DAlmeida%26aufirst%3DL.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DBlock%26aufirst%3DM.%26aulast%3DHoward%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DHuszar%26aufirst%3DD.%26aulast%3DRead%26aufirst%3DJ.%2BA.%26aulast%3DRivard%2BCosta%26aufirst%3DC.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DZinda%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25201-methyl-1H-imidazole%2520derivatives%2520as%2520potent%2520Jak2%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D144%26epage%3D158%26doi%3D10.1021%2Fjm401546n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP','PDB','3FUP'); return false;">PDB: 3FUP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI','PDB','5EEI'); return false;">PDB: 5EEI</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i124"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_41084"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02111?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02111</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Supporting tables; <sup>1</sup>H NMR, and <sup>13</sup>C NMR of all target compounds; HPLC spectra and HRMS of the representative compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula stings (CSV) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_002.csv">CSV</a>)</p></li><li><p class="inline">Predicted binding mode of <b>6a</b> in the ATP pocket of JAK2; surface representation of <b>6a</b> in the ATP pocket of JAK2 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_003.pdb">PDB</a>)</p></li><li><p class="inline">Predicted binding mode of <b>15d</b> in the ATP pocket of JAK2 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_004.pdb">PDB</a>)</p></li><li><p class="inline">Predicted binding mode of <b>16b</b> in the ATP pocket of JAK2 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>)  (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_005.pdb">PDB</a>)</p></li><li><p class="inline">Predicted binding mode of <b>6a</b> in the active site of HDAC6; surface representation of <b>6a</b> in the active site of HDAC6 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI">5EEI</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_006.pdb">PDB</a>)</p></li><li><p class="inline">Predicted binding mode of <b>15d</b> in the active site of HDAC6 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI">5EEI</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_007.pdb">PDB</a>)</p></li><li><p class="inline">Predicted binding mode of <b>16b</b> in the active site of HDAC6 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI">5EEI</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_008.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_001.pdf">jm0c02111_si_001.pdf (4.71 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_002.csv">jm0c02111_si_002.csv (2.62 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_003.pdb">jm0c02111_si_003.pdb (784.85 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_004.pdb">jm0c02111_si_004.pdb (469.24 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_005.pdb">jm0c02111_si_005.pdb (469.24 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_006.pdb">jm0c02111_si_006.pdb (549.42 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_007.pdb">jm0c02111_si_007.pdb (549.62 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_008.pdb">jm0c02111_si_008.pdb (549.62 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c02111&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c02111%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c02111" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                12MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66e0af678940a35a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
